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ABSTRACT OF THE DISSERTATION
Potential Mechanisms Explaining the Antitumor Effect
of Total-Body Irradiation
by
Glen Michael Miller
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, June 2003
Dr. Daila S. Gridley, Chairperson
While numerous reports have documented that radiation exposure increases the
risk for malignancy and suppresses immune mechanisms, increasing evidence has
suggested that low-dose total-body irradiation (TBI) may alter leukocyte composition and
function leading to heightened immune responsiveness and long-term remission of
certain cancers. Having observed that moderate-dose TBI produces an antitumor effect
in the Lewis lung carcinoma (EEC) model, the major goal of this study was to determine
whether changes in tumor growth could be correlated with radiation-induced alterations
of immune system parameters. The governing hypothesis was that selective immune
augmentation, i.e. upregulation of specific leukocyte subsets, is primarily responsible for
the reduction in lung carcinoma progression that follows administration of moderate-dose
TBI.
Alterations in cytokine secretion, lymphocyte cytotoxicity, and immune cell
population densities were investigated at sequential time points when delivery of TBI
(0.46 to 3.0 Gray of y-rays) preceded EEC implantation in the C57BL/6 mouse model.
Tumor volumes and mouse weights were measured throughout each protocol; and
immunohistochemical analyses were performed on tumors excised from control and test
mice to evaluate leukocyte infiltration. In later studies, mice were injected with depleting

xvn

antibodies to eliminate NK populations, in order to determine the contribution of the NK
subset to the antitumor effect of TBI.
Collectively, the data demonstrated for the first time that a selective radiationinduced reconstitution of T suppressors, NK, and NKT populations as well as cytokine
profile are correlated to a protumoricidal immune environment following TBI. Changes
in the relative percentages and activation status of immune cell compartments, that
accompany TBI, functioned to slow tumor progression.

Further, experimentation

substantiated that asialo GM1+ and NK1.1+ cells operated in tumor surveillance in the
LLC tumor model and were involved in mediating the antitumor effect of TBI. The
findings also demonstrated that radiation exposure can activate NK cells, inducing
increased population densities and cytotoxicity, thereby leading to tumor suppression.
The finding, that moderate-dose TBI can enhance tumor surveillance of NK cells,
warrants further study and evaluation.

xvm

CHAPTER ONE
INTRODUCTION
Cancer
Overview
Cancer is an insidious disease in which the body’s own cells become increasingly
transformed. Whether by one or by many complicating factors, the cells ignore normal
growth signals, to the extent that they proliferate and compete for the nutritional and
spatial requirements of normal cells. Having become malignant, these cells are wanton in
their destruction of the tissues and organs they invade, while promoting their own
advancement. If uncontrolled, the end result is the destruction of the very organism
which begat them.
Lung Cancer
According to the American Cancer Society, in 2003 alone, it is estimated that
over 556,500 lives will succumb to some form of this disease (Jemal et al., 2003). Cancer
ranks as the second leading cause of death in the U.S.A., behind only heart disease, thus
accounting for more that 1,500 deaths per day.
In the United States, lung cancer is the second most commonly diagnosed cancer
among men and women, and the primary cause of cancer mortality (Greenlee et al.
2001); close to 28% of all cancer deaths are expected to be due to lung cancer this year
(Table 1.1). The American Cancer Society estimates that 171,900 new cases of lung
cancer will have been diagnosed by the end of 2003, and these cases will be divided
almost equally between men and women (53% and 47%, respectively). It is also
estimated that lung cancer will claim 157,200 lives during this time, a figure which
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Table 1.1. Ten leading cancer sites that will be responsible for cancer-related death in
2003. Lung and bronchus cancer ranks first among the leading sites of estimated cancer
death. Adapted from Jemal et ah, 2003.

Estimated Cancer Deaths* - 10 Leading Sites by Gender. US, 2003
Men

Women

Lung &Bronchus
31%
25%
Lung & Bronchus
Prostate
10%
15%
Breast
Colon & Rectum
Colon & Rectum
10%
11%
Pancreas
5%
6%
Pancreas
Ovary
Non-Hodgkins Lymphoma 4%
5%
4%
Leukemia
4%
Non-Hodgkin’s Lymphoma
Esophagus
4%
4%
Leukemia
Liver
Uterine Corpus
3%
3%
Urinary Bladder
2%
Brain
3%
2%
Multiple Myeloma
Kidney
3%
22%
All other sites
All other sites
23%
*Excludes basal and squamous cell skin cancer and in situ carcinomas except urinary bladder.
Percentages may not total 100% due to rounding.
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indicates a poor outcome following diagnosis and treatment.

Overall, the five-year

survival rate for lung cancer stands at 15.8%, due mostly to the fact that the majority of
new cases are diagnosed at a regional or distant stage in which survival is especially poor
(Ries et ai, 2000). Despite the current technology for early detection, only 16% of new
diagnoses are classified as localized stage, and fewer than 25% of patients are
asymptomatic at the time of diagnosis (Black, 1999).
For treatment considerations, lung cancer is divided into two categories based
upon histology - small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
NSCLC incorporates three different histologies of pulmonary tumor including squamous
carcinoma, adenocarcinoma, and large cell carcinoma; all of which originate from
advanced cell types but bear a common classification because, when localized, all have
the potential for cure with surgical resection. SCLC presents a more aggressive clinical
course, frequently involving distant metastases, and as a result localized treatments rarely
produce long-term survival (Prasad et al., 1989).
Staging plays a critical role in determination of therapy, and this is based upon a
combination of clinical (physical examination, radiologic, etc.) and pathologic (lymph
node biopsy, bronchoscopy, etc.) factors (Ginsberg, 1990).

In NSCLC, the most

potentially curative therapeutic option for pulmonary tumor is surgery. Radiation therapy
can produce cure in a small minority, but palliation is the reality for the majority of
patients. Chemotherapy is used for advanced-stage disease, but typically offers only
modest improvements in median survival and overall survival is poor (Souquet et al,
1993). The current and explorative chemotherapeutic agents which show activity against
NSCLC

include

taxol,

taxotere,

topotecan,
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vinorelbine,

and

gemcitabine.

Immunotherapies, including interferon and anti-idiotype regimens, are also considered as
a treatment option for NSCLC. It should be noted that a combination of modalities may
be employed to reduce the likelihood of developing regional or distant metastases, which
occurs in many cases following surgery (Martini et al, 1995; Swisher et al., 2002).
Radiation
Discovery
The discovery of x-rays by Wilhelm Conrad Roentgen over a century ago ushered
in a new era of medicine, which incorporated the application of radiation for the
treatment of diseases such as cancer. Radiation exerts its effect on biological materials
through the transfer of energy to electrons. Such absorption may lead to a state of either
ionization or excitation, depending on whether the radiation has sufficient energy to eject
one or more orbital electrons from either an atom or molecule or merely raise these
electrons to a higher energy level. X-rays and y-rays may be thought of as streams of
photons, or “packets” of energy, which deposit energy into tissues and cells. These are in
contrast to particulate forms of radiation (consisting of electrons, protons, iron ions, etc.)
which directly interact with atoms and molecules to produce chemical and biological
alterations (Bristow, 1998; Hall, 2000).
Energy deposition and cellular damage
X-rays and y-rays deposit energy to tissue by one of three processes: the
photoelectric effect, pair production, or the Compton effect. The Compton effect is by
far the most common in biological systems within the energy ranges used for
radiotherapy.

Under this process, the photon collides with an outer orbital electron,

resulting in a displacement of the electron and a redirection of the traveling photon. Both
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the electron and photon are capable of causing further ionizations or excitations
depending on the initial energy of the photon (Bristow, 1998).
Cellular injury can occur directly by the deposition of energy to distinct
macromolecules or indirectly through the production of reactive mutagenic species.
Cellular damage can cause three possible outcomes including: 1) delay of cell division, 2)
reproductive failure, and 3) apoptosis. Notably, injury type is related to the type of cell
affected as well as the dose absorbed by the cell (Bolus, 2001).
On a subcellular level, radiation produces its greatest effects on genomic DNA,
although other cellular components and transduction pathways are simultaneously
influenced. Damage to cellular DNA can occur by multiple processes including direct
ionization of DNA, reactions with electrons or solvated electrons, and reactions with
oxygen radicals (Ward, 1994). Originally it was thought that single-strand breaks (ssb) to
DNA, and later that double-strand breaks (dsb), comprised the majority of biological
damage and that these correlated with the biological effectiveness of radiation. However,
due to the efficiency of repair mechanisms, including homologous and non-homologous
recombination for dsb, the role of single-strand and double-strand breaks in critical
damage has been redefined. Track structure analysis has revealed that clustering of DNA
damage beyond simple double-strand breaks is likely to occur at biologically relevant
frequencies with ionizing radiation (Goodhead, 1994).

Indeed, focal areas of DNA

damage, which involve both ssb and dsb in the sugar-phosphate backbone, arise because
of clustering of ionizations within a few nanometers of the DNA (Ward, 1994). When
these DNA lesions are left unrepaired or are incorrectly repaired, they can result in the
generation of mutations, malignant transformation, or cell death following cell cycling.

5

The generation of reactive radical intermediates can indirectly affect DNA. Of
the intermediates produced, the hydroxyl radical is probably the most destructive.
Reactive oxygen species, such as the hydroxyl radical, can also interact with proteins in
the cell membrane, some of which are likely to be involved in signal transduction
pathways (Bristow, 1998).
Apoptosis represents one of the major cellular responses to radiation because
damage to organelles, cellular components, and DNA can elicit apoptosis through a
variety of transduction pathways. The tumor suppressor protein/transcription factor, p53,
plays a pivotal role in mediating cellular response to nuclear DNA injury (Bristow et al.
1996). Depending upon the severity of the insult, p53 is involved in regulating cell cycle
delay, and in cases of irreparable damage, is capable of inducing apoptosis (Khanna and
Jackson, 2001). The various mechanisms by which p53 mediates the apoptotic response
to radiation are not completely known. One likely possibility involves the ability of p53
to alter the expression of Bcl-2 family members, which serve to inhibit the mitochondria
from releasing caspase-activating factors, such as cytochrome c (Miyashita et al, 1994;
Miyashita and Reed, 1995; Zhan et al, 1994). When cytochrome c is released following
mitochondrial insult, a virtual cascade of events, beginning with the activation of Apaf-1
and concluding with cleavage of death substrates by effector caspases, ensues (Kuwana et
al, 1998; Slee et al, 1999). The stress-activated protein kinase or c-Jun N-terminal
kinase (SAPK/JNK) pathway also appears to be important in apoptosis signaling
following radiation. This is demonstrated by experiments that have shown that cells,
which are resistant to the lethal effects of radiation, fail to activate the SAPK/JNK
pathway (Chen et al, 1996) (Figure 1.1). The generation of ceramide, the hydrolysis
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Figure 1.1. Induction of apoptosis by radiation. Three main pathways of apoptotic
induction exist including a) activation of p53 following DNA damage, b) mitochondrial
disruption resulting in the release of caspase-activating factors, and c) activation of the
SAPK/JNK pathway by ceramide or other membrane-derived signals. Adapted from
Verheij and Bartelink, 2000.
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product of sphingomyelin, also has been implicated as a mediator of apoptotic response
following radiation, and some studies implicate ceramide as an activator of the
SAPK/JNK pathway (Pena et ai, 1997; Verheij et al, 1996; Westwick et al, 1995). All
told, the various insults induced by apoptotic inputs culminate in the activation of
caspases, beginning with the initiator caspases (e.g. caspase 8) which in turn activate the
effector caspases (e.g. caspases 3 and 7) (Slee et al., 1999; Verheij and Bartelink, 2000).
Salvesen and other researchers have recently concluded that activation of apical and
effector caspases occurs through distinct yet related mechanisms. Apical caspases appear
to be activated by proximity induced dimerization, whereas effector caspases require
cleavage and catalytic processing prior to activation (Boatright et al, 2003; Riedl et al,
2001).

Radiotherapy
It is estimated that approximately one-half of all cancer patients treated in the
U.S.A. will receive radiation as part of their therapeutic regimen (Coia, 1994).

The

difficulty encountered in radiotherapy lies not in the ability to control the tumor but rather
the necessity to limit total dose to the surrounding normal tissue because of complications
(both acute and late responses). The choice of radiation dose is based on assessment of
risk, which considers the severity of damage to normal tissue compared with the
probability of eradicating the tumor. Radiation oncologists must also take into account
different factors which influence tumor responsiveness to radiation, including: hypoxia,
proportion of clonogenic cells, inherent radiosensitivity of the particular tumor type, and
repair of radiation damage (Hall, 1987; Travis, 1989). Furthermore, results from several
tumor models have shown a correlation between the level of apoptosis prior to irradiation
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and the tumor response following radiation, thereby arguing that apoptosis may
determine radiosensitivity (Meyn et al., 1993; Stephens et al, 1991). Treatment efficacy
is also affected by the extent of nutrient depletion, acidosis, hypoxia, and waste
accumulation within different regions of the tumor mass (Kim, 2001). Taken together,
the efficacy of radiation treatment is influenced by factors which are unique to each
individual tumor.
Total Body Irradiation
Total body irradiation (TBI) refers to systemic exposure of the individual. This
approach is especially common for lymphomas and leukemias and is used clinically for
the treatment of these malignancies because of their disseminated nature and heightened
radiosensitivity (Wheldon, 1997). Low-dose TBI has been used to achieve remission with
some success in chronic lymphocytic leukemia and low-grade non-Hodgkin’s
lymphomas in advanced stages (Del Regato, 1974; Dobbs et al, 1981; Richaud et al.
1998). Cumulative doses during these regimens reach approximately 1.5 to 2 Gy although
a fractionation schedule is typically followed which limits the dose per fraction to less
than 0.25 Gy. A similar treatment protocol has been used for patients who suffer with
autoimmune diseases. While the mechanism of TBI management of autoimmune
disorders is not known, it may be related to the destruction of disease-mediating effectors
cells or TBI may somehow shift the balance between immunity and tolerance. There has
also been a renewed interest in TBI because of pioneering work in autologous bone
marrow transplantation. Thomas and colleagues showed that a supralethal dose of both
TBI and cytotoxic drugs followed by bone marrow rescue can be used for the control of
malignancies that have become refractory to conventional therapies (Thomas et al.
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1975). Autologous bone marrow transplantation coupled with TBI is also one of the
treatment options

for various

autoimmune diseases including systemic lupus

erythematosus (Burt and Traynor, 1999).
The major side effect observed for low-dose TBI is thrombocytopenia, following
doses that exceed 1 to 1.5 Gy (Johnson and Ruhl, 1976; Mendenhall et al, 1989). The
risk of leukemia is also enhanced among patients receiving low-dose TBI in conjunction
with chemotherapy (Travis et al, 1996). In contrast, interstitial pneumonitis is the
foremost dose-limiting cytotoxicity found upon administration of high-dose TBI (Weiner
et al, 1986).

Several approaches have been used to combat sequelae including

fractionation of the TBI regimen, which can reduce the risk of pneumonitis without
increasing the rate of tumor recurrence, and protection of the lungs with radiation barriers
(Lin, 1997; Thomas et al, 1982).
Numerous experiments have documented alterations in lymphocyte populations
following TBI (Chambers et al, 1998; Harrington et al, 1997; Kajioka et al, 2000).
Ionizing radiation triggers apoptosis in peripheral blood lymphocytes, although the
mechanism of induction, as well as the degree of sensitivity, appears to be distinct among
different subsets. In particular, TCR a/(3+ (T helper and T cytotoxic) T cells and B cells
demonstrate susceptibility to p53-mediated apoptosis, whereas, neither TCR y/6+ T cells
nor NK cells show a similar induction of the p53 protein following irradiation at doses
equaling 15 Gy (Seki et al, 1994). Consequently, the relative expression of p53 seems to
be an indicator of radiosensitivity. Several studies indicate that B lymphocytes (CD 19+)
are the most susceptible to radiation, although reconstitution is observed by day 15 after
administration of a single 3 Gy dose (Harrington et al, 1997; Kajioka et al, 1999). CD4+

10

T helper cells exhibit a similar recovery in population density by day 29, while CD8+ T
cytotoxic cells fail to recover by this time point. Radiation injury does result in a shift of
lymphocyte percentages demonstrating a relative increase in both the CD3+ T y/5+ and
NK cell populations (Chambers et al., 1998). The proportion of NK cells can rise as
much as 9-fold, four days following a 7 Gy exposure even though the NK cell population
is only slightly increased numerically. It has even been suggested that the patterns of
alterations in relative proportions of lymphocyte subsets, especially B lymphocytes and
NK cells, represent indicators of immune damage caused by radiation. While a 3 Gy dose
of TBI does result in a marked, yet transient, immune suppression, it is undetermined
why and how this altered environment may be tumor promotive or inhibitory.
Therapeutic lymphoid irradiation has been shown to produce a long-term impact
on lymphocyte subpopulations and immunologic responsiveness (Fuks et al, 1976; Haas
et al, 1984). Irradiation to portions of the lymphatic system, used for the treatment of
Hodgkin’s disease, has been correlated with augmentation of NK cell populations and
activity. Hodgkin’s disease patients undergoing treatment with lymphoid irradiation have
demonstrated an increased NK cell activity compared with untreated counterparts,
although it was not determined if the increased cytotoxicity was due to alterations of NK
cell number or lytic activity (Pinel et al, 1998). Experiments, performed by Macklis and
colleagues, suggest that irradiation causes a preferential increase in circulating large
granular lymphocytes such that while CD16+CD57+ NK subsets are proportionally
amplified, the reverse effect is seen in CD16-CD8+ T cell subsets (Macklis et al, 1993).
While these researchers concluded that lymphoid irradiation appears to induce a
generalized expansion of the entire NK compartment rather than changes in cytotoxic
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capability of NK cells, they had previously shown that irradiated patients do display
proportionately increased cytoxocity in vitro (Macklis et al, 1992). This cytoxicity data
paralleled increases in phenotypic proportions of NK cells. It has also been shown that
NK activity remains normal during a continued state of remission of Hodgkin’s disease
(Douer et al, 1987). Cumulatively these data suggest that increasing population size and
perhaps even a heightened cytotoxicity comprise the NK cell response to lymphoid
irradiation.
Experimental and clinical research has provided cursory evidence that low-dose
TBI can in fact be immune-stimulatory and even, in some instances, capable of inducing
a degree of tumor regression and/or metastasis suppression. Explanations for the immune
enhancement of low-dose TBI tend to lean toward two basic mechanisms: 1) the
elimination of a T-suppressor subset, or 2) the augmentation of immune responsiveness
of varied parameters (Safwat, 2000). Anderson and colleagues were among the first to
suggest that radiation could eliminate a suppressor T cell population which restricted
immune-mediated elimination of tumor in an unirradiated state (Anderson and Lefkovits,
1979). This finding was consistent with previous results that allogeneic spleen cells
could exert suppressor activity as exhibited by a reduced level of cell-mediated
cytotoxicity subsequent to adoptive transfer (Sabbadini, 1974). Low-dose immune
augmentation was found to be abolished by either transfer of T cell enriched spleen cells
or bonemarrow restoration of irradiated animals; leading to the postulation that
elimination of suppressor T cells could be a possible adjuvant therapy for humans
(Anderson et al, 1982; Enker and Jacobitz, 1980; Hellstrom et al, 1978). The attempt to
identify the nature of these radiosensitive suppressor cells has fomented speculation.
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Originally, the suppressor cells were thought to be Lyt-1,2+ T cytotoxic cells but this was
later followed by reports that a CD4+ suppressor subset provides a barrier to adoptive
immunotherapy as opposed to CD8+ cells (Awwad and North, 1990; Spellman and
Anderson, 1982). It is known that the relative number of functioning T and NK cells do
increase in the spleens of irradiated mice compared with the relative number of B cells,
but as yet this does not confirm a differential sensitivity between T helper and T
suppressor cells (Fourquet et al, 1993).
It also seems plausible that low-dose TBI can enhance immune responses as a
result of changes in certain additional parameters after irradiation (Liu, 1989). Low-dose
TBI has been shown to increase the proliferative capacity of splenic and thymic
lymphocytes when stimulated by various mitogens through signal transduction pathways
(Liu et al, 1994a; Liu et al, 1994b). Mitogenic stimulation assays indicate that totalbody, chronic low doses of ionizing radiation specifically augment the proliferative
capacity of T cells as opposed to B cells (Nogami et al, 1994). Hashimoto et al
described lymphocyte anti-tumor responses following a dose of 0.2 Gy TBI as being a
function of CD8+ cell involvement and the cytokine network (Hashimoto et al, 1999).
This conclusion was based on a correlation between a decreased incidence of lung tumor
metastasis and an upregulation in mRNA expression of both TNFa (Tumor necrosis
factor-alpha) and IFNy (Interferon-gamma), a decline in TGFp (Transforming growth
factor-beta) mRNA, and an increase in the proportion of CD8+ splenocytes and tumorinfiltrating lymphocytes. Further, some evidence suggests that T cells may be indirectly
activated by low-dose irradiation due to the release of cytokines (IL-1, Interleukin 1) by
monocytes and lymphocytes (Galdiero et al, 1994). The implication of other leukocyte
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involvement also exists. Macrophage activation post-irradiation has been associated with
increased respiratory burst activities and neutrophil infiltration (Lorimore et al., 2001).
This enhanced phagocytic cell activity has been shown to be sustained beyond the
removal of apoptotic bodies.
Radiation in space/working environments
Total-body irradiation or exposure of large body areas can occur in occupational
settings (e.g., astronauts on extended voyages in space, health care and nuclear plant
workers), as well as during radiotherapy for cancer and other pathological conditions.
The lethal dose of ionizing radiation to 50% of the population at thirty days post
exposure (LD50/30) for humans is approximately 2.5-4.5 Gy, although it should be noted
that this value is an estimate of empirical data (Bolus, 2001). The LD50 for mice, without
consideration to individual species differences, is approximately 7.0 Gy (Hall, 2000). The
average annual dose to the U.S. population from all sources, including cosmic and
terrestrial radiation, has been calculated at 0.36 cGy. When evaluating toxicities
following radiation exposure, it is generally considered that doses below 0.5 Gy yield
stochastic biological effects in humans. At doses greater than this, the acute effects of
radiation follow a predictable and linear path. Chronic effects following radiation appear
to be more random in nature but after threshold levels of exposure, some effects do show
linear correlation to a point, as in the case of leukemia (Ladou, 1990). Clinical symptoms
that are seen following exposure of 2-6 Gy include hematological and gastrointestinal
syndromes. These are especially life threatening when considering that no person has
survived a single dose of 5 Gy or higher without a blood transfusion and/or bone marrow
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transplant. Conversely, the clinical symptoms of central nervous system syndrome are
seen at doses greater than 50 Gy (Bolus, 2001).
It is estimated that the highest levels of radiation received during an extended
mission in deep space will fall within a range of 1 Gy to 5 Gy (Wilson, 1991). In
contrast, biological doses received by astronauts during the ANTARES and ALTAIR
space missions were calculated to range from 95 to 455 mGy (Testard et al., 1996).
Absorbed doses received by crew members on a 115 day mission aboard Mir-18 were
measured by physical dosimeters to be 5.2 cGy (Yang et al, 1997). Radiation, within the
higher dose range approximations, is capable of significant cell killing and as a
consequence could affect the viability of several cellular compartments/organ systems
and thus also overall health (Todd et al, 1999).

Both the myeloid and lymphoid

compartments are of particular interest when considering severe radiation damage
because they retain relatively small stem cell populations along with a minimum capacity
to regenerate progenitor cells (Todd et al, 1999). Doses absorbed during space travel
could reduce hematopoietic regenerative capacity as well as overall immune
responsiveness to infection and increase the risk for diseases such as cancer and
autoimmunity.
Conversely, some evidence suggests that certain immune cell populations are
upregulated and/or activated by low-dose irradiation.

Cytotoxic T-cells have

demonstrated enhanced responsiveness to PHA and Con A following exposure to total
doses between 0.1 and 0.5 Gy, along with heightened proliferation (Gualde and Goodwin,
1984). Radiation (5-20 Gy) has also been shown to result in increased human NK cell
activity (Brovall and Schacter, 1981). These findings coincide with epidemiological
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studies of Hiroshima and Nagasaki victims, exposed to less than 0.5 Gy, where evidence
points to enhanced NK cell activity combined with a higher mitogenic response of
lymphocytes and increased interferon-y levels in cell culture supernatants of activated
lymphocytes (Bloom et al, 1987).

Because of these contrasting results (i.e.,

immunodepression versus immune enhancement), it is important to clarify the health risk
component of space travel that may be attributable to radiation, specifically as it pertains
to immunological function and capacity. In addition, further clarification is needed so
that appropriate countermeasures can be developed to ameliorate any adverse effects that
may be observed.
Tumor environment
The prevailing idea regarding cancer recognizes its development as being a multistep process proceeding from multiple genetic mutations (Weinberg, 1989). Still,
malignant tissues do not exist in isolation and, as a consequence, normal cells associated
with tumor can modulate its progression and structural characteristics (Park et al, 2000).
In fact, the formation of a tumor is largely dependent upon the surrounding cellular
environment, which at least partly establishes and sustains its growth. This surrounding
nonmalignant tissue, or tumor stroma, is a loosely defined structural framework that
surrounds and infiltrates the tumor.

As illustrated in Figure 1.2, tumor stroma is

composed of fibroblasts, smooth muscle cells, vasculature, and lymphatic channels as
well as numerous cellular infiltrates (Milas, 1998).

Because each tumor interacts

differently with its surrounding environment, the composition and network of tumor
stroma is unique to each tumor type.
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Figure 1.2. Tissue microenvironment. Both the tissue and tumor microenvironment rely
upon an extensive interplay between a number of different cell types and architecture
including fibroblasts, migratory immune cells, extracellular matrix, and neural elements
all supported by a vascular network. Adapted from Park et. al. 2000.
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Studies have identified fibroblasts, a major cell type of the stromal compartment,
as potential contributors in tumorigenesis (Adam et al., 1994; Skobe and Fusenig, 1998).
Fibroblasts can be activated by platelet-derived growth factor (PDGF), after which these
fibroblasts can stimulate keratinocytes to continued proliferation and eventual tumor
transformation (Skobe and Fusenig, 1998). Evidence for the involvement of PDGF in
tumorigenesis is important because it demonstrates that an activated stromal
compartment, as well as the secretion of growth factors involved in normal processes
such as wound healing, can promote conversion of nontumorigenic epithelium.
Researchers have also found that fibroblasts associated with prostate carcinomas are
capable of directing the progressive growth of initiated prostate epithelial cells (Olumi et
al, 1999). The initiation step in this study involved immortalization with the SV40-large
T antigen. However, it was documented that carcinoma-associated fibroblasts did not
cause sustained growth of normal prostate epithelium, although this may be attributed to
the variability of these fibroblasts. Nevertheless, the activation of dermal fibroblasts may
result from many stimuli including the degranulation of infiltrating mast cells (Coussens
et al, 1999) and activation may perpetuate the growth of initiated and/or tumorigenic
cells.
Angiogenesis, or vasculature formation, is also fundamental to the growth of
tumor cells. Recent studies of angiogenesis have emphasized the critical nature of blood
supply to the growth of solid tumors and their metastases (Folkman, 1990). Small clusters
of cells, typically less than 106, are capable of survival due to the diffusion of nutrients
from the surrounding microenvironment (Paweletz and Knierim, 1989), but any tumor
beyond approximately 1 mm3 requires a vascular network to further tumor development
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(Hahnfeldt et al, 1999). To this end, tumors are not only capable of inducing
angiogenesis by the production of growth factors, they can also secrete enzymes which
operate to release angiogenic factors stored within tumor stroma and stop synthesis of
anti-angiogenic molecules (Bouck, 1993).

The participation of tumor stroma in

activating angiogenesis is exemplified by the fact that even inflammatory mast cells may
participate in this process by the release of sequestered angiogenic factors following
degranulation (Coussens et al, 1999).
Vascular endothelial growth factor (VEGF) is one of the most potent angiogenic
cytokines identified. Tumors induce angiogenesis, at least partly, through the secretion
of VEGF.

However, it has been recently demonstrated that leukocytes (e.g., T

lymphocytes, neutrophils, and macrophages) also are capable of secreting the factor,
threby suggesting that they may contribute to tumor vasculature formation. Biological
response modifiers, such as antiangiogenic agents, can induce vascular obliteration,
necrosis, and direct cytotoxic effects when used in combination with ionizing radiation
(Hallahan et al, 1999).

The administration of these factors, including angiostatin, has

been shown to potentiate a stronger antitumor effect when used in combination with other
modalities (Gorski et al, 1998; Mauceri et al, 1998). As a singular entity, radiation
damages endothelial cells by causing a progressive loss, such that the loss rate is
inversely proportional to cell cycle time (Archambeau et al, 2000). Yet the late effects of
radiation also include manifestation of injury, not only to the endothelial cell population.
but also to the basement membrane (Baker and Krochak, 1989). Furthermore, ionizing
radiation activates the inflammatory cascade and enhances the procoagulative state within
blood vessels of tumors through induction of oxidative injury (Hallahan et al, 1999).
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The tumor bed phenomenon describes observations about tumor progression
following the application of ionizing radiation to tumor stroma. The effect observed is
that when tumor cells are transplanted to subcutaneous tissue, that has previously been
irradiated with high doses of radiation, establishment of the tumor cells is delayed in
comparison to growth in nonirradiated tissues (Hewitt and Blake, 1968; Urano and Suit,
1971). While the underlying causes of this effect are not completely understood, it is
thought to result from a reduced ability of radiation-injured tissue to provide a sufficient
vascular supply to tumors (Jirtle et al., 1978; Penhaligon et al, 1988). Consequently, the
inhibition of angiogenesis is manifested in a relatively low tumor-progression rate.
It is known that the tumor bed effect (TBE) is dependent upon the tumor type as
well as the radiation dose delivered to the tumor microenvironment. Researchers have
demonstrated that the TBE for the majority of tumors begins to appear at doses between 5
to 10 Gy. As the dose rises above 10 Gy, a sharp increase in the TBE has been observed
until a plateau is reached somewhere between 20-30 Gy (Milas et al, 1986). The TBE is
also observed when the radiation dose is fractionated (2Gy, five times a week). For the
Lewis lung carcinoma (LLC), Ohizumi and colleagues demonstrated that the TBE was
apparent after the administration of 15 Gy (Ohizumi et al, 1987). What is more, these
researchers found that the metastasis of LLC tumors in irradiated animals showed a
similarity in the time for developing the first metastatic mass compared to unirradiated
controls, while the total number of metastases was reduced in mice receiving irradiation.
When considering the tumor microenvironment, it is interesting to note that some
discrepancy does exist between studies on tumor stroma and those explaining the TBE.
One set of experiments suggests that irradiation of mammary gland stroma, with a dose
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of 4 Gy, promotes the conversion of epithelial cells to a tumorigenic state (Barcellos-Hoff
and Ravani, 2000). It has been argued that TGF-(3 may be involved in this response by
acting to inhibit the growth of normal epithelial cells while encouraging the growth of
TGF-(3 insensitive tumorigenic cells. This stands in stark contrast to the inherent notion
that TGF-P acts to stimulate endothelial cell proliferation (Schreiber et al, 1986) and that
radiation subsequently reduces the secretion of angiogenic promoting compounds in the
TBE.
The immune system and cancer
Immune surveillance
The concept of immune surveillance was postulated to underscore the role of the
immune system in the prevention of cancer growth (Ehrlich, 1909). Although the concept
of immune surveillance remains controversial, there is now considerable evidence
supporting a role for T lymphocytes, NK cells, monocyte-macrophages, and neutrophils
in eradicating malignant cells through apoptosis and/or cytolysis (Flescher et al, 1984;
Hellstrom and Hellstrom, 1998; Lichtenstein, 1986; Melder et al, 1993). In conjunction
with this idea, tumor incidence and progression are enhanced when the immune system is
compromised, as observed in patients suffering from AIDS or severe combined
immunodeficiency disease (Martinez-Maza et al, 1998; Murray et al, 1997).
T cytotoxic (CD8+) cells
T cytotoxic (Tc) cells, distinguished by the CDS marker, are the effector arm of
cell-mediated, acquired immunity. Activation of Tc cells occurs through recognition of
specific peptides, presented within the groove of major histocompatibility complex
(MHC) class I molecules, by the T cell receptor (TCR). Tc cells can identify intracellular
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infection in a ubiquitous manner because MHC class I molecules are expressed on
virtually all nucleated cells. TCR binding in conjuction with other positive signaling
induces the release of lytic mediators and cytokines to eliminate neoplastic, virus-infected
cells, and otherwise aberrant cells.
Conflicting results have been documented in describing the role of T cells in
tumor surveillance and therapy. Activation of T cells with the combination of anti-CD3
monoclonal antibody (mAb) + IL-2 was shown to rapidly expand cultures of cytolytic
cells possessing in vivo antitumor efficacy (Anderson et al., 1989). Non-MHC restricted
cytotoxic T lymphocytes, activated NK cells, and cytokine-activated killer cells were all
found to be activated by anti-CD3 (Hoskin et al, 1989). Further, the depletion of CD8+
cells within animal models has been shown to result in enhanced tumor growth while
adoptive transfer of antitumor CD8+ T cells can delay tumor progression (Barth et al,
1991; Svane et al, 1999). Nevertheless, infiltration of Tc cells alone is not sufficient to
elicit tumor regression but appears to depend upon contribution by CD4+ cells and other
mediators (Matsui et al, 1999). Added to this, it has been difficult to determine whether
antitumor efficacy is related to the ability of Tc cells to lyse tumor cells or their ability to
secrete cytokines at the tumor site (Kemp and Ronchese, 2001).
In theory, Tc cells respond to tumor-associated antigens presented within MHC
class I molecules and initiate cell death. Tc killing of tumor targets can occur as a result
of the engagement of perforin, Fas ligand, or TNF-a. The latter two molecules induce
apoptosis in cells expressing corresponding receptors. Also, the production of growth
suppressing factors, like TNF-a and IFN-y, is another means of tumor control by CD8+ T
cells (Prevost-Blondel et al, 2000).
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Several guidelines seem to function in regulating Tc tumor immunity. First,
tumor-associated antigens may be insufficient as epitopes to elicit tumor rejection by
CD8+ T cells, as in the case of MUT1 and MUT2 in the Lewis Lung carcinoma model
(Mandelboim et al, 1994). Second, co-stimulatory signals via CD28 and CD40 can
override inhibitory signals, causing lymphocyte proliferation as well as the production of
TNF and IFN-y (Hellstrom et al, 2001). It appears that IFN-y makes an important
contribution to the antitumor effect mediated by Tc cells, whereas the production of type
II cytokines, including IL-4 and IL-5, seems to be less critical (Kemp and Ronchese,
2001; Matsui et al, 1999). Finally, differentiation and specificity of Tc populations may
be important. A particular T cell subset, expressing y/5 TCR, has shown stronger
antitumor cytotoxicity against a rat sarcoma than T cells with the classical a/p TCR
(Ericsson et al, 1991). But some contradiction surrounds the role of these y/5 T cells.
Some researchers have concluded that a cytotoxic T lymphocyte (CTL)-inhibitory factor
is secreted by y/5 T cells and this factor facilitates the escape of tumor cells from tumorspecific T lymphocytes, whereas others have surmised that y/5 T cells are rarely found in
lung tumor infiltrates (Fajac et al, 1992; Seo and Egawa, 1995). This is contrasted
distinctly with other data which showed that y/5 T cells isolated from lung tumor
infiltrates were capable of killing autologous tumor cells (Zocchi et al, 1990). This latter
finding correlates well with several studies implicating the upregulation/proliferation of
these cells against pancreatic and renal cancers (Kitayama et al, 1993; Kowalczyk et al.
1996). Lastly, y/5 T cells may also function to prime macrophages by the secretion of
TNF-a (Nishimura et al, 1995).
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T helper (CD4+) cells
The concept of intracellular communication and cross-talk within the immune
system is never more central than when discussing the role of T helper (Th) cells. Th
cells coordinate virtually all antigen-specific immune responses through the secretion of
cytokines and as a result can control a wide variety of cellular functions including
activation, cytolytic capability, and differentiation. CD4+ cells can be divided into two
distinct subsets based upon cytokine profile. Thl (T helper 1) cells, which promote cellmediated immunity, are distinguished by producing IL-2 and IFN-y, as well as other
factors. Th2 cells, on the other hand, produce cytokines such as IL-4, IL-5, and IL-10
which in turn play a key role in humoral immunity. As part of the acquired branch of the
immune system, Th cells are activated by the recognition of foreign antigens presented
within an MHC class II context. Priming of Th cells occurs upon an interaction, between
the T cell receptor and antigen bound within MHC class II molecules, of sufficient
affinity. Priming of T helpers facilitates the production and secretion of cytokines, which
tailor the nature of the immune response.
The participation of CD4+ cells in antitumor responses has largely been ignored
because of the ability of CD8+ cells to mediate direct tumor cell killing in contrast with
the MHC Class II restricted activity of Th cells. Tumor cells as a rule are positive for
MHC class I molecules and negative for MHC class II expression, although some studies
have shown certain tumors can express mutated forms of MHC class I molecules or even
be entirely deficient of these products (Pardoll and Topalian, 1998). Based on the lack of
MHC class II molecules, Th antitumor response would appear to be of secondary
importance. However, recent experiments, including those involving CD4+ knockout
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and depletion models, have elicited a greater interest in the role of CD4+ T cells in
immune surveillance (Pardoll and Topalian, 1998). It is now well accepted in tumor
immunology that CD4+ cells play a role in cross-priming tumor-specific CTLs (cytotoxic
T lymphocytes) as a result of interactions between CD40 ligand with CD40 and CD28
with B7 on CD4+ T cells and antigen-presenting cells (APCs) respectively (Figure 1.3).
This stimulus is capable of activating APCs, which can then present antigens to and
stimulate CTLs (Hung et al, 1998; Pardoll and Topalian, 1998; Ridge et al., 1998).
Other researchers have found that while cross-priming of CTLs can occur independently
of CD4+ cells, Th cells are critical for complete tumor rejection, long term memory
protection, CD8+ population maintenance, and tumor infiltration (Hu et al., 2000; Marzo
et al, 2000). Beyond this, Th cells, which are specific for tumor antigens, can induce
tumor destruction independently of CD8+ T cells by activating macrophages (Hung et al.
1998). The activation of macrophages in combination with the production of nitric oxide
and superoxide, as well as the recruitment and activation of eosinophils, can achieve a
significant antitumor effect (Hung et al., 1998). Thl and Th2 cells are able to confer a
distinct response as Thl cytokines, especially IFN-y, can activate macrophages resulting
in the release of reactive oxygen intermediates whereas Th2 cytokines induce eosinophils
to release granule contents. The difference between Thl and Th2 involvement in tumor
eradication has been observed in other models.

In an ovalbumin transgenic system,

tumor-specific Thl cells induced a marked lymphocyte infiltration into tumor resulting in
eradication via cellular immunity. Cell adhesion interactions, including the expression of
P-selectin, appear to facilitate immune cell migration (Nishimura et al., 1999).

In

contrast, Th2 cells can coordinate an inflammatory response at the tumor site through the
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secretion of IL-4, leading to tumor necrosis. Inflammation can involve both neutrophil
and eosinophil reactivity to tumor. Interestingly, both arms of the Th response may rely
upon CD8+ T cell reactivity to tumor through communication by IFN-y and other
cytokines (Nishimura et al, 1999). Taken together, CD4+ T cells do play a pivotal role
in mediating tumor rejection and maintaining protective memory.
B cells
Th2 driven responses elicit the involvement of humoral immunity. In this regard,
B lymphocytes participate in host defense by synthesizing antibody against infectious and
other immunogenic agents. Antibodies or immunoglobulins, which consist of five
different classes, bind unique epitopes on the surface of macromolecules.

Antigenic

stimulation of membrane-bound immunoglobulins expressed by B lymphocytes leads to
cell division and differentiation into memory cells, lymphoblasts, and plasma cells
(Cruse, 1999). Secreted antibodies from plasma cells can serve to neutralize the function
of bound macromolecules, activate complement upon crosslinking, generate cytolysis of
target cells through antibody-dependent cell-mediated cytotoxicity (ADCC), and
stimulate clearance by phagocytes.
B cells have a relatively low profile in antitumor immunity compared with other
lymphocytes. However, some cancer therapies have sequestered the use of monoclonal
antibodies against a cancer cell epitope found on Her-2/neu, a growth factor receptor
overexpressed by aggressive breast cancers, as well as certain other, malignant types.
Attachment of antibodies to antigens on tumor targets can induce complement activation
and binding, trigger ADCC by macrophages and NK cells, and initiate apoptosis or
growth arrest (Cragg et al, 1999). Yet there is some indication that the production of
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tumor-specific antibodies by activated B cells can in some cases protect the tumor from
cytolysis by preventing recognition by potential effector cells, resulting in enhanced
tumor growth (Taitz et al., 1995). Furthermore, the antibody coating tumor cells may be
of the IgG4 subclass that is incapable of activating complement or mediating ADCC (i.e.,
"blocking antibody"). For these reasons, the contribution of B lymphocytes to antitumor
immunity has not been clearly established and appears to be quite variable.
NK and NKT Cells
Natural killer cells are a class of lymphocytes involved in both innate immunity
and tumor surveillance. These large granular lymphocytes were first termed “natural”
killers because of their inherent ability to lyse leukemia cells (Kiessling et al, 1975a;
Kiessling et al, 1975b). Subsets of NK cells are currently identified by the NK1.1,
PanNK, and asialo GM1 markers in mice, although substantial overlap exists in the
expression of these markers. NK cells are a unique lymphocyte subset because they do
not require prior presentation of antigen in an MHC context before activation against
targets such as virally-infected cells and neoplastic cells. Although NK cells are not MF1C
restricted according to the classical understanding, they possess a variety of receptors
which are capable of influencing cytolytic activity through signaling mechanisms. The
Ly49 proteins impose a type of MHC restriction upon NK cells because recognition of
MHC molecules by Ly49 receptors can induce NK tolerance (Miller, 2001). Inhibitory
receptors, including Ly49, CD94, and KIR (killer inhibitory receptor) families, recruit
specific phosphatases (e.g. SHP1) to prevent the lytic process following interaction with
MHC class I molecules on target cells (Eriksson et al, 1999). It has been shown that a
downregulation of MHC class I molecules incurs a susceptibility of transformed or
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infected cells to NK cell lysis (Lanier et al, 1997; Raulet and Held, 1995). NK cell
expression of inhibitory receptors depends upon the MHC class I environment in which
the NK cell matures although receptor expression is not permanently fixed during
maturation but rather is adapted to MHC class I changes on surrounding cells (Kase et
al, 1998; Khoo et al, 1998). Conversely, 2B4, NKp46, NKp44, NKp30, and NKG2D
have been identified as activating receptors (Cantoni et al, 1999; Diefenbach et al, 2000;
Nakajima et al, 1999; Pende et al, 1999). Ligands to these activating receptors, which
can be upregulated on numerous tumor cells, serve as potent stimulators of NK cells
(Diefenbach et al, 2000; Nakajima et al, 1999). As depicted in Figure 1.4, natural killers
can also be activated nonspecifically by numerous cytokines including IL-2, IL-12, IL-15
and IL-18 (Camaud et al, 1999; Perussia, 1996).
Upon activation, NK cells lyse targets through a variety of mechanisms similar to
those utilized in T-cell mediated cytotoxicity. NK cells can respond to stimulation by
releasing granules containing perforin, which is able to punch pores into the cytoplasmic
membrane of target cells (Podack, 1995).

Additionally, granules may contain

proteinases, such as granzymes A and B, which activate apoptosis (Seaman, 2000).
Although perforin mediated pathways account for the majority of natural killing in
experimental settings, NK cells can also induce apoptosis through the attachment of Fas
ligand as well as through the expression of TNF-related apoptosis inducing ligand
(TRAIL) or membrane-bound TNF-ot (Bossi and Griffiths, 1999; Seaman, 2000).

A

final killing mechanism is ADCC which involves the attachment of NK cells to the Fc
portion of IgG that has become attached to the surface of a target cell. Besides their
cytolytic capability, NK cells are able to amend the immune response through the
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Figure 1.4. Natural killer cell cytotoxicity against tumor targets. Non-specific activation
of NK cells can occur via numerous cytokines resulting in the upregulation of Fc
receptors and/or killer-activating receptors. Expression of ligands and subsequent
recognition by NK cell receptors results in the release of cytotoxic substances including
perforin as well as granzymes A and B. Release of granular contents leads to tumor cell
destruction.
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secretion of diverse cytokines including TNF and IFN-y (Carson et al., 1999).

The

release and synthesis of IFN-y can strongly enhance the function of macrophages against
foreign cells, as well as mediate the differentiation of the Thl subset (Tomura et al.
1999).
Research over the past 20 years, has provided a growing body of evidence for the
role of NK cells in tumor rejection. While NK cells have been known to participate in the
innate immune response against transformed cells in vivo, they can also mediate
spontaneous cytotoxicity against MHC class I-deficient tumor cells and their metastases
(Smyth et al, 2000; Talmadge et al, 1980; Trinchieri, 1989). In vivo depletion of NK
cells by administration of anti-NKl.l has been shown to enhance the progression of
implanted tumor cells in animals (Seaman et al, 1987). Conversely, the blockade of
several NK inhibitory receptors, including Ly49C and I, can augment antitumor effects
against leukemia (Koh et al, 2001). Smyth and colleagues have demonstrated that NK
cell-mediated tumor rejection does not require the involvement of NKT cells.
NKT cells are a distinct subset characterized by the dual expression of the NK1.1
marker and the TCRa/p receptor (T cell receptor) (Smyth et al, 2000). NKT cells can
mediate tumor rejection without participation by NK or conventional T cells as
demonstrated in a number of tumor models (FBL-3, B16, and LLC) (Cui et al, 1997). IL12 induction of NKT cells is critical for this response. The elicitation of certain antitumor
defenses may also depend upon CD1.1 activation of NKT cells (Burdin et al, 1998;
Kawano et al, 1998). The experimental evidence for tumor surveillance by NK cells
suggests some interplay with NKT cells. NKT cells can stimulate NK cells through IFNy secretion; and subsequent transactivation can occur quite rapidly following a-
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galactoceramide (a-GalCer) induction of NKT cells (Camaud et al, 1999). Additionally,
since NKT cells can also produce IL-4, these cells are able to control both arms of the T
cell mediated response after interaction with APCs (Tomura et al, 1999). The relative
contribution of NK and NKT cells to target destruction may depend upon tumor type
among other factors as demonstrated by the effect of both timing and dose of IL-12
administration (Smyth et al, 2000; Soloski, 2001).
Neutrophils
Neutrophils constitute not only the vast majority of granulocytes in circulation but
also the largest sub-population of leukocytes in the blood. These phagocytes have a
characteristic multi-lobed nucleus and thus are often referred to as polymorphonuclear
neutrophils (PMNs).

PMNs maintain a critical role in immunity as the first line of

defense against bacterial infection and also act as potent effectors of inflammation (Di
Carlo et al, 2001). They are able to release soluble chemotactic factors and proteases
which can alter the microenvironment and recruit both specific and nonspecific immune
responders. Data evaluating the involvement of neutrophils in tumor rejection have led to
varied conclusions. Under some conditions, elimination of granulocyte infiltration into
tumor has resulted in the inhibition of tumor growth (Pekarek et al, 1995).
Corresponding to this, activated inflammatory cells, including neutrophils, can stimulate
the progression of epithelial cells, the remodeling of extracellular matrix, and the
promotion of angiogenesis. Such alterations can destabilize epithelial cells and thereby
provide a microenvironment that is conducive for malignant transformation and/or
promoting metastatic spread (Coussens and Werb, 2001). In contrast, some researchers
have noted that PMNs may be an ideal weapon against cancer by facilitating the
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suppression of tumor growth and rejection through T-cell memory reactions. The ability
of PMNs to respond to and secrete cytokines involves them in cross-talk with antitumor
effector populations (Colombo et al, 1992; Di Carlo et ai, 2001). In addition, PMNs
produce several cytotoxic mediators, which can faciliate tumor destruction, including
reactive oxygen species, proteases, membrane-perforating agents and other soluble
mediators of cell killing, such as TNF-oc, IL-ip, and interferons (Di Carlo et al, 2001).
Macrophages/Monocytes
Macrophages are another phagocytic arm of the immune system, but are distinct
from neutrophils in that they are able to persist long-term in tissues and function by
engulfing infectious agents and particles, internalizing these particles, and eventually
destroying them (Roitt, 1998). Monocytes perform similar functions and play a role in
supplementing macrophage populations because they migrate into tissues and mature into
macrophages. Monocytes are also phagocytic and do play a role in antigen processing
and presentation. Nevertheless, macrophages are the principal source of cytokines
potentiating innate immunity (Abbas and Lichtman, 2001).
The tumoricidal activity of macrophages may involve several mechanisms.
Firstly, macrophages can mediate direct tumor lysis through the secretion of TNFoc,
which can be toxic to cells expressing high affinity TNF receptors. Furthermore, TNFoc
can prefemtially act on tumor vasculature leading to hemorrhagic necrosis (Cruse, 1999).
Activated macrophages may participate in ADCC through the expression of Fey receptors
which are able to anchor tumor-specific antibodies. Triggering of ADCC results in the
release of degradative lysosomal enzymes and reactive oxygen intermediates that lyse
tumor cells. Macrophages can also participate indirectly in tumor rejection by degrading
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both protein and polysaccharide antigens and presenting processed peptides in the groove
of MHC class I and/or II molecules, thus eliciting an acquired immune response
involving T and B lymphocytes (Cruse, 1999). Finally, macrophages may modulate the
tumor microenvironment through the secretion of varied cytokines and chemokines. The
release of both IL-12 and IFN-y by macrophages appears to serve as one means of Thelper 1 (Thl) induction (Wang et al, 1999).
While these are effective strategies for tumor eradication, cancer cells may resist
lysis by altering their microenvironment in order to prevent the host from mounting a
successful immune response. This process can involve the recruitment of macrophages to
aid in providing a pro-tumorigenic environment. Macrophages are capable of secreting
sufficient amounts of prostaglandin E2, TGF-(3, IL-10, and other immunosuppressive
agents to curb Thl or alternative defense responses (Sica et al, 2000; Young et al.
1986). Tumor-induced macrophages can also demonstrate tumor cell growth-promoting
abilities including the production of growth factors like L-arginine-derived polyamines
(Elgert et al, 1998). Besides assisting in growth, macrophages can potentially stimulate
every phase of angiogenic progression (Sunderkotter et al, 1994). It has been established
that solid tumors will rapidly die without macrophages to facilitate the growth and
development of tumor-sustaining blood vessels, which provides some explanation as to
why macrophages can sometimes contribute to over a half of a tumor’s mass
(Sunderkotter et al, 1994). While macrophages may directly augment tumor growth,
there is substantial evidence that tumor-derived molecules actually manipulate
macrophage activities in order to orient them toward fostering tumor development.
Tumor-derived molecules, including IL-4, IL-6, IL-10, TGF-|3, M-CSF (Macrophage-
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colony stimulating factor) among others, can potentially activate tumor-peripheral resting
macrophages and down-regulate in situ activated macrophages (Elgert et al., 1998).
Down-regulation can suppress cytotoxic activity as well as inhibit the production of
macrophage-derived molecules, which are required for lysis of spontaneous tumors.
Because of the interplay of macrophage-derived cytotoxic molecules in prompting an
immune response, it has been suggested that the inhibition of only one type of cytotoxic
molecule may be sufficient for the tumor to escape lysis (Wallace et al, 1994). Tumors
may also act to limit macrophage synthesis of immunostimulatory molecules (especially
IL-12), shift macrophage subpopulations toward those with suppressor phenotypes, and
induce macrophages to suppress lymphoproliferation through the production of
proinflammatory and cytotoxic cytokines including TGF-P and IL-10 (Gamer et al.
1987; Sica et al, 2000).
Significance of the study
This study seeks to better understand the various mechanisms by which total-body
irradiation can reduce tumor progression. The research is unique within our laboratory
because it emphasizes the impact of exposure on tumor challenge when the total-body
irradiation occurs prior to tumor implantation. As a consequence, the direct effect of
radiation upon the host and its immune system is targeted rather than the direct effect of
radiation upon tumor cell survival. Several studies within Dr. Gridley’s laboratory have
evaluated radiation-induced modulation of the immune system but under a different set of
conditions. The effect of whole-body irradiation has been described with subsequent
challenge using LPS and a viral antigen. These studies, which were initiated after the
studies described in this dissertation, do not account for tumor immunity mechanisms.
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Other experimental protocols have evaluated the effects of radiation on varied cancer
models in conjunction with other therapeutic modalities including plasmid vectors for
TNF-a and Bax. Under past and current protocols, the studies have not involved the use
of total-body irradiation. Because this study seeks to clarify the role of radiation in a
lung cancer model, the data provide an important assessment of potential factors that
could be augmented for the prevention of primary tumor growth and metastasis. Also,
since whole-body irradiation of large body areas can occur in occupational settings and
may be used for cancer therapy, it is imperative to evaluate the effects of sublethal
irradiation to immune system parameters.

More significantly, because much is still

unknown about the immunobiology of TBI, its clinical potential and possible synergism
with chemotherapy, biological response modifiers, or immunotherapy have yet to be fully
realized. This lack of comprehensive knowledge restricts the optimal and extensive use
of this intriguing and potentially useful treatment modality in clinical protocols (Safwat,
2000). These findings serve to further the body of knowledge within radiation oncology
as they seek to clarify the role of NK and T cytotoxic cells in antitumor effects.
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CHAPTER TWO
MATERIALS AND METHODS
Animals
Male C57BL/6 mice were purchased from Charles River Breeding Laboratories,
Inc. (Hollister, CA) at 8-9 weeks of age unless otherwise specified. Mice were
acclimatized for a period of one to two weeks prior to testing.

The animals were

maintained in self-contained filter-top cages (maximum of 8 mice per cage) in our
Animal Care Facility controlled for temperature, humidity, and a 12:12 hr lighfdark
cycle. Standard rodent food (Purina Lab Chow) and water were provided ad libitum.
Mice were observed at least three times weekly for signs of toxicity (lethargy, bloating.
and ruffling of fur) following irradiation.

Mice were euthanized humanely by rapid

asphyxiation in 100% CO2 in compliance with the American Veterinary Medical Panel
on Euthanasia. All animal care is under the direction of a licensed veterinarian, and all
studies involving animals received prior approval from the Institutional Animal Care and
Use Committee of Loma Linda University.
External beam irradiation
In experiments performed to determine the effects of time and TBI, independent
of localized irradiation, each mouse was placed individually into a rectangular plastic box
(3 cm x 3 cm x 8.5 cm) and up to 8 animals were irradiated simultaneously. The walls of
the boxes were 1 mm thick and a series of holes provided ample air for respiration. A
total-body dose, 3 Gray (Gy) of photons, was delivered by a 60Cobalt (60Co) source. The
vertical beam was adjusted to project to a 20 x 20 cm field size, 80 cm from the radiation
source.
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For experiments comparing the effects of localized radiation and experiments in
which portions of the animal body were shielded from radiation, anesthetic was given
prior to exposure. Mice were anesthetized by intraperitoneal (i.p.) injection of a low-dose
xylazine (5.2 mg/kg) and ketamine (80 mg/kg) combination. Anesthetic was given to all
mice, regardless of treatment group, in order to equalize any effects due to stress. The
utilized irradiation field size was maintained at 20 x 20 cm. The leg was held inside
(localized irradiation groups) or outside (shielded leg irradiation groups) the field using
masking tape (Figures 2.1 and 2.2); and the body mass outside of the radiation field was
protected by a 3-inch Lipowitz metal alloy block. The leg (localized irradiation groups)
and body (shielded leg irradiation and TBI groups) were covered with a bolus
(‘superflab’) of 0.5 cm thickness. Total doses in these experiments ranged from 0.46 Gy
to 3.0 Gy of gamma (y) irradiation.
All irradiations were performed using a retired AECL Eldorado therapy unit
(Atomic Energy of Canada, Ltd., Commercial Products Division, Ottawa, Canada)
located in the Animal Care Facility in the Loma Linda University Medical Center. The
Eldorado unit was calibrated using a Capintec Model Pro6-G cylindrical thimble
ionization chamber, traceable to the National Institute of Standards and Technology
(NIST). Exposure time and subsequent total doses were determined by the following
equations: 1) Dose rate = OP (Output factor; corrects for decreasing output of source as a
function of half life) x T.A.R. (Tissue to air ratio; corrects for radiation scattered off the
air between target and sample) x Sc (Collimator scatter factor; corrects for radiation
scattered off depleted uranium collimator jaws) x T.F. (Tray Factor; corrects for specialty
collimators) x O.A.R. (Off Axis Ratio; corrects for the attenuation of the beam based on
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Figure 2.1. Total-body irradiation (TBI) versus out of field irradiation (leg shielded). The
rectangular area designates the radiation field.
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Figure 2.2. Total-body irradiation (TBI) versus localized irradiation (leg only). The
rectangular area designates the radiation field.
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divergence from the center) x B.D.F. (Beam divergence factor; correction for source
2

(1/r ) intensity based on the isocenter of 80 cm) and 2) Exposure time = desired dose/
dose rate.
Tumor cells and tumor induction
The Lewis Lung Carcinoma (LLC) cell line is hypotetraploid with modal
chromosome number 72 (Dus et ai, 1985). Syngeneic to C57BL mice, LLC cells can
metastasize to the lungs of these mice following subcutaneous implantation, consequently
allowing for the assessment of both primary and metastatic tumor growth. The metastatic
potential of the cell line varies by clone according to the expression of a diverse array of
cell markers. This potential is dependent upon the expression of c-jun, c-fos, TP53, and
the transforming growth factor-(31 (TGF-pi) gene (Narumi et al, 1993; Perrotti et al.
1991; Rizzo et al, 1993; Yamit-Hezi et al, 1994).

The expression of cell surface

markers that are correlated with metastases from the site of the primary tumor, enable
homing of tumor-specific effectors and negative regulatory T cells (Gelber et al, 1992).
LLC were obtained from two sources: the laboratory of Beverly Teicher, Ph.D.
and Gulshan Ara, Ph.D (Dana Farber Cancer Institute, Boston, MA) and the American
Type Culture Collection (ATCC, Rockville, MD). LLC cells were cultured in Dulbecco’s
minimal essential medium (DMEM) (Irvine Scientific, Santa Ana, CA) supplemented
with 10% fetal calf serum (FCS) (Hyclone Laboratories, Logan, Utah), penicillin at 100
units/ml and streptomycin at 100 pg/ml (Gibco BRL, Grand Island, NY). The cells were
incubated at 37° C in 5% CO2 until near-confluency, harvested with lx trypsin solution,
washed, and passaged.

42

In several studies, mice were injected with LLC maintained by in vivo passage.
Tumors growing subcutaneously (s.c.) were harvested from maintenance mice, processed
into a slurry, counted, diluted in sterile PBS and injected s.c. (~lxl06 cells/mouse in a
volume of 0.1 ml) into the right hind flank of mice to be used in experiments. In other
studies, mice were injected with cultured LLC cells. In this procedure, LLC cells were
harvested, counted using the trypan blue exclusion method, and adjusted to the
appropriate concentration in sterile PBS. Tumor cells were also injected s.c. into the right
hind flank (IxlO6 cells/mouse/0.1ml). Tumor dimensions were measured with vernier
calipers and volumes were calculated: tumor volume (mm3) = (H x W x L)/2, where H =
height, W = width, and L = length of the tumor.
Hybridoma maintenance and antibody isolation
The PK136 hybridoma, a mouse B cell myeloma, secretes a mouse monoclonal
antibody (IgG2a) that reacts with mouse NK cells. The cell line was produced by fusing
Sp2/0-Agl4 myeloma cells with spleen cells from (C3H x BALB/c)Fl mice that had
been immunized with bone marrow and spleen cells from CE mice. The PK136
hybridoma was obtained from ATCC and cultured in Hybri-care medium (ATCC)
supplemented with 10% PCS, penicillin-streptomycin, and sodium bicarbonate (J.T.
Baker Chemical Co., Phillipsburg, NJ). PK136 cells were weaned from serum after two
passages by culturing in EX-CELL™ 620 HSF (JRH Biosciences, Lenexa, KS) with 5%
FCS, sodium bicarbonate, and 2mM L-glutamine (Cellgro Mediatech, Herndon, VA).
After expansion and two passages in 5% serum, cells were centrifuged at 1000 rpm (<200
g) for 5 min. Cells were counted by trypan blue exclusion and the cell density was
adjusted to 2-5xl05 viable cells/ml in cultured in EX-CELL™ 620 HSF without FCS.
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These cells were grown in 150 cm2 culture flasks at a volume of 50 ml. Flasks were
placed in a humidified 37° C, 5% CO2 incubator until cells were overgrown, i.e. the
medium became acidic and the cells died (~7 days). The flask contents were transferred
into sterile 50 ml falcon tubes, centrifuged for 10 min at 3000 rpm (2000 g).

The

supernatant was collected and filtered (20 jum filter, Nalgene, Rochester, New York).
To isolate immunoglobulins from the serum-free supernatant, the supernatant was
passed through a Sepharose G 4 fast flow 25 ml column (Amersham Pharmacia,
Piscataway, NJ) overnight at a flow rate of 2 ml per minute. Prior to passing through the
column, the supernatant was supplemented with Tris buffer and azide to a final
concentration of 100 mM Tris and 0.05% azide (pH = 8). Following this, PBS was used
to extend the medium through the column. After attaching to an alternate peristaltic
pump, the column was reversed and first washed with PBS for approximately five
column volumes following the unbound protein spike (flow rate of 5 ml per minute for 25
min). During this time the wash was evaluated by UV detection to observe the elution of
unbound proteins (as determined by a small spike in gain above baseline). Glycine (0.1M,
pH=3.0) was used for the elution buffer of bound protein for approximately 12 min at a
flow rate of 2.5 ml per min. A significant spike for bound protein was observed and
elution was terminated when the spike diminished. Bound protein was obtained in 30 ml
of elution buffer. The pH was immediately adjusted to approximately 7, as tested by
litmus strips, using several drops of 1M Tris buffer. Protein content in the sample was
estimated using 250 pi of Coomassie Protein Assay Reagent (Pierce, Rockford, IL) and 5
pi of standards (ranging from 0.5 mg/ml to 2.0 mg/ml) or sample. Initial protein content
was determined to be above 1 mg/ml. The protein was concentrated and washed by using
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Centriprep-50 centrifugal concentrators (Amicon Inc., Beverly, MA). Traces of glycerin
were removed from the concentrators by dipping in pyrogen-free water. The sample (30
ml) was equally distributed amongst four concentrators and centrifuged at 2500 rpm
(1250 g) for 10 min. Afterwards, excess liquid was removed and the concentrated protein
was washed three times in PBS by filling up to maximum mark and centrifuging at 2500
rpm (1250 g) twice and then re-washing after discarding the excess (total of 7
centrifugations and 3 washes). The volume of the sample was brought up to 31 ml with
PBS. The protein concentration in the sample was determined by the Coomassie Protein
Assay as before, but read with an ELISA plate reader. Concentration was determined to
be 2 mg/ml. The sample was filtered with a pyrogen-free 0.2 pm filter and stored in 1 ml
aliquots in a -20°C freezer. This procedure was performed several times in order to
obtain enough antibody for in vivo testing. In the final purifications, a Sepharose A
column was substituted for the Sepharose G 4 fast flow 25 ml column. This column
allowed elution with citrate (pH = 5.0) while still retaining specificity for mouse IgG2a
antibodies.
Relative spleen weight values, lysed and unlysed spleen preparation
Spleens were excised from euthanized mice and weighed. Relative spleen weight
(RSW) values were calculated as follows: RSW = (spleen weight (g) x 104)

-h

body

weight (g). Each spleen was then placed in a labeled 12 x 75mm polystyrene tube in a
total volume of 2 ml LTT medium directly after weight measurement. LTT medium
consisted of RPMI 1640 (Irvine Scientific, Santa Ana, CA) supplemented with 10% heat
inactivated PCS, penicillin-streptomycin, hepes buffer (Cellgro), and (3-mercaptoethanol
(Sigma, St. Louis, MO). Spleens were mashed using autoclaved wood applicator sticks to
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yield a single cell suspension. Mashed spleens were then filtered into petri dishes using
40 pm cell strainers (Becton Dickenson, Franklin Lakes, New Jersey). The remaining
contents of tubes were rinsed with 1 ml of LTT medium and filtered into the same petri
dish. Leukocytes in aliquots of unlysed spleen suspensions (-250 pi) were counted using
the Vet ABC-Diff Hematology Analyzer (HESKA Corporation, Waukesha, WI). The
remaining unlysed samples were centrifuged at 1,500 rpm (200 g) for 5 min, and the
supernatant was discarded. Cold ACK lysing buffer (0.1 M KHCO3/O.I54 M
NH4CL/O.OI mM EDTA) was added at 2 ml and tubes were incubated at 4° C for 5 min
to lyse the erythrocytes. The remaining leukocytes were washed with LTT medium,
centrifuged twice and finally resuspended in 2ml of LTT medium. The cells were then
counted and dilutions were made to give a final concentration of 2x106 cells/ml.
Peripheral blood collection and hematological analyses of blood and spleen
Whole blood was collected in EDTA-containing tuberculin syringes by cardiac
puncture immediately following euthanasia of mice. Samples of whole blood, unlysed
spleen, and lysed spleen (12 pi) were evaluated using the Vet-Diff Hematology Analyzer
which was initially programmed to analyze dog blood, but only thrombocyte counts
required adjustment for the mouse. Unlysed and lysed spleen samples were subject to
dilution. The measurements included white blood cell count (WBC; 106/ml), red blood
cell count (RBC; 109/ml), hemoglobin concentration (HGB; g/dl), hematocrit levels
(HCT; percent volume of whole blood composed of RBC), mean corpuscular volume
(MCV; average volume per RBC; fl), mean corpuscular hemoglobin (MCH; amount of
hemoglobin in an average RBC; pg), mean corpuscular hemoglobin concentration
(MCHC; the concentration of hemoglobin in the RBC component of the blood; g/dl), red
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blood cell distribution width (RDW), mean platelet volume (MPV; fl), and platelet counts
(PLT;

106/ml).

A

3-part

differential

count

for

leukocytes

(lymphocytes,

monocyte/macrophages and granulocytes) was also determined. After an updated version
of the mouse programming card became available from HESKA Corp., eosinophil counts
(106/ml), RDW (red blood cell distribution width) and MPV (mean platelet volume) were
also included.

The underlying principle of the instrument is based on electrical

impedence, a process whereby individual cells are passed through microscopic apertures
for counting and sizing. Electrodes maintain an electrical current across the aperture
opening. Cell-free reagent conducts the current easily, but when a cell passes through the
opening, it acts as an insulator, causes resistance to the flow of current, and produces a
spike in voltage that is interpreted by the analyzer as a cell. The size of the voltage spike
is proportional to the size of the cell passing through the aperture, as defined by Ohm’s
law (U = R x I, where U = voltage, R = resistance and I = current).
Spontaneous blastogenesis of blood and spleen leukocytes
The sequence of plate design for the 96-well plates was recorded to trace the order
of different samples for later analysis. Aliquots (50pl) of whole blood and spleen
leukocyte suspensions standardized for cell number were mixed with 150 pi of LTT
medium. [3H]-TdR was added at lpCi/50pl/well.

The samples were dispensed in

triplicate into flat-bottomed wells of 96-well microculture plates and incubated for 3 hr at
37° C in a humidified atmosphere containing 5% CO2. After incubation, cells were
harvested onto fdters using a Tomtec multiple sample harvester and the amount of [3H]TdR incorporated into cell DNA was counted in the Wallac beta scintillation counter.
The leukocyte counts/ml and volume (50pl) of tested blood and spleen were used to
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convert the raw counts per minute (cpm) into cpm/106 leukocytes. Spontaneous
blastogenesis was standardized by the following formula: cpm/106 cells = (averaged cpm
for triplicate wells x 20)/(WBC count from hematology analyzer x dilution factor [if
any]).
PHA-stimulated spleen supernatant
The sequence of plate design for the 96-well plates was recorded to trace the order
of different samples. The first six wells of each row were filled with 100 pi of pre-titrated
phytohemagglutinin (PHA; Sigma) diluted in LTT medium and the proceeding three
wells were aliquoted with 100 pi of LTT medium alone. Aliquots (100 pi) of spleen
leukocyte cell suspensions (2x106 cells/ml) were dispensed into each row such that each
sample was designated to a certain row. The plates were then incubated at 37° C in 5%
CO2 for two days. After two days, stimulated and unstimulated cell supernatants were
collected, aliquoted and stored frozen for later analysis of cytokines.
Mitogen-induced splenocyte proliferation
The sequence of plate design for the 96-well plates was recorded to trace the order
of different samples. Aliquots (100 pi) of each cell suspension (2xl06 cells/ml) were
dispensed in triplicate into flat-bottom wells of 96-well microtiter plates and cultured
with 100 pi of PHA, concanavalin A (ConA), lipopolysaccharide (LPS; E. coli serotype
0111 :B4), or medium alone. All mitogens were purchased from Sigma Chemical Co. and
pre-titrated for maximal response. The plates were incubated at 37° C in 5% CO2 for two
days. During the last 4 hr of incubation, [ H]-TdR (specific activity = 46 Ci/pmol; ICN
Radiochemicals, Costa Mesa, CA) was added at lpCi/50pl/well.

The cells were

harvested using a Tomtec multiple sample harvester, and the uptake of radioactivity
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(cpm) was quantified in the Wallac beta scintillation counter. Counts were standardized
to be expressed as a stimulation index (SI) as follows: SI = (cpm with mitogen - cpm
without mitogen) -r- cpm without mitogen.
Flow cytometry analysis of spleen and blood populations
Blood and spleen lymphocytes were directly stained with fluorescence-labeled
monoclonal antibodies (mAb) and measured by a FACSCalibur™ 4-channel dual laser
flow cytometer (Becton Dickinson, Inc., San Jose, CA). All mAbs, conjugated with
fluorescein isothiocyanate (FITC), R-phycoerythrin (PE), allophyocyanin (APC), or
peridinin chlorophyll protein (PerCP), were purchased from Pharmingen (San Diego,
CA). Subpopulations of lymphocytes were defined by multiparameter flow cytometry
using side scatter (SSC-cell granularity) versus CD45 (leukocyte common antigen) and
appropriate antibodies labeled with unique fluorochromes. The use of multiple antibodies
enabled single-antibody histogram analysis as well as resolution of distinct cell
populations. Tables 2.1 and 2.2 identify the cell markers that were used to delineate
leukocyte subsets and provide a brief description of the function of these cell types.
Lyse/No Wash Protocol
For this study, the mouse “Lyse/No Wash Staining Protocol” developed by
Pharmingen was used to assess lymphocyte populations within blood and spleen samples
(4-color, 2-tube preparation).

Pharmingen designed mAb specific for CD3+ T,

CD3+/CD4+ T helper (Th), CD3+/CD8+ T cytotoxic (Tc), B220+ B and NK1.1+ NK
cells in collaboration with Becton Dickinson for use by investigators in the Radiobiology
Program at Loma Linda University. Custom antibody conjugates consisted of the
following:
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Table 2.1. Cell markers used to distinguish between various leukocyte subsets.
Cell
Type

Cell
Marker

Specificity
of Cell Marker

Leukocytes

CD45

Leukocyte Common Antigen, also known as Ly-5

Macrophages

Mac-3

110-kDa antigen present on mononuclear phagocytes

Neutrophils

Ly-6G/C

Myeloid differentiation antigen

B cells

B220

B lymphocyte-lineage differentiation antigen

T cells (Tc and Th)

CD3

T cell receptor-associated CD3 complex

TCRP

Common epitope of |3 chain of TCR on o,p TCRexpressing T cells

T cytotoxic cells (Tc) CDS

Differentiation antigen on MHC class I restricted
T cells

T helper cells (Th)

CD4

Differentiation antigen on MHC class II restricted
T cells

NK cells

NK1.1

Type II integral protein encoded by NKR-P1 gene
family

Asialo-GMl Glycosphingolipid expressed on mouse NK
and some Tc cells
Activation Marker

CD25

IL-2 receptor

CD71

Transferrin receptor

CD: cluster of differentiation; TCR: T cell receptor; MHC: major histocompatibility
complex.
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Table 2.2. Lymphocyte function as designated by cell markers
Cell
Type

Cell
Marker

Distinction of
Cell Subset

Macrophages

Mac-3

Mononuclear phagocytic cells in tissues that also
function as Antigen Presenting Cells (APCs)

Neutrophils

Ly-6G/C

Phagocytic granulocytes within circulation, and one
of 1st lines of defense against infection

B cells

B220

Lymphocytes which secrete Ab and act as APCs

T cytotoxic cells (Tc) CDS

MHC-class I restricted thymocytes which exhibit
cytotoxic activity against virus-infected cells, tumor
cells, etc.

T helper cells (Th)

CD4

MHC-class II restricted thymocytes which
orchestrate immune response through secretion of
cytokines

NK cells

NK1.1

Non-MHC restricted granular lymphocytes

Asialo-GMl Non-MHC restricted granular lymphocytes, also
some Tc cells
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CD3 *FITC/CD8 *PE/CD45 *PerCP/CD4* APC
Clones 145-2C11, 53-6.7, 30-F11, and RM4-5 respectively.
and
CD3*FITC/NK1.1 *PE/CD45*PerCP/B220* APC
Clones 145-2C11, PK136, 30-F11, and RA3-6B2 respectively.

Twenty microliters of custom antibody combinations were aliquoted into 12 x 75 mm
polystyrene tubes. Peripheral blood and spleen samples were then aliquoted (50 pi) into
designated tubes and incubated for 20 min in the dark at room temperature after mixing.
Aliquots (450 pi) of pre-warmed lysing buffer was added to each tube. Tubes were then
capped, vortexed, and incubated in a 37° C water bath for 20 min. Following incubation,
samples were placed on ice until flow cytometry data acquisition.
“Cell gating” was used to specifically capture the cells of interest and then display
other parameters within the gated lymphocyte population. In this study, leukocytes were
resolved

using

CD45

to

initially

gate the

lymphocytes

prior to

assessing

immunophenotype by other antibodies. Approximately 10,000 lymphocyte events/tube
were acquired with the threshold trigger on FL3 using the Lyse/No Wash FACSComp
setting. Acquisition occurred within 6 hr of staining.
Multiparameter analysis was performed using CellQuest™ software version 4.0
(Becton Dickinson). Purity calculations of the gated lymphocytes, which were based on
the sum of the percentages of B220, CD4, CDS, and NK1.1 positive cells, were used to
convert the raw percentage of each subpopulation to normalized percentages. To obtain
the absolute density of each lymphocyte populations, the following formula was used:
number of cells in population/ml = number of leukocytes/ml x percentage of population.
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Tables 2.1 and 2.2 describe cell marker specificity and lymphocyte function as
distinguished by cell subset.
Lyse/Wash protocol
To quantify cell populations expressing CD25, CD71, TCR(3, and NK1.1, a
separate procedure was followed, using the mouse “Lyse/Wash Staining Protocol”
developed by Pharmingen. This assay was performed in order to evaluate the expression
of activation markers and the presence of NKT cells within blood and spleen samples.
Custom antibody conjugates consisted of the following:
CD45 *PerCP/CD25 *PE/CD71 *FITC
Clones 30-F11, PC61, and C2 respectively.
or
CD45*PerCP/TCRp*PE/NKl. 1 *FITC
Clones 30-F11, H57-597, and PK136 respectively.

Ten micro liters of custom antibody combinations were aliquoted into 12 x 75 mm
polystyrene tubes.

Peripheral blood and spleen samples were aliquoted (50 pi) into

designated tubes and incubated for 20 min in the dark at room temperature after mixing.
Aliquots (450 pi) of pre-warmed lysing buffer was added to each tube. Tubes were then
capped, vortexed, and incubated in a 37° C water bath for 15 min. Samples were washed
with 450 pi of PBS twice and finally resuspended in 500 pi of PBS. Following washing,
samples were placed on ice until flow cytometry data acquisition. “Cell gating” and
multiparameter analysis were followed according to the procedure outlined in the
“Lyse/No Wash Staining Protocol.”
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Cytokine analysis by ELISA
Commercially available ELISA (Enzyme linked immunosorbent assay) kits were
used to quantitate the levels of IL-2, IL-12, IL-18, IgG, IFN-y, TGF-pl, and VEGF in
plasma, tumor and/or spleen supernatants. Plasma was obtained from whole blood
samples after microcentrifugation at 8,000 rpm (4,000 g) for 5 min. Tumor supernatants
were obtained from minced tissue centrifuged at 400 g for 10 min. Spleen cell
supernatants were harvested after culture as previously described.

Analyses were

performed by following the assay protocol prescribed by the kit instructions. Briefly,
reagents and samples were brought to room temperature. Reagents, standards, and
controls were prepared according to the protocol. Typically, 50 pi of assay diluent was
added to the center of each well of the provided 96 well plate. Then 50 pi of standard,
control, or sample was added to the center of each. The plate was tapped gently for 1 min
and allowed to incubate for 2 hr at room temperature. Wells were aspirated and washed
four times with wash buffer solution. After washing, 100 pi of conjugate was added to
each well. The plate was covered and allowed to incubate for 2 hr at room temperature.
Wells were again aspirated and washed four times with wash buffer solution. Then 100 pi
of substrate solution (enzyme activation step) was added to each well and the plate was
allowed to incubate for 30 min in the dark. Finally, 100 pi of stop solution was pipetted
into each well. The optical density of the wells was read at 450 nm using an ELISA plate
reader (Dynex technologies [currently Thermo Lab Systems], Chantilly, VA). All ELISA
kits were purchased from R&D Systems, Minneapolis, MN except for the kit for IL-18
which was obtained from MBL Co., LTD, Naka-ku Nagoya, Japan, and the IgG kit which
was obtained from ZeptoMetrix Corporation, Buffalo, New York.
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Cytokine analysis by bead array and flow cytometry
Spleen leukocytes were counted, diluted with supplemented RPMI 1640 medium
(Irvine Scientific) to 1 x 106 cells/ml, and 0.1 ml aliquots were dispensed into wells of
96-well microculture plates. Aliquots of PH A (Sigma) were immediately added at 0.1
ml/well. After a 48 hr incubation period, the supernatants were aspirated, cells and debris
were removed by centrifugation, and the levels of IFN-y, TNF-a, IL-2, IL-4, and IL-5,
were quantified using the Cytometric Bead Array Assay (CBA Assay, Becton Dickinson)
according to the manufacturer's instructions. These cytokines are typically secreted by
activated Thl (IL-2, IFN-y and TNF-a) and Th2 (IL-4 and IL-5) lymphocyte subsets.
Supernatants from non-stimulated cells were collected and tested for background
cytokine levels. This assay uses amplified fluorescence detection by flow cytometry to
measure soluble analytes in a particle-based immunoassay. The CBA capture bead
mixture is in suspension to allow for the detection of multiple analytes in a small volume
sample.

Cytokine concentrations in each test sample were interpolated from the

appropriate standard curve.
Immunofluorescence and laser scanning cytometer analysis
At euthanasia, tumors from representative tumor-bearing mice were excised and
frozen in OCT/Histoprep using liquid nitrogen. Tumor samples were stored at -70° C
until sectioning. Central and peripheral sections (5pm) of tumors were taken using the
microtome to give fresh frozen sections. Slides were kept at -70° C until immunostaining.
Slides were fixed in 70% ethanol at -20° C for 15 min immediately prior to staining.
Slides were then rehydrated in PBS with 0.05% azide for 5 min while rocking gently on a
shaker. Each slide was blotted with a paper towel and the section area was demarcated
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using a pap pen.

Slides were blocked using 50 jul of goat serum (10 mg/ml), or

equivalent serum corresponding to the secondary antibody (Ab), for 15 min in wet boxes.
Following this, sections were stained for macrophages, neutrophils, Tc cells, and NK
cells using the following mAb, respectively: Mac-3 (1:40; BD Pharmingen International),
Ly-6G (1:100; BD Pharmingen International), anti-CD8 (1:500; BD Pharmingen
International), and anti-asialo GM1 (1:1000; Wako Chemicals USA, Inc., Richmond,
VA) and incubated overnight at 4° C. Following a washing procedure with PBS/Tween20, sections were stained with FITC conjugated secondary antibodies (CHEMICON
International, Inc., Temecula, CA) and incubated overnight at 4° C. The sections were
washed three times with PBS/Tween-20 and incubated with propidium iodide (PI) for 30
min at room temperature. Slides were then dipped in PBS w/ 0.05% azide and mounted
with coverslips using permaflour.
The dried slides were then analyzed using a microscope based multiparameter
laser scanning cytometer (Compucyte Corp., Cambridge, MA) and Wincyte™ software.
Multiple sorters detected the fluorescence from cells emitted upon laser beam excitation
with red Pi-stained cell nuclei delineating individual cells. The scanning cytometer was
set to identify all cells within a specified area encompassing the tumor section.
Fluorescence intensity contour level determined the projected cell area of green
fluorescent, positive cells. The integral green fluorescence was measured for each cell
and plotted as cell frequency versus fluorescence intensity.
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NK cytotoxicity assay by flow cytometry
YAC-1 target cells (ATCC) were cultured in RPMI 1640 (Sigma) with 10% FBS,
200 mM L-Glutamine (Cellgro), lx non-essential amino acids (Cellgro), 100 units/ml
penicillin and 100 pg/ml streptomycin (Cellgro) at 37° C in 5% CO2. On the day of the
assay, YAC-1 cells were labeled with a 1:250 dilution of 3,3’ dioctadecyloxacarbocyanine (DiO, Molecular Probes, Eugene, OR) in culture medium for 20 min. After
labeling, cells were counted by trypan blue exclusion assay and adjusted to a
concentration of lxl06/ml.
Lymphocytes were isolated from unlysed splenocytes by animal Ficoll-Hypaque
(Accurate Chemical & Scientific Corporation, Westbury, NY). Briefly, 1 ml of unlysed
spleen cells was washed once in RPMI 1640 complete medium. Pelleted cells were
resuspended in 6 ml of RPMI then carefully layered over 3 ml NycoPrep™ in a 15 ml
Falcon tube. Tubes were centrifuged at 600g for 17 min.

Mononuclear cells were

harvested from the interface using a Pasteur pipette. Mononuclear cells were transferred
to a separate tube and washed twice with 9 ml of complete culture medium then finally
resuspended in 1 ml of complete culture medium.

Concentration of ficoll separated

lymphocytes was determined using the ABC Vet Hematology Analyzer (HESKA Corp.).
Lymphocytes were adjusted to a concentration of lxl06/ml in medium.
Unstained lymphocyte cells and DiO-stained YAC-1 cells were added to 12 x
75mm polystyrene tubes at effector:target cell ratios of 40:1, 20:1, 10:1, 5:1. Control
tubes contained effector and target cells separately. Aliquots of 130 pi of 3.75 mM PI
(Molecular Probes) was added to each tube and the tubes were incubated in a 5% C02
atmosphere at 37° C for 2 hr after centrifuging to a button (1800 rpm, 460 g for 30 sec).
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At the end of the incubation, cell buttons were dislodged and tubes were placed in an ice
bath until flow cytometric evaluation. Fluorescence of target cells was measured by a
FACSCalibur™ 4-channel flow cytometer using two-parameter dot blots after gating on
target cells stained with DiO and/or PL

Percent cytotoxicity was calculated by the

formula: % Dead target cells/[100 -%(Target cell debris and fragments)] x 100.
T cell cytotoxicity (JAM) assay
C57BL/6 mouse splenocytes were prepared according to the lysing procedure
previously described. The concentration of mouse splenocytes was adjusted to 2xl06
cells/ml in IMDM medium with 10% FBS and |3-mercaptoethanol (IMDM 10) after
analysis by the ABC Vet Hematology Analyzer (HESKA Corp.). Lewis lung carcinoma
cells were inactivated by exposure to 100 Gy of 60Co irradiation or by exposure to 50
pg/ml of Mitomycin C (Sigma Chemical Co.). Inactivated LLC cells were harvested
with lx trypsin, counted with a hemacytometer, and resuspended to a concentration of
1x106 cells/ml in IMDM 10 medium. One milliliter of splenocytes was mixed with 1 ml
of inactivated LLC cells in each well of a 24-well plate. Two wells were designated for
each animal. Control wells consisted of inactivated LLC cells alone. Plates were
incubated for 5 days at 37° C with 5% CO2.
On days 4 and 5, target cells were prepared by H-TdR pulse-radiolabeling.
Briefly, LLC cells were grown in single wells of a 24-well plate at a concentration of
5xl05 cells in 1 ml of DMEM plus 10% FBS. 50 pi of 3H-TdR (0.1 pCi/ml or a 1:10
dilution) was added to each well. Target cells were incubated with the label for 4 hr at
37° C with 5% CO2. Target cells were pelleted after harvesting, washed twice in complete
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IMDM 10 medium and resuspended in 5 ml of fresh complete media. All washings were
discarded as radioactive waste.
Also on day 5, Tc killers were prepared by combining cells in two wells of the 24well plate into a 15 ml conical tube. The cells were pelleted by centrifuging at 200 g for
5 min and then resuspended in 600 pi of fresh IMDM 10 medium. Tc cells were
aliquoted in a volume of 150 pi into each of three wells of a 96-well u-bottom plate.
Three-fold dilutions were made by removing 50 pi of first wells into the next wells, pre
filled with 100 pi of medium. This process was repeated until at least four to five
dilutions were made. The first dilution yielded a 66.5:1 effector to target ratio.
Tc cells and target cells were combined by adding 100 pi of 3H-TdR labeled LLC
cells to the pre-diluted Tc killers in the 96-well u-bottom plate.

After pelleting by

centrifugation, cells were incubated for 4 hr at 37° C in 5% CO2. Plates were harvested
onto pre-wet fiber-glass filter membranes, following the protocol of the harvester’s
manufacturer. Cytoxicity was calculated using the formula, % specific killing = (S-E/S) x
100; where S is the retained DNA in the absence of killers (spontaneous lysis) and E is
the experimentally retained DNA in the presence of killers (in cpm).
Oxidative burst assay
C57BL/6 mouse splenocytes were prepared according to the lysing procedure
previously described and adjusted to a leukocyte concentration of 2x106 cells/ml. Spleen
leukocytes (100 pi) were added to designated wells in 96-well plates. Plates were
incubated at 37° C for 1 hr to allow cells to settle. Ten microliters of DCFH-DAZymosan (2,,7,-dichlorodihydrofluorescin diacetate) working solution was added to each
well. DCFH-DA is a membrane permeant diacetate derivative of 2’,7’ dichlorofluorescin
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(DCFH). The working solution was prepared by diluting 15 pi of 10 mM DCFH-DA
stock in 1 ml of Zymosan solution (20 mg of Zymosan/1 ml HBSS). DCFH-DA was
added to the Zymosan solution just a few minutes before adding to the wells in order to
keep it from being oxidized. After adding the working solution, plates were incubated for
1 hr at 37° C. The fluorescent intensity (relative fluorescence unit, RFU) was read at 490
nm excitation and 530 nm emission wavelengths.
Statistical analysis
Data were subjected to one-way and/or two-way analysis of variance (ANOVA)
and Tukey’s HSD (honestly significant difference) multiple range test. Differences
between groups were assigned only if the p value was less than 0.05. These statistical
analyses were conducted using SigmaStat™ software version 2.03 (SPSS Inc., Chicago,
IL).
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CHAPTER THREE
OBJECTIVE, HYPOTHESIS, AND AIMS OF RESEARCH
Our studies focus on the cellular mechanisms by which whole-body irradiation
produces an antitumor effect in a lung cancer model, when exposure precedes tumor cell
implantation.

A correlation between tumor growth inhibition and radiation-induced

alterations of immune system parameters has been suggested within the literature.
However, the data are fragmentary and incomplete. While localized radiation targeted
directly to a tumor can reduce tumor load by such actions as single and double strand
DNA breaks, apoptosis, impairment of tumor vasculature formation, and tumor stroma
damage, there have been no conclusive reports that explain the inhibitory effect of wholebody irradiation to total doses that should have little or no effect on tumor progression.
Consequently, the major objective of this work was to elucidate the radiation-induced
alterations in cellular components and immunomodulatory cytokines that may contribute
to the delayed growth of Lewis lung carcinoma (LLC). Although the study centered
upon changes in immune cell population density and function, the potential impact of
radiation on angiogenesis and tumor stroma was also investigated.
Cursory to this work are the phenotype and immunogenicity of LLC cells. The
LLC cell line is hypotetraploid, with modal chromosome number 72 (Dus et al., 1985).
Syngeneic to C57BL/6 mice, LLC cells metastasize to the lungs following subcutaneous
implantation, allowing for the assessment of both primary and metastatic tumor growth.
The metastatic potential of the cell line varies by clone according to the manifestation of
a diverse array of cell markers. This potential has been found to be dependent upon the
expression of c-jun, c-fos, TP53, and TGF-fil genes (Narumi et al, 1993; Perrotti et al,
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1991; Rizzo et al., 1993; Yamit-Hezi et al., 1994). The expression of cell surface markers
that are correlated with metastasis from the site of the primary tumor, enable homing of
tumor-specific effectors and negative regulatory T cells. The LLC metastatic phenotype
is also dependent upon the expression level of H-2Kb MHC class I antigens (Plaksin et
al., 1988). While this speaks to immunogenicity, the MUT1 and MUT2 tumor-specific
antigens have been identified as binding H-2Kb molecules (Mandelboim et al, 1994).
These peptides, which are derived from a mutated connexin 37 gap-junction protein, can
serve as epitopes for presentation to CD8+ T cytotoxic cells, but are insufficient by
themselves to induce complete tumor destruction (Mandelboim et al, 1995; PrevostBlondel et al, 2000). Additionally, NK cells have been shown to play a significant role
in limiting the local growth and metastatic spread of the LLC tumor (Aboud et al, 1993;
Goldfarb et al, 1998; Morita et al, 1996).

The C57BL/6 mouse is fully

immunocompetent, possessing T cell, B cell, and NK cell populations as well as all other
factors necessary to wage an attack against tumor.
The governing hypothesis of this research was that immune augmentation,
represented by the upregulation of specific leukocyte subsets, is primarily responsible for
the antitumor effect caused by the administration of moderate doses of whole-body
irradiation. Corresponding to this, the investigation also sought to take into account other
factors that may be contributing to the effect mediated by irradiation. In order to test the
hypothesis, several specific aims were set forth. First, we tested the hypothesis that the
reduction of lung carcinoma progression by whole-body irradiation was correlated with
selective immune upregulation independent of vasculature changes. Varying doses of
radiation were utilized at this juncture to quantify the relationship between the total dose
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and the antitumor effect when irradiation occurred prior to tumor implantation. Second,
we investigated the relationship of lymphocyte subset activation following the
administration of incremental doses of irradiation. Critical to this aim was the
identification and quantification of tumor-infiltrating leukocyte populations and the
capacity to produce immunomodulatory cytokines. Finally, we evaluated LLC
progression (primary tumor) and immunological parameters when tumor implantation
was preceded by moderate doses of whole-body irradiation and combined with the
administration of systemic doses of anti-NK monoclonal antibodies. The purpose of this
last aim was to determine if NK cells were major players in the observed antitumor effect
of the radiation.
The study described in Chapter Four serves to demonstrate that significantly
slower subcutaneous tumor growth follows administration of whole-body irradiation and
is correlated with selective immune system upregulation. While the former observation
was noted in preliminary experiments, it was imperative to report this within the
scientific literature and to broaden the range of radiation doses from low to moderate in
an experimental setting. Furthermore, we also varied the timing of irradiation prior to
tumor implantation in order to determine if the time interval between TBI and tumor cell
injection would influence tumor growth. To correlate slowed tumor growth with
immunomodulation, we evaluated a number of parameters that may alter tumor
progression, including spontaneous blastogenesis of blood and spleen cells, mitogen
stimulation indices, cellular changes in immune compartments, NK cytotoxicity, T cell
cytotoxicity, cytokine production, and immune cell activation status. In this way, we
hoped to measure the activity of the major cell populations that were playing a significant
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role in immune response against LLC tumor in the irradiated animals. Chapter Five
supplements the conclusions of Chapter Four by accounting for additional factors that
may have altered tumor growth independent of the immune system’s contribution. These
considerations specifically addressed the imprecision of radiation dosing and sought to
distinguish the antitumor effect from alterations to the tumor bed rather than whole-body
compartments.
The study described in Chapter Six relates directly to the first aim and correlates
reduction in lung carcinoma progression to immune upregulation. By testing differences
in NK cell populations between irradiated and non-irradiated mice, as well as the
production of several regulatory cytokines, we sought to further establish the contribution
of the NK response to slowed tumor growth following TBI. We also monitored the
expression of activation markers in order to measure possible alterations in immune
surveillance. Again focusing on immune cell populations, we evaluated changes in the
CD4 and CDS T subsets so as to identify the status of cell-mediated and humoral
responses.
Flaving established a correlation between delayed tumor growth and NK
activation, NK population changes, and NK cytotoxic activity, the experiments in
Chapters Seven and Eight evaluated the ability of NK depleting antibodies to abrogate
the antitumor effect of TBI. Chapter Seven presents preliminary experiments that were
undertaken to determine the concentration of anti-NKl.l antibody needed to achieve in
vivo depletion. Antibody titration was necessary since the antibody was purified from a
mouse hybridoma, grown within our laboratory. Following titration, Chapter Eight
describes a study that investigates the effect of two depletion antibodies (anti-NKl .1 and
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anti-asialo GM1) on tumor mediation following delivery of TBI. In addition to tumor
volume, we specifically analyzed alterations in NK1.1+, CD8+, and CD71+ cells as well
as other broader based immunological parameters in order to clarify the contribution of
NK cells relative to other leukocytes.
Chapter Nine seeks to combine the conclusions derived from each series of
experiments and to integrate these into a cohesive discussion. Potential mechanisms that
contribute to the antitumor effect of whole-body irradiation are examined. In addition,
future experiments are proposed that could enhance our current understanding of the
biological impact of TBI. Finally, Appendix One presents hematological and
immunological data that were not included within the published-paper format chapters
(Chapters Four, Six, and Eight) and are described as “data not shown.”
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Chapter Introduction
In order to test our hypothesis, we performed a series of experiments to
demonstrate that the reduction of lung carcinoma progression by whole-body
irradiation is correlated with selective immune upregulation. As the title indicates,
the study also evaluated the contribution of timing and dose to the antitumor effect of
whole-body irradiation.

The LLC syngeneic lung cancer cell line was used in

C57BL/6 mice to closely model spontaneous malignant induction. Hematological and
immune parameters were measured in order to determine if immune status and/or cell
populations could be correlated to the antitumor effect.
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ABSTRACT

The major goal of this study was to examine the effects of total-body irradiation on lung
carcinoma progression and determine if changes in tumor growth could be correlated
with radiation-induced alterations of immune system parameters. Lewis lung tumor cells
were injected subcutaneously into syngeneic C57BL/6 mice that had been irradiated with
a single 3.0 Gy dose of y-rays (60Co) at four time points either before or after tumor cell
implantation. Subsequently, a second group of mice were irradiated two hours prior to
tumor injection with sequential doses of y-rays (0.46 to 2.66 Gy range). Assays were
performed on blood and spleen from mice euthanized 16 days post-implantation. Tumor
growth was consistently slower regardless of the timing of radiation exposure. However,
dose of radiation influenced tumor growth delay. The pre-irradiated tumor-bearing mice
had high CD4:CD8 T lymphocyte ratios along with increasing percentages of NKT cells
in the blood supply with dose. Tumor-induced immunomodulation was also present, as
evidenced by splenomegaly, low proliferative response to mitogens and decreased
spontaneous blastogenesis of leukocytes within the blood compared to normal values (P
<_0.01). Anemia and thrombocytopenia were not observed with either tumor presence or
irradiation. The present study demonstrates that a modest dose of total-body irradiation
prior to tumor cell implantation resulted in a beneficial antitumor effect. A selective
radiation-induced depletion of CD8+ T lymphocytes and changes in NKT cell
percentages correlated with findings from cytotoxicity assays were indicative of a protumoricidal immune environment.
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INTRODUCTION

Low-dose total-body irradiation (TBI1) is frequently part of the therapeutic regimen
in cases of low-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, with
total doses delivered typically ranging from 1.5 to 2.0 Gray (Gy) (1). In spite of the low
level of irradiation, the procedure can induce long-term remission. It has been suggested
that immune enhancement, rather than direct killing of tumor cells by radiation, may play
a significant role in the beneficial tumor outcome. Animal, as well as clinical, studies
have identified several possible mechanisms by which low-dose TBI may modulate
immunological status, thereby leading to increased tumor control. However, much of the
data is incomplete or fragmentary and the immunomodulatory effects of low-dose
radiation remain unclear. A better understanding of the mechanisms by which radiation
can enhance lymphoid cell activity may be of considerable importance in refining
treatment protocols that employ low-dose TBI.
It has long been known that lymphoid cells and organs are extremely sensitive to the
effects of ionizing radiation (2, 3). While the lymphoid system is critical in defense
against infectious agents and in the maintenance of homeostasis, it is also thought to play
an important role in the removal of neoplastic cells. Although the concept of
immunological surveillance remains controversial, there is now overwhelming evidence
that T lymphocytes, natural killer (NK) cells, monocyte-macrophages, and neutrophils
can kill tumor cells through cytolysis and/or apoptosis (4-7). In cases where the immune
system is compromised, such as in AIDS or severe combined immunodeficiency disease,
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tumor incidence and progression are enhanced (8, 9). Under experimental conditions,
TBI at doses ranging from 1-3.5 Gy has been used to enhance tumor progression (10, 11).
In contrast, substantial evidence indicates that radiation can augment certain aspects
of immune responsiveness and that sublethal TBI can lead to immunologically-mediated
tumor regression (12-17). Subsets of lymphoid cells, including NK cells and y/5 T cells,
may participate in this mediation because they possess potent tumoricidal activity and are
resistant to p53-mediated apoptosis (18-20). This latter observation is significant since
apoptotic cell death induced by radiation has been frequently associated with
upregulation of p53 expression. Research has also suggested that a suppressor T cell
population depletion may be involved in regulating the positive effects of sublethal
irradiation (12, 16, 17, 21).

In the great majority of these studies, tumor regression

occurred when radiation was administered after, but not before, the induction of anti
tumor immunity. Timing of radiation exposure in relation to tumor presence, as well as
immunogenicity and size of tumor, may determine whether the effects of ionizing
radiation promote or inhibit tumor growth.
The overall goal of the present study was to evaluate timing and dose effects of TBI
on the growth of lung carcinoma cells implanted post-irradiation and to correlate any
observed changes with radiation-induced modulation of specific lymphocyte populations.
The data show that irradiation at a modest dose slowed tumor progression and support the
conclusion that the underlying mechanisms included variable radiosensitivity of different
lymphocyte populations as well as antitumor mediation by NK and NKT cells.
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METHODS & MATERIALS
Animals, tumor cells, and tumor induction
C57BL/6 mice (n = 112; Charles River Breeding Laboratories, Inc. Hollister, CA)
were purchased at 8-9 weeks of age and acclimatized for 1-2 weeks prior to testing. The
animals were housed in our vivarium under standard conditions.

Animals, used to

investigate timing effects and cytotoxicity, were injected with Lewis lung carcinoma
(LLC), maintained by in vivo passage. These cells were donated by Beverly Teicher,
Ph.D. and Ara Gulshan, Ph.D. (Dana Farber Cancer Institute, Boston, MA). Tumor cells
were processed into a slurry, counted and injected subcutaneously (s.c.) into the right
hind flank (~lxl06 cells/mouse). Mice, used in dosing experiments, were injected with
cultured LLC cells obtained from the ATCC (Rockville, MD). Cells were cultured in
Dulbecco’s minimal essential medium (DMEM) (Irvine Scientific, Santa Ana, CA)
supplemented with 10% bovine calf serum (BCS) (Hyclone Laboratories, Logan, UT),
100 units/ml penicillin and 100 pg/ml streptomycin (Gibco BRL, Long Island, NY). The
cells were incubated at 37°C in 5% CO2 until near-confluency, harvested with lx trypsin
solution, washed, counted using the trypan blue exclusion method, and adjusted to the
appropriate concentration. Tumor cells were injected s.c. into the right hind flank (1 x 106
cells/mouse). Tumor dimensions were measured with vernier calipers and volumes were
calculated: tumor volume (mm3) = (H W L)/2, where H = height, W = width, and L =
length of the tumor. Euthanasia was performed by rapid CO2 asphyxiation, in compliance
with the American Veterinary Medical Association Panel on Euthanasia. This study was
approved by the Institutional Animal Care and Use Committee.
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Total-body irradiation
For timing and cytotoxicity experiments, each mouse was placed into a rectangular
plastic box (3 x 3 x 8.5 cm) and up to 8 animals were irradiated simultaneously with a
single dose of 3 Gy photons from a 60Co source. Three different groups were irradiated at
2 hr (including animals used for cytotoxicity analyses), 1 day, and 4 days prior to
implantation of tumor cells; a fourth group was irradiated 1 day after implantation. For
dose experiments, irradiation was performed 2h prior to tumor implantation. Mice were
anesthetized by intraperitoneal (i.p.) injection of a low-dose xylazine (5.2 mg/kg) and
ketamine (80 mg/kg) combination. Anesthetic was given to all mice, regardless of
treatment group, in order to equalize any effects due to stress. TBI was delivered to four
to eight mice simultaneously with a single dose of 0.46, 1.33, or 2.66 Gy (1.37 Gy/min)
photons from a 60Co source. A bolus of 0.5 cm thickness was placed over each mouse to
ensure electronic equilibrium.

Irradiation was performed using an AECL Eldorado

therapy unit (Atomic Energy of Canada, Ltd., Commercial Products Division, Ottawa,
Canada).

Calibration was performed using a Capintec Model PR06-G cylindrical

thimble ionization chamber, traceable to the National Institute of Standards and
Technology (NIST).

Total leukocyte counts, spontaneous and mitogen-induced blastogenesis, and relative
spleen weight
Whole blood was collected by cardiac puncture in EDTA-containing syringes. Body
and spleen weights were measured and relative spleen weights (RSW) were calculated:
RSW = spleen weight (g) x 104/mouse weight (g). The remaining procedures have been
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previously reported in detail (22, 23). Briefly, leukocytes in blood and spleen were
counted using the Vet ABC Hematology Analyzer (Heska Corporation, Waukesha, WI).
In the spontaneous blastogenesis test, 50 pi aliquots of either whole blood or spleen
leukocytes were mixed with 200 pi of complete RPMI 1640 medium containing 1 pCi of
3H-thymidine (3H-TdR; specific activity = 46 Ci/mmol; ICN Radiochemicals, Irvine, CA)
and plated into 96-well microtiter plates. After a 3-hr incubation period in 5% CO2 at
37°C, the cells were harvested and the amount of incorporated 3H-TdR was quantified in
a beta-scintillation counter. These results are expressed as counts per minute (cpm)/106
cells. In mitogen-induced proliferation tests, spleen cell suspensions (2 x 106cells/ml)
were

dispensed

into

wells

of 96-well

plates

(100

pl/well).

Pre-titrated

phytohemagglutinin (PHA), concanavalin A (ConA), and lipopolysaccharide (LPS) were
added (100 pl/well) in triplicate; control wells contained medium without mitogen. All
mitogens were obtained from Sigma Chemicals, Inc., St. Louis, MO. The plates were
incubated for 48 hr and a pulse label of 3H-TdR was added for the final 4 hr. After cell
harvesting, incorporated 3H-TdR was determined as described above. The results are
expressed as a stimulation index (SI): SI = (cpm with mitogen

cpm without

mitogen)/cpm without mitogen.

Analysis of lymphocyte populations
Lymphocyte populations in blood and spleen were phenotyped by direct
immunofluorescence using a FACSCaliburTM 4-channel flow cytometer (Becton
Dickinson, Inc., Rutherford, NJ). The CD3+ T, CD4+ T helper (Th), CD8+ T cytotoxic
(Tc), B220+ B, and NK1.1+ NK cells were identified using 4-color, 2-tube mixtures of
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fluorescence-labelled monoclonal antibodies (MAb).

Pharmingen (San Diego, CA)

designed these MAb mixtures in collaboration with Becton Dickinson for use by
investigators in the Radiobiology Program at Loma Linda University.

Additionally,

MAbs against CD25, CD71, TCR|3 and NK1.1 (Pharmingen) were used to quantify
cellular activation and NKT populations respectively. All MAbs were conjugated with
fluorescein isothiocyanate (FITC), R-phycoerythrin (PE), allophycocyanin (APC), or
peridinin chlorophyll protein (PerCP).

Analysis was performed using CellQuest

TM

software version 3.1 (Becton Dickinson).

Analysis of erythrocytes and platelets
Samples (12 pi) of whole blood collected in EDTA were evaluated using the Vet ABC
Hematology Analyzer.

Measurements included red blood cell (RBC) counts,

hemoglobin, hematocrit (% of whole blood composed of RBC), mean corpuscular
volume (MCV; mean volume per RBC), mean corpuscular hemoglobin (MCH; mean
weight of hemoglobin contained in the average RBC), and mean corpuscular hemoglobin
concentration (MCHC; concentration of hemoglobin in the average RBC). Thrombocyte
counts and volume (MPV, mean platelet volume) were also determined.

DNA fragmentation/T cell cytotoxicity assay

The JAM test was performed to study the killing of EEC tumor targets by effectors
(24) with some modification by our laboratory. Briefly, effector cells were generated by
co-culturing spleen leukocytes with mitomycin C-treated EEC cells at a ratio of 2:1.
EEC cells were disrupted from cell cycling by treatment with mitomycin C (Sigma) at a
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concentration of 50 |ixg/ml for 45 min. On Day 5, LLC tumor targets were labeled with
3H-TdR (0.1 jaCi/ml) by incubating in a humidified atmosphere with 5% CO2 at 37°C for
3.75 hr.

Excess 3H-TdR was washed off and IxlO3 LLC targets labeled with 3H-TdR

were cultured with various ratios of effector cells in triplicate in 96-well round-bottom
plates. Plates were incubated for 3.75 hr and harvested onto glass-fiber filters which
were later measured in a beta-scintillation counter. % DNA fragmentation = (S-E)/S x
100, where S is retained DNA in the absence of killers (spontaneous) and E is
experimentally retained DNA in the presence of killers (experimental release). DNA
fragmentation was quantified on days 4 and 10 following irradiation and tumor
implantation.

NK cytotoxicity assay
NK cytolytic activity against YAC-1 target cells, a mouse lymphoma cell line, was
assessed by a flow cytometry assay using the 3,3’-dioctadecyloxacarbo-cyanine (DiO,
Molecular Probes, Eugene, OR) membrane dye to stain YAC-1 cells and the propidium
iodide (PI, Molecular Probes) nuclear dye to stain dead cells (25, 26). Briefly, YAC-1
cells (ATCC) were maintained in culture in RPMI 1640 (Sigma) with 10% FBS at 37°C
in a humidified 5% CO2 incubator. On the day of the assay, YAC-1 cells were labeled
with DiO for 20 min. Lymphocytes were separated from spleen leukocytes by animal
Ficoll-Hypaque (Accurate Chemical & Scientific Corporation, Westbury, NY). After
washing, unstained lymphocyte cells and DiO-stained YAC-1 cells were added to 12 x75
polystyrene tubes at effector:target ratios of 40:1, 20:1, 10:1, and 5:1. Control tubes
contained effector and target cells separately. 130 pi of PI (3.75 mM) was added to each
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tube and the tubes were incubated in a 5% CO2 atmosphere at 37°C for 2 h. Fluorescence
of target cells was measured by a FACSCalibur1M 4-channel flow cytometer using twoparameter dot blots after gating on target cells stained with DiO and/or PI. Percent
cytotoxicity was calculated by the formula: % Dead target cells/[100 - %(Target cell
debris and fragments)] x 100. NK cytolytic activity was measured 4 and 10 days post
irradiation and tumor implantation.

Statistical analysis
The data were analyzed using one-way analysis of variance (ANOVA) and Tukey's
HSD (honestly significant difference) multiple range test,

These analyses were

performed with SigmaStat™ software version 2.0 (SPSS Inc., Chicago, IL). A P value of
<0.05 was chosen to indicate significant differences.
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RESULTS
Timing and dose of irradiation effects tumor growth
Figure 1 presents tumor progression followed in four separate experiments. The
data show that tumor volumes were consistently smaller in mice receiving total-body
irradiation, regardless of when the radiation was delivered in relation to the time of tumor
cell implantation (the only exception being day 14 for mice irradiated 4 days prior to
tumor cell injection).
Tumor growth in mice, receiving cumulative TBI doses ranging from 0 to 2.66 Gy,
are depicted in Figure 2. The data show that tumor volumes were consistently smaller in
animals given either 1.33 or 2.66 Gy of total-body irradiation, when the radiation was
delivered two hours prior to implantation. Statistical significance was obtained at day 13
for the 2.66 Gy group and at day 15 for both the 1.33 and 2.66 Gy groups compared to
the non-irradiated tumor-bearing control.

Mouse body weight and spleen parameters
Tumor-bearing irradiated mice were of equivalent body weight compared to nonirradiated animals with tumor at the time of euthanasia except for the 2.66 Gy group
which was significantly lighter (23.8 +/- 0.3 g vs. 24.8 +/- 0.3 g). Data for spontaneous
blastogenesis and leukocyte responses to mitogens are presented in Table 1.
Splenomegaly, leukocytosis and low response to both T and B cell mitogens were noted
in all tumor-bearing groups. The basal uptake of 3H-TdR by splenocytes was slightly, but
not significantly, enhanced by tumor presence.
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Hematological and other parameters in peripheral blood
In consideration of leukocyte populations, WBC counts were higher in all tumor
bearing mice compared to the normal control group; non-irradiated mice with tumor had
the highest mean value (P < 0.001). In contrast, the spontaneous uptake of 3H-TdR was
significantly depressed in all tumor-bearing groups. Mice with tumor, regardless of
irradiation, did not exhibit a significant depletion of RBC numbers, hemoglobin content,
or hematocrit. Other measured parameters for the erythrocytes were similar to normal
(data not shown), with two exceptions: a significantly lower mean corpuscular
hemoglobin concentration (MCHC) was seen in irradiated mice with tumor (0.46 Gy and
2.66 Gy); and an increased RBC distribution width (RDW) was observed in two
irradiated groups (1.33 Gy and 2.66 Gy) compared to tumor-bearing and normal controls
(P < 0.02).

Major lymphocyte populations in spleen and blood
Major lymphocyte populations in the blood and spleen were determined by flow
cytometry (Figure 3A,B). In both the blood and spleen, non-irradiated mice with tumor
had consistently higher levels of CD3+ T, CD3+/CD4+ Th, and CD3+/CD8+ Tc cells
compared to non-irradiated animals without tumor, although statistical significance was
not always attained. However, irradiation with either 1.33 Gy or 2.66 Gy resulted in
significantly lower CD3+T, CD3+/CD4+Th, and CD3+/CD8+Tc cell counts in spleens
from tumor-bearing animals compared to their non-irradiated tumor-bearing counterparts.
In contrast to T cells, NK cell numbers in blood and spleens of irradiated mice with
tumor were higher than for normal controls at all points of measurement. CD4:CD8
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lymphocyte ratios (Table 2) in the blood were found to linearly increase with increasing
dose of total-body irradiation (R2 =0.658).

In non-irradiated tumor-bearing mice, a

lymphocyte ratio of 1.49:1 was found, whereas the ratio was enhanced to 2.31:1 in mice
irradiated with 2.66 Gy. A similar pattern was noted in the spleen (Table 3).

Percentages of NKT cells and lymphocytes expressing activation markers
NKT (NK1.1 and TCR|3 double positive) cell percentages in the blood were
significantly reduced in the 0.46 Gy tumor-bearing irradiated mice compared to nonirradiated tumor-bearing controls, although all animals having tumor had higher
percentages than normal control levels (Table 2). The other tumor-bearing irradiated
groups (1.33 and 2.66 Gy) exhibited elevated percentages with increasing dose. In the
spleen, no differences in the NKT cell population were found among normal controls,
tumor-bearing non-irradiated controls, or tumor-bearing irradiated mice. Cells expressing
CD25 and CD71 activation markers were minimally altered by dose of radiation in both
the blood and spleen; however, percentages of CD71+ spleen lymphocytes were
depressed in tumor-bearing mice receiving either 1.33 or 2.66 Gy TBI compared with
non-irradiated tumor controls (P<0.03).

NK and T cell cytotoxicity
NK cytolytic activity against YAC-1 cells was enhanced in mice receiving radiation
4 days following exposure, regardless of tumor presence (Figure 4).

Significance,

however, was only achieved for irradiated non-tumor bearing mice when compared with
non-irradiated groups. This heightened activity subsequently declined to near normal

80

levels by day 10 although irradiated non-tumor bearing mice still evidenced the most
pronounced cytotoxicity at all effector to target ratios. T cytotoxicity analyses of effector
cells did not reveal statistical differences related to either tumor presence or exposure to
radiation (data not shown).

Tumor-bearing mice receiving a 3 Gy dose of y-rays

demonstrated the lowest T cytolytic activity compared to all other groups at days 4 post
irradiation (2.7% vs. 16.0% for untreated normal controls) while irradiated non-tumor
bearing mice showed a similar depression on day 10 even though statistical significance
was not seen at either time point.
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Table 1. Spleen parameters in irradiated tumor-bearing mice

Tumor-bearing

Normal

0.46 Gv

1.33 Gv

2.66 Gv

31.9+/-2.1c,e 74.7+Z-3.9

50.8+/-3.4e

46.5+/2.8e

54.3+/-4.5

17.8+/-1.1'

45.1+/-4.7

32.9+/-4.2

25.5+/-1.9e

33.5+/-3.2

Spont. blast.
(cpm xl03/106 cells)

19.0+/-3.3

26.2+/-2.5

19.4+/-2.9

20.8+/-2.5

29.5+/-2.2

PHA-SI

91.3+/-19.5

21.0+/-4.7d

14.1+/-4.9d

10.8+/-3.1d

8.8+/-1.7d

ConA-SI

111.5+/-30.3

13.8+/-2.9d

26.2+/-12.7d 17.5+/-7.6d

4.7+/-1.3d

LPS-SI

157.1+/-25.0

83.6+/-9.6d

60.9+/-17.4d 71.9+/-10.1d 80.4+/-11.9d

Assay3

control

RSWb
Leukocytes

Control

d,e

(x 103/|iil)

Performed 16 days after irradiation and tumor cell injection.
bRelative spleen weight (RSW) = [weight of spleen (g) x 103]/body weight (g).
cMean +/- SEM, n = 8-12 mice/group.
dP < 0.05 vs. normal control.
eP < 0.05 vs. tumor control.
SI (stimulation index) = (cpm with mitogen - cpm without mitogen)/cpm without
mitogen.
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Table 2. CD4+:CD8+ (Th:Tc) ratio and NKT percentage of lymphocytes in irradiated
tumor-bearing mice3
Tumor-bearing

Normal
control
CD4+;CD8+
1.62+/-0.05b
Spleen
Blood

1.94+/-0.20d

NKT % (xlO i
7.52+/-0.62b
Spleen
Blood

1.78+/-0.39

0.46 Gv

Control

1.33 Gv

2.66 Gv

1.85+/-0.07 1.75+/-0.05 1.98+/-0.07c 2.1 l+/-0.07c’d’e
1.49+/-0.07 1.58+/-0.08 2.01+/-0.07<l’e 2.31+/-0.08d,e

5.81+/-1.11 5.61+/-0.49 7.71+/-0.89

6.23+/-0.77

15.10+/-2.82c 6.28+/-1.30d 8.47+/-3.21 11.20+/-1.20c

Performed 16 days after irradiation and tumor cell injection; ratios are based on cell
numbers.
bMean +/- SEM, n = 8-12 mice/group.
CP < 0.05 vs. normal control.
AP < 0.05 vs. tumor control.
eP < 0.05 vs. tumor + 0.46 Gy TBI.
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Days after tumor cell implantation

Days after tumor cell implantation

Fig. 4.1. Timing of irradiation and tumor progression. Each point represents the mean +/SEM for 2-10 mice/group. (•) : non-irradiated, (O): irradiated with a single fraction of
3.0 Gy y-rays. Vertical arrows indicate time of irradiation in relation to tumor cell
implantation (day 0).
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Fig. 4.2. Tumor growth following sequential dose of irradiation. Each point represents
the mean +/- SEM for 8-12 mice/group. (•) : non-irradiated, (O): irradiated with a
single fraction of 0.44 Gy y-rays, (T): irradiated with a single fraction of 1.33 Gy y-rays,
(V): irradiated with a single fraction of 2.66 Gy y-rays. Irradiation occurred at 2 hr prior
to tumor cell implantation on day 0. a: ^<0.05 vs. normal control.
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Fig. 4.3. Major lymphocyte populations from total-body irradiated and non-irradiated
mice in A) peripheral blood and B) spleens. Each point represents the mean +/- SEM for
8-12 mice/group on day 16 after irradiation and tumor cell implantation. Control mice
(^); tumor-bearing mice (q). a: p<0.05 vs. normal control; b: p<0.05 vs. tumor control
(non-irradiated).
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DISCUSSION

The data show that all mice injected with LLC cells developed progressively
growing tumors.

However, the growth was consistently slower in animals receiving

moderate doses of total-body irradiation regardless of when the radiation was delivered
in relation to tumor cell injection. A minimum dose of 1.33 Gy was required for tumor
growth inhibition. Analysis of lymphocyte populations indicated that a possible
explanation for the radiation-induced inhibition of tumor progression was an elevation in
the CD4:CD8 T lymphocyte ratio. The increase can be attributed to the greater sensitivity
of CD8+ T lymphocytes, as compared to the CD4+ T cell subset, to the direct effects of
radiation (27-30). In addition it has been reported that tumor necrosis factor-a (TNF-a),
a radiation inducible cytokine, preferentially triggers apoptotic cell death in CD8+ cells
over CD4+ cells (31). North and colleagues have suggested that the immunotherapeutic
action of radiation is due to a preferential elimination of the radiosensitive, tumorinduced suppressor T cell population, which results in the generation of a higher level of
antitumor immunity (32).

We were unable to detect any apparent increase in T

cytotoxicity following irradiation but rather observed that irradiated mice exhibited
slightly depressed cytolytic activity against LLC targets at both time points of
measurement. This finding correlates with research purporting that CD8+ T cells,
although typically associated with cytotoxic activity, can also exhibit suppressor
functions (33). Other studies indicate that a selective sparing of radioresistant activated
effector T cells is also needed to destroy the tumor in the absence of suppression (34, 35).
It has been demonstrated that alterations in various lymphocyte subsets are related to the
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stage of disease and that a reversed CD4/CD8 ratio is highly correlated with rapid growth
of certain cancers (36, 37).
Lymphocyte activation as determined by expression of CD25 (IL-2 receptor) and
CD71 (transferrin receptor) was neither augmented nor suppressed as a result of
irradiation at the time of testing. The slight (statistically non-significant) upregulation of
cells with these activation markers within both the blood and spleen can be attributed to
tumor presence alone. CD25 and CD71 are expressed on major lymphocyte subsets upon
activation and indicate heightened activity and/or proliferation (38,39). It is of interest to
note that Harrington and colleagues have previously shown that total-body irradiation up
to 7 Gy increases the expression of CD71 in spleens of CD57BL/6 mice (28). The
seeming discrepancy between these results and those presented here may be due to
differences in the time of analyses (i.e. within the first week of irradiation versus 16 days
post-irradiation in the present study).
Although T lymphocytes are unquestionably the most important cell type in defense
against immunogenic tumors, NK cells and their corresponding subsets can also exhibit
strong anti-tumor activity and are the cells most likely to function in immune surveillance
(40, 41). NK cytotoxicity analyses showed that irradiated mice exhibited heightened NK
activity against YAC-1 cells 4 days following exposure. This increase appeared to be
transient because slightly higher values were observed for irradiated non-tumor bearing
mice alone on day 10. NKT cells, a lymphocyte subpopulation that expresses both NK1.1
and a single invariant T cell receptor, possess potent tumoricidal activity against LLC
cells, as well as other neoplastic cell types, and are induced by IL-12 (42-45). It appears
that these cells may also play a key role in regulating the anti-tumor activities of
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conventional T-cells, perhaps through the secretion of factors such as interferon-y (46).
Our data support an overall increase in NKT cell percentage in the blood supply as a
result of tumor presence. It seems possible that the tumoricidal function of these cells
was allowed to proceed more readily in the irradiated tumor-bearing mice, if the radiation
resulted in depletion of cells with suppressor activity. Alternatively, the appearance of
radiation-inducible cytokines may have facilitated cytotoxic mechanisms in the NKT, as
well as other effector cell populations. A migration of these cells into the blood
compartment may facilitate cytotoxicity.
According to our evaluation, B lymphocyte numbers were slightly reduced following
radiation, indicating that their recovery was not yet complete. Our previous studies show
that these cells are severely depleted during the first 10 days post-irradiation and that
antibody production is diminished, as well as delayed for up to a month (22). Production
of tumor-specific antibodies by activated B cells can sometimes protect target cells from
immune attack by coating the tumor target, resulting in accelerated tumor growth (47). It
is possible, therefore, that radiation-induced reduction of B cells may decrease the
development of tumor-specific antibodies, which could potentially block the anti-tumor
action of T cytotoxic and NK cells. This possibility is strengthened by the finding that
LLC cells possess immunogenic MUT1 and MUT2 antigens (48).
DNA synthesis, as measured by spontaneous uptake of 3H-TdR, was depressed in all
tumor-bearing animals at 16 days following irradiation. Mitogen-induced blastogenesis
was included in this study, since this assay has been frequently used to assess the status
of the immune system in general (i.e. ability of the T and B lymphocytes to respond to a
stimulating agent). The data show that the proliferative responses to both B and T cell
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mitogens were consistently lower in all tumor-bearing groups. Taken in conjunction with
statistically similar tumor volumes at day 16 between irradiated and non-irradiated
tumor-bearing animals, it seems unlikely that the mechanisms responsible for the
significant reduction in tumor progression were sustained until this time-point.
Consequently, the immunomodulation observed may be simply indicative of an earlier
immune response that is either abrograted or exhausted by the time point of
measurement.
The data also show that neither the Lewis lung carcinoma nor total-body irradiation
induced anemia or thrombocytopenia, as evidenced by measurements of RBCs, platelets,
hemoglobin, and hematocrit.

Anemia is a relatively common finding in cases of

advanced cancer, and may signal a poor prognosis. Conversely, tumor presence greatly
enhanced hematopoiesis, a process that is dependent upon cytokines for cell growth and
differentiation.
The present study demonstrates that acute, total-body exposure to a modest dose of
y-radiation resulted in consistently slower growth of Lewis lung tumors. Tumor growth
delay was dependent on timing and the total dose of radiation utilized. The tumorinhibitory effect was observed at 1.33, 2.66, and 3.00 Gy doses of y-rays. Based on the
obtained data, the radiation-induced increase in the CD4:CD8 T lymphocyte ratio and the
enhancement in NK activity combined with a higher percentage of NKT cells within the
blood supply may have contributed to the antitumor effect during tumor establishment.
The data prompt further investigation to evaluate the initiation and timing of anti-tumor
responses and to refine techniques so that radiation-induced immune system upregulation
can potentially be utilized as an adjunctive form of cancer therapy.
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CHAPTER FIVE
INTERVENING DISCUSSION ONE
Introduction
Along with a discussion of the previous chapter, this chapter will include
additional results that elaborate on the nature of the antitumor effect, specifically relating
tumor progression to systemic or local phenomena.

Based on the evaluation of the

former study, tumor growth delay can be correlated with a number of immunological
variables including enhancements in the CD4/CD8 T lymphocyte ratio and NK activity,
as well as an increased percentage of NKT cells within the blood supply in the Lewis
lung tumor model. Tumor progression was shown to be a function of both timing of
irradiation and total dose administered. However, while higher total doses of TBI were
demonstrated to be advantageous in decreasing tumor progression, the conclusion that
systemic immunological factors played a predominant role in its mediation was not
clearly established.

In part, the study did not distinguish between regional control

exhibited at a tumor stroma level and a potential contribution of specific immune cell
infiltrates that are more pervasive and widespread; assuming that immunological
alterations at the tumor site are in fact critical to control of malignant cell proliferation.
However, the study did demonstrate that certain immunological parameters are dependent
upon total dose of irradiation, most importantly the levels of lymphocyte populations
within the blood and spleen and overall immune status (as measured by spontaneous
blastogenesis and mitogen stimulation), as well as the relative radiosensitivity of CD4
and CDS T cells.
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In addition to these findings, the hypothesis that the reduction in lung carcinoma
progression by TBI can be correlated with selective immune system upregulation, needed
to be confirmed by showing that similar patterns in tumor inhibition were independent of
localized or regional radiation. The rationale behind these predictions was based on
radiation doses administered in other research studies. Traditionally, a minimum dose of
10 Gy of localized radiation has been used to target tumor vasculature, thereby causing
the inhibition of angiogenesis (i.e., the tumor bed effect). In contrast, a total dose of 0.4
Gy has been shown to augment the proliferative response of immune cells isolated from
the spleen (Nogami et al, 1994). Consequently, we were concerned with distinguishing
between the contribution of localized radiation and TBI to the antitumor effect and how
subsequent alterations in the distribution of lymphocyte populations and their functional
status may be related.
Experimental protocols
Two studies were undertaken in order to clarify these issues. The first experiment
was performed to observe changes in tumor progression and immunological variables
when the tumor implantation site was shielded during administration of moderate doses
of systemic radiation (out-of-field). The second study compared the effects of localized
radiation (leg only) with those caused by equivalent doses of TBI. Both studies were
performed in duplicate.
Two hours prior to tumor cell implantation, mice were irradiated with a single
dose of photons from a 60Co source not exceeding 3 Gy. Mice were anesthetized with a
low-dose xylazine (5.2 mg/kg) and ketamine (80 mg/kg) combination by i.p. injection.
Anesthetic was administered to animals from all groups, regardless of treatment, in order
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to equalize any effects due to handling stress and/or anesthesia.

For out-of-field

irradiation, the right hind leg of each mouse was taped to extend outside of the radiation
field underneath lead blocks while the bodies of the mice were exposed (See Figures 2.1
and 2.2 in Materials and Methods section). To administer localized radiation, the right
hind leg of each mouse was taped to extend inside the radiation field while the bodies of
animals were shielded from exposure by lead blocks and were outside the perimeter of a
20 x 20 cm radiation field.

Irradiation was performed using the calibrated AECL

Eldorado therapy unit described in the previous chapter.
In these experiments, the methods for tumor induction and administration of FBI
were similar to those performed previously. Mice were injected with cultured EEC cells
maintained in DMEM, supplemented with 10% BCS and antibiotics, at 37°C in 5% CO2.
These cells were obtained from the ATCC. At near confluency, cells were harvested, as
described in the previous chapter, then adjusted to 1x107 cells/ml in sterile PBS. Mice
were injected with 0.1 ml of the tumor cell suspension (1x106 cells) after cleaning the
injection site with isopropyl alcohol prep pads. Tumor growth was measured using
vernier calipers and volumes were calculated according to the standard formula.
At the time of sacrifice (Day 16 post-irradiation for the out-of-field study and day
17 post-irradiation for the localized study), mice were euthanized by rapid CO2
asphyxiation. Afterward, the same set of assays (with one exception) were performed so
that direct comparisons could be made between the two irradiation conditions.

The

assays included relative spleen weight, total leukocyte counts, spontaneous and mitogeninduced blastogenesis, analysis of lymphocyte populations by flow cytometry, and
analysis of activation markers by flow cytometry (out-of-field radiation study only).
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Results were compiled and the data were evaluated statistically using ANOVA and
Tukey’s HSD multiple range test.
Radiation set-up and exposure
Since our objective was to compare the antitumor efficacy of both out-of-field and
localized radiation with that provided by TBI, radiation dose and dose-volume effects
were critical parameters in the interpretation of collected data. As such, this section seeks
to describe the radiation set-up that was employed, as well as to estimate the dose
absorbed for test mice, taking into account scatter and the penumbra of the radiation field.
For both the out-of-field and localized radiation experiments, correction factors
were used to adjust for the physics of y-rays. Two polystyrene blocks were used as a
base to prevent scatter. The distance from the head of the irradiator to the front surface of
the target (Source to Axis Distance or S.A.D.) was maintained at 80 cm through the
majority of experiments. The Beam Divergence Factor (B.D.F.) was set at 1.000 as
calculated relative to the isocenter of 80 cm. A Tissue to Air Ratio (T.A.R.) of 1.059 was
needed to reach a depth of 0.5 cm for a 20 x 20 cm field size. Taking into account this
field area, the collimator scatter factor (Sc) was estimated at 1.043. Correcting for the
attenuation of the beam with distance from the beam center, the Off Axis Ratio (O.A.R.)
was set at 0.961. The Tray Factor (T.F.) was kept at 1 because a special set-up was not
used. Finally the Output Factor (O.P.) was determined by the calendar date and rate of
decay of the 60Co source.
In each experiment, lead blocks were used as a barrier to limit exposure outside of
the radiation field (Figure 5.1). For the out-of-field experiment, lead blocks were used to
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Figure 5.1. Radiation set-up using the AECL Eldorado therapy unit. A bolus of
superflab (0.5 cm in thickness) was placed over the area of the mice extending into the
field of exposure. Lead blocks were spaced along the edge of the radiation field to shield
unexposed volumes.
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spare the leg from exposure. Alternatively, the lead blocks were intended to shield the
bodies of mice in the localized experiments.
In order to evaluate dose received outside the 20 x 20 cm field, Steve Rightnar,
B.S. (Research Specialist) and I exposed several sheets of Kodak X-Omat V film
(Eastman Kodak Company, Rochester, NY) to a total dose of 50 cGy using the AECL
Eldorado b0Co source (Figure 5.1). The set-up was arranged to mimic that used in each
study. Briefly, the film, inside its light-proof package, was placed in the center of the
field. Using the light source to delineate the field, lead blocks mounted on plastic frames
were aligned at the very edge of the field. Boluses of superflab were placed in a manner
so that half of the bolus lay within the field and the other half outside or so that the entire
bolus lay within the field up to its very edge. Boluses were placed near or underneath the
lead block frames. Holes were made in the film using a nail to identify the edge of the
field as visualized by the light source. Films were developed and scanned using the VRX16 Dosimetry Pro scanner (Vidar Systems Corporation, Herndon, VA). RIT113 software
(Version 3.05, Radiological Imaging Technology, Colorado Springs, CO) provided leftto-right and gantry-to-table profiles (Figure 5.2). These profiles were used to calculate
approximate isodoses to regions on the x-ray film.
Based on the analysis of the film, it was concluded that the lead blocks did not
totally shield against y-rays. The lead blocks were raised several inches above the bodies
of the mice and, due to this height and the angle of the radiation source, they did not offer
complete protection. Instead the blocks may have been a source of additional backscatter.
Analysis of the film demonstrated that the radiation dose was attenuated to approximately
30% of its maximum at the border of the field. Furthermore, this dose was reduced to nil
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within an additional centimeter distance from the beam edge (Figure 5.2). Consequently,
the dose received to the leg of out-of-field mice was a gradient from 30% to 0% of the
total dose to the portion of the leg that was 1 cm outside of the irradiated area. In reverse,
locally irradiated mice received a similar dose gradient to 1 cm of the trunk of the body.
Thus, although the spleen was protected from exposure, this was not the case for all
associated lymphoid tissues (e.g., lymph nodes and circulating cells).
In retrospect, this technique, while imperfect, provided a practical means by
which to compare the different effects of out-of-field, localized, and total-body
irradiation. Ideally, another sparing technique could have provided a more definitive
boundary of exposure but this would have come at the complication of following the
scale seen in clinical settings. In the clinic, conformal radiation therapy (CRT) involves a
spectrum of radiation planning and delivery techniques, that rely on three-dimensional
imaging to define and target an area of interest (tumor) and to distinguish it from
unexposed (normal) tissues, as well as adjusting shielding to spare normal tissues. CRT
can be used to shape the prescription dose to the irradiated area so as to avoid or reduce
dose to the normal, unexposed tissues (Merchant et al, 2002). An additional approach
would have been to construct a lead mold fitting the body and the leg of the mouse so as
to provide a more precisely contoured barrier that could have blocked penetration and
scatter of y-rays. In our experiments, scatter could have been generated from a number of
sources. Likely causes of scatter were the uranium jaws of the AECL Eldorado therapy
unit, the polystyrene surface that served as a base, air, the superflab placed over mice,
and the mouse body itself. Whereas approximately 6% of the dose can issue from metal
surfaces, the polystyrene base should have limited this backscatter. From the estimated
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penumbra, these sources of backscatter did not exceed 10% of the total dose outside of a
perimeter 1 cm beyond the edge of the field.
The term ‘integral dose’ accounts for the total energy absorbed by irradiated
tissues and organs both inside and outside the field of exposure. Integral dose can be
defined as the product of the mass of tissue and the dose that it receives. In our system,
the integral dose is equal to the energy absorbed after a beam of radiation enters the
mouse body and can be calculated according to the formula derived by Johns and
Cunningham described below:

D = J pA • D(x) • d(x)
o
2

.

.

where A denotes the field area (cm ); p is the tissue density; D(x) is the dose as a function
of depth along the beam direction (cm); x refers to the depth (cm), and t = thickness of
the body (cm) (Johns and Cunningham, 1969). The units of integral dose are typically
expressed as joules (10 ergs). This approach has been previously used to compare the
integral dose received by cancer patients undergoing proton and/or photon radiotherapy
(Gridley etal, 1996).
In addition to total energy absorption, out-of-field effects may compound the
activity of irradiation. In a study of cellular response to partial lung irradiation in rats, it
was demonstrated that a directional effect exists beyond the volume irradiated as
determined by the production of micronuclei (Khan et al., 1998). This out-of-field effect
was dependent on tissue type since it was noted that the base and apex regions of the lung
had marked differences in micronuclei yield when the complementary region was
exposed.

Upon investigating this further, Moiseenko and colleagues questioned the

validity of applying a dose-volume histogram analysis to predict normal tissue
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complication probability (NTCP) due to the responsiveness of the apex and base of the
lung (Moiseenko et al, 2000). However, they did suggest that dose-volume relationships
should be evaluated in order to characterize the effects of regional radiation. It should
mentioned that these models for incorporating out-of-field and in-field effects were
predicted from volume irradiation data using doses equaling 10-13 Gy or higher, where
dose volume-effects refer to the direct action of irradiation on the tissue. Dose-volume
response to radiotherapy, in some cases, can be predicted as a sum of the products of the
volume receiving a particular dose of radiation (Merchant et al, 2002). From these
results, it is possible that out-of-field effects did occur in our model beyond what can be
attributed to scatter. However, the above experiments also suggest that these effects were
minimal based on the relative radiosensitivity of the tissues evaluated (the lung compared
with the base of the leg) and the doses administered.
A final consideration when evaluating the total dose of radiation is the exposure
of blood within the circulation, especially when contrasting the immunological effects of
localized radiation with TBI. With the conversion of 90 ml of total blood volume/kg of
mouse body mass, an average mouse (25 g) would have an estimated 2.25 ml of total
blood volume (Podolsky and Lukas, 1999). At a heart rate of 600 beats/minute (reported
range of 592-631 beats/minute) (Crispens, 1975), and a stroke volume of 33 pl/beat
(Hartley et al, 1995), the cardiac output would be approximately 19.8 ml per minute. At
this rate, the entire blood supply would circulate at greater than eight times in 60 seconds,
and hence would be exposed to some level of radiation while passing through the hind
limb area. Estimating that 12.5% of the blood supply resides in the right hind limb at any
given time, the blood components would receive 12.5% of the radiation dose (0.375 Gy
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for every 3 Gy administered), given a uniform circulation and an exposure rate that
permits a complete cycle of circulation.

The exposure time was approximately 45

seconds per Gy, and thus the total exposure for 3 Gy (roughly 2.25 minutes) should result
in 18 cycles of circulation. Dose received per individual blood cell would vary according
to mean residence time within the exposed area.

A significant portion of the bone

marrow in the femur would also be subject to irradiation.
Tumor volumes
Figure 5.3 compares tumor progression after varying total doses of out-of-field
radiation (body irradiated, leg excluded) and TBI, each delivered in a single fraction.
Significant growth inhibition was seen by day 13 following administration of 1.33 Gy
and 2.66 Gy of either out-of-field irradiation or TBI when compared to non-irradiated
animals. A slight, but statistically insignificant, decrease in progression was observed
with the smallest dose of 0.46 Gy. Irradiation with 2.66 Gy of out-of-field irradiation and
TBI showed sustained inhibition up to the 16-day time point. However, no differences in
tumor volumes were seen between mice receiving out-of-field irradiation and TBI at any
time point or with any dose.
When localized radiation was given to the leg (site where tumor cells were
implanted 2.5 hr later), in exclusion of the trunk of the body, tumor progression was
virtually identical to that observed for the non-irradiated control group (Figure 5.4). Mice
irradiated with 3 Gy of TBI exhibited the slowest tumor growth, although statistical
significance was not achieved at any time point of measure between the 12 to 17 days
following radiation. This experiment was planned to terminate at essentially the same
time point as the one shown in Figure 5.3.
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However, in retrospect, experiment

Figure 5.3. Tumor progression following sequential doses of out-of-field irradiation and
TBI. Each point represents the mean + SEM for 8-12 mice/group. Panel A compares
(•): tumor control mice (non-irradiated tumor bearing mice), (O): mice irradiated with a
single out-of-field fraction of 0.44 Gy y-rays, and (T): mice irradiated with a single TBI
fraction of 0.44 Gy y-rays. Panel B compares (•): tumor control mice (non-irradiated
tumor bearing mice), (O): mice irradiated with a single out-of-field fraction of 1.33 Gy yrays, and (T): mice irradiated with a single TBI fraction of 1.33 Gy y-rays. Panel C
compares (•): tumor control mice (non-irradiated tumor bearing mice), (O): mice
irradiated with a single out-of-field fraction of 2.66 Gy y-rays, and (T): mice irradiated
with a single TBI fraction of 2.66 Gy y-rays. Irradiation occurred 2 hours prior to tumor
cell implantation on day 0. lP < 0.05 vs. tumor control.
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termination based on tumor volume in the non-irradiated control group may have been
preferable. Given the slope of the tumor volume curves for the non-irradiated and TBI
groups in Figure 5.4, it appears that TBI would have eventually resulted in significantly
smaller tumors compared to both the non-irradiated and locally irradiated groups.
Based on previous findings, one immunological variable that correlated with
tumor growth inhibition was an increased CD4:CD8 (Th:Tc) cell ratio. Panels A and B
of Figure 5.5 illustrate alterations in the ratio within the blood and spleen, respectively,
following exposure to out-of-field radiation and TBI. Regression analysis of the blood
data showed a linear relationship between the CD4:CD8 ratio and increasing doses for
out-of-field radiation (R2 = 0.536) and TBI (R2 = 0.658).

The upward shift in the

CD4:CD8 ratio was not dependent on the type of radiation set-up utilized (out-of-field vs.
TBI). However, a radiation dose-dependent increase was evident in the blood. Within the
spleen, the ratio of Th:Tc cells was significantly elevated in the groups irradiated with
2.66 Gy of y-rays when compared to one or more of the other groups.
Spontaneous splenic blastogenesis is a measure of leukocyte proliferation and
activation that reflects in vivo status. Figure 5.5 (Panel C) illustrates standardized splenic
blastogenesis values following administration of out-of-field radiation and TBI. Tumor
bearing mice receiving either 2.66 Gy of out-of-field radiation or 2.66 Gy of TBI showed
the highest levels of spontaneous splenic blastogenesis compared to all other groups
measured.
Similarly, changes in the CD4:CD8 ratio were seen when comparing the effect of
localized irradiation with TBI. Within the blood, mice receiving TBI had higher levels of
Th cells relative to Tc cells compared to locally-irradiated mice, regardless of tumor
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Figure 5.4. Tumor progression following a dose of leg-only irradiation or TBI. Each
point represents the mean + SEM for 8-12 mice/group. The graph shows tumor
progression in (•): tumor control mice (non-irradiated tumor bearing mice), (O): mice
irradiated with a single leg-only fraction of 3.0 Gy y-rays, and (T): mice irradiated with a
single TBI fraction of 3.0 Gy y-rays. Irradiation occurred 2.5 hours prior to tumor cell
implantation on day 0.
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Figure 5.5. Ratio of CD4:CD8 T lymphocytes within the blood and spleen and splenic
spontaneous blastogenesis on day 16 after sequentially increasing doses of out-of-field
radiation and TBI. Each bar represents the mean + SEM for 8-12 mice/group. Panel A
compares CD4:CD8 ratio within the blood between a) tumor control mice (non-irradiated
tumor bearing mice), b) mice irradiated with a single leg-only fraction of 0.44 Gy y-rays,
c) mice irradiated with a single TBI fraction of 0.44 Gy y-rays, d) mice irradiated with a
single leg-only fraction of 1.33 Gy y-rays, e) mice irradiated with a single TBI fraction of
1.33 Gy y-rays, f) mice irradiated with a single leg-only fraction of 2.66 Gy y-rays, g)
mice irradiated with a single TBI fraction of 2.66 Gy y-rays. Panel B compares
CD4:CD8 ratio within the spleen and Panel C compares spontaneous splenic
blastogenesis for identical groups. Spontaneous splenic blastogenesis was calculated as
cpm/106 leukocytes. Irradiation occurred 2 hours prior to tumor cell implantation on day
0. XP < 0.05 vs. tumor control mice, 2P < 0.05 vs. 0.44 Gy out-of-field mice, 3P < 0.05
vs. 0.44 Gy TBI mice, 4P < 0.05 vs. 1.33 Gy out-of-field mice. Black bars denote tumor
bearing mice.
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presence (Figure 5.6, Panels A and B). The splenic values showed a similar pattern,
although tumor-bearing mice receiving local irradiation did evidence higher CD4:CD8
ratios than normal control, tumor control, and local irradiation control mice.
In the localized irradiation experiment, TBI-irradiated mice showed higher levels
of spontaneous blastogenesis than each group of control mice; and in particular, values
for tumor-bearing mice given TBI were significantly greater than any other group (Fig. 6,
Panel C). Equivalently, mice receiving a 3 Gy dose of leg-only irradiation also had
increased spontaneous blastogenesis compared to all groups of control mice.
We also examined the percentage and population density of NK cells within the
spleen and circulating blood after exposure to gradations of radiation. Corresponding to
the results from the previous chapter, NK percentages were enhanced as a consequence of
irradiation, especially at higher out-of-field and TBI doses (Figure 5.7, Panels A and B).
NK cell numbers were not increased at the time of measurement in either the blood or
spleen. Based on the results from the experiments in which TBI was compared to legonly irradiation, TBI contributed to a greater enhancement in NK percentage within the
blood supply (Figure 5.8, Panels A and B). The largest proportion of NK cells in the
spleen was seen for radiation control mice, both those receiving localized irradiation and
those receiving TBI. At the 17-day time point, non-tumor bearing mice receiving TBI
had the lowest NK cell numbers in the blood and spleen compared to other groups,
demonstrating that reconstitution of this particular cell type had not occurred in this
compartment (Figure 5.8, Panels C and D). Tumor-bearing mice receiving localized
radiation or TBI had higher numbers of NK cells within the blood, but not the spleen.
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Figure 5.6. Ratio of CD4:CD8 T lymphocytes within the blood and spleen and splenic
spontaneous blastogenesis following a dose of leg-only irradiation or TBI. Each bar
represents the mean + SEM for 8-12 mice/group. Panel A compares CD4:CD8 ratio
within the blood between a) normal control mice (non-irradiated non-tumor bearing
mice), b) tumor control mice (non-irradiated tumor bearing mice), c) local control mice
(non-tumor bearing mice irradiated with a single leg-only fraction of 3 Gy y-rays), d)
local test mice (tumor bearing mice irradiated with a single leg-only fraction of 3 Gy yrays, e) TBI control mice (non-tumor bearing mice irradiated with a single TBI fraction
of 3 Gy y-rays, and f) TBI test mice (tumor bearing mice irradiated with a single TBI
fraction of 3 Gy y-rays. Panel B compares CD4:CD8 ratio within the spleen and Panel C
compares spontaneous splenic blastogenesis for identical groups. Spontaneous splenic
blastogenesis was calculated as cpm/106 leukocytes. Irradiation occurred 2.5 hours prior
to tumor cell implantation on day 0. XP < 0.05 vs. normal control mice, 2P < 0.05 vs.
tumor control mice, 3P < 0.05 vs. local control mice, 4P < 0.05 vs. local test mice, 5P <
0.05 vs. TBI control mice. Black bars denote non-tumor bearing mice and white bars
denote tumor-bearing animals.
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Figure 5.7. NK cell percentages and population densities within the blood and spleen
following varying doses of out-of-field radiation and TBI. Each bar represents the mean
+ SEM for 8-12 mice/group. Panel A depicts the percentage of NK cells comprising
lymphocyte populations within the blood between a) tumor control mice (non-irradiated
tumor bearing mice), b) mice irradiated with a single leg-only fraction of 0.44 Gy y-rays,
c) mice irradiated with a single TBI fraction of 0.44 Gy y-rays, d) mice irradiated with a
single leg-only fraction of 1.33 Gy y-rays, e) mice irradiated with a single TBI fraction of
1.33 Gy y-rays, f) mice irradiated with a single leg-only fraction of 2.66 Gy y-rays, g)
mice irradiated with a single TBI fraction of 2.66 Gy y-rays. Panel B shows the
percentage of NK cells within the splenic lymphocyte population. NK cell counts are
also depicted in the blood (Panel C) and the spleen (Panel D). Irradiation occurred 2
hours prior to tumor cell implantation on day 0. XP < 0.05 vs. tumor control mice, 2P <
0.05 vs. 0.44 Gy out-of-field mice, 3P < 0.05 vs. 0.44 Gy TBI mice, AP < 0.05 vs. 1.33 Gy
out-of-field mice. Black bars denote tumor-bearing mice.
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Figure 5.8. NK cell percentages and population densities within the blood and spleen
following a dose of leg-only irradiation or TBI. Each bar represents the mean + SEM for
8-12 mice/group. Panel A depicts the percentage of NK cells comprising lymphocyte
populations within the blood between a) normal control mice (non-irradiated non-tumor
bearing mice), b) tumor control mice (non-irradiated tumor bearing mice), c) local control
mice (non-tumor bearing mice irradiated with a single leg-only fraction of 3 Gy y-rays),
d) local test mice (tumor bearing mice irradiated with a single leg-only fraction of 3 Gy yrays, e) TBI control mice (non-tumor bearing mice irradiated with a single TBI fraction
of 3 Gy y-rays, and f) TBI test mice (tumor bearing mice irradiated with a single TBI
fraction of 3 Gy y-rays. Panel B shows the percentage of NK cells within the lymphocyte
population. NK cell counts are also depicted in the blood (Panel C) and the spleen (Panel
D). Irradiation occurred 2.5 hours prior to tumor cell implantation on day 0. XP < 0.05 vs.
normal control mice, 2P < 0.05 vs. tumor control mice, 2P < 0.05 vs. local control mice,
4P < 0.05 vs. local test mice, 5P < 0.05 vs. TBI control mice, 6P < 0.05 vs. TBI test mice.
Black bars denote non-tumor bearing mice and white bars denote tumor-bearing animals.
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Conclusions
When compiled, these data indicate that the antitumor effect of TBI is systemic in
nature as opposed to being related to local phenomena. This is best illustrated by the
tumor progression data, which show that the slow tumor growth due to TBI correlates
with that induced by out-of-field, but not localized, irradiation. Various immune
parameters including the increases in CD4:CD8 T cell ratio, spontaneous splenic
blastogenesis, NK cell percentage, and NK population density correlate with decreased
tumor growth following either TBI or out-of-field irradiation. It should also be noted that
in certain instances, the time point of measurement is critical in assaying these
parameters. The NK cell population density is of particular note since it has been shown
that at day 10 NK cell populations are increased in tumor-bearing mice receiving a 3 Gy
dose of y-irradiation while NK numbers return to normal levels by day 16 and 17. The
data also serve to demonstrate that a number of immunological factors may be involved
in limiting tumor growth following pre-exposure to radiation and that the interaction of
multiple factors may contribute to the overall effect observed.

A change in each

individual factor, in and of itself, may not be sufficient to tip the balance in favor of
effective immune attack against tumor cells. Thus, measurement of a single factor may
not be predictive of biological outcome.
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Chapter Introduction
The previous study implicated several factors that could have altered tumor growth
independent of systemic immunomodulation (e.g. tumor bed effect). By assessing the
radiation set-up, we were able to clarify the dose of radiation absorbed by the trunk and
leg of mice; thereby differentiating between the contribution of total-body and localized
radiation to the antitumor effect. It was evident that immune changes, seen within
systemically irradiated groups, closely mirrored each other, as did delays in tumor
progression. Further, we were able to establish that increasing doses of radiation, up to
2.66 Gy, resulted in an amplification of the antitumor response.
Based on these findings, along with those presented in Chapter Four, the data
supported the hypothesis that the reduction in lung carcinoma progression by whole-body
irradiation is correlated with selective immune upregulation independent of vasculature
or stromal changes at the tumor cell implantation site. Additionally, these investigations
pointed to a relationship between lymphocyte subset activation changes and the
administration of radiation.

Most importantly, the data implicated NK cell activity

changes. In keeping with our hypothesis, it was critical to characterize NK and T
lymphocytes in the blood and spleen, determine if an inflammatory cell infiltrate was
present within tumors, and determine the identity of infiltrating cells. The presence of
cytokines (IL-12, IL-18, etc.) within these various compartments was also evaluated
because these factors are potent activators of NK and T cells.
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Abstract
Alterations in cytokine secretion, activation marker expression, and immune cell
concentrations were investigated at sequential time points following delivery of totalbody irradiation (TBI) to C57BL/6 mice (n=64) in the Lewis lung tumor model.
Significantly slower tumor growth was observed when a 3 Gy dose of TBI was
administered two hours prior to tumor implantation (PcO.OS). The antitumor effect was
correlated with an increased CD4:CD8 T cell ratio and heightened leukocyte
blastogenesis. TBI was also found to induce an expansion of natural killer (NK) cells in
the blood and spleens of tumor-bearing animals at 10 days post-irradiation (2.8xl06 NK
cells/spleen in test mice compared to 8.9xl05 NK cells/spleen in normal control animals).
However, no significant differences were found in NK cell levels within the tumor tissue.
Enhanced production of interleukin-12 (IL-12) and IL-18 from spleen supernatants was
consistent with an augmentation of the NK cell response. Significant reductions in
transforming growth factor-pl (TGF-pl) and vascular endothelial growth factor (VEGF),
both of which are associated with immune suppression, were also noted. Furthermore,
TBI induced changes in expression of CD25 and CD71 activation markers, suggesting
that radiation may alter tumor surveillance. Taken together, the relative percentages and
activation status of immune cell compartments support the conclusion that these TBIinduced changes function to slow tumor progression.
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Introduction
While numerous experiments have documented the immunosuppressive effect of highdose total-body irradiation (TBI) [1,2], mounting evidence suggests that an augmentation
of certain immune parameters can be achieved when TBI is given in low-doses [3,4].
Current therapeutic regimens for low-grade non-Hodgkin’s lymphoma and chronic
lymphocytic leukemia, which have resulted in long-term remission in some patients,
include treatment schedules that prescribe a total cumulative dose between 1.5 to 2.0
Gray (Gy) [5,6]. Experimental findings, supporting the immune-stimulatory effects of
low-dose TBI, have even prompted the suggestion of using radiotherapy for the treatment
of patients with AIDS [7]. However, the optimization and use of this approach in further
applications has been limited because the underlying mechanisms remain unclear.
Within the last decade, research has suggested immune intervention as a possible
mechanism whereby low-dose TBI enhances the control of malignant processes.
Hashimoto and colleagues correlated a reduction in metastases to an augmentation in
tumor-tissue infiltrating lymphocytes and a proportional increase in CD8+ T cells
following a 0.2 Gy dose of TBI [3]. An upregulation of interferon-y (IFN-y) and tumor
necrosis factor-a (TNF-a) mRNA combined with a decrease in transforming growth
factor-P (TGF-P) expression by splenocytes were also noted. Other studies have reported
that T cells are responsive to low-dose irradiation and can proliferate more extensively
than B cells [4]. Furthermore, splenic and thymic lymphocyte proliferation induced by
TBI are potentially mediated through signal transduction within these cells [8,9].
Despite the conclusions of these reports, the comparison of immune compartment
changes incurred by moderate- and low-dose TBI is imprecise, especially when these
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differences are applied to the functioning of antitumor responses. Although NK cells
have traditionally been considered the cells primarily involved in immune surveillance,
the tumoricidal properties of T lymphocytes, monocyte-macrophages, and neutrophils
have also been demonstrated [10-13]. The observation that immunocompromised
individuals are predisposed to enhanced tumor incidence and progression lends credence
to the conclusion that the collective tumor destruction waged by these cells is substantial
[14]. While it is known that lymphoid cells and organs are extremely susceptible to the
effects of ionizing radiation, different cell types display varying degrees of
radiosensitivity [15,16]. Certain populations, including NK cells and y/5 T lymphocytes,
may participate in limiting tumor progression after TBI because they have been shown to
possess potent tumoricidal activity and are resistant to p5 3-mediated apoptosis, a
mechanism by which ionizing radiation can induce cell death [17-19]. Research has
suggested that immune augmentation can also result from a depletion of T suppressor
populations following sublethal irradiation [11,20].
This study was undertaken to follow lung carcinoma progression after a moderate,
sublethal dose of TBI and to investigate the corresponding effect of irradiation on
immune status. This interaction was evaluated when tumor cells were implanted post
irradiation. We correlated several underlying mechanisms with slowed tumor growth up
to a time point of 10 days post-irradiation. Significant variations in immune parameters
included shifts in the relative percentages and numbers of lymphocytes, alterations in
activating and suppressive cytokines, as well as changes in activation marker expression.
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Materials and Methods
Animals
Eight- to nine-week old, C57BL/6 male mice (n=64) were purchased from Charles River
Breeding Laboratories, Inc. (Hollister, CA), acclimatized, and housed under standard vivarium
conditions. At study initiation, the animals were assigned to four groups: 1) Normal control - no
radiation, no tumor; 2) Tumor control

no radiation, tumor; 3) Radiation control - radiation, no

tumor, and 4) Test - radiation, tumor. There were 8 mice/group at each of the two time points of
assay (days 4 and 10).

In compliance with the American Veterinary Medical Panel on

Euthanasia, mice were euthanized humanely using rapid C02 asphyxiation.

This study was

approved by the Institutional Animal Care and Use Committee of Loma Linda University.

Total-Body Irradiation
At the time of TBI, all mice were restrained individually in 1 -mm thick, rectangular plastic
boxes (3 x 3 x 8.5 cm) with air holes. Two groups (radiation control and test mice) were
irradiated with a single 3 Gy dose of photons (1.36 Gy/min) from a 60Co source with up to 8
animals per field of exposure. An AECL Eldorado therapy unit (Atomic Energy Canada, Ltd.,
Commercial Products Division, Ottawa, Canada) was used for radiation delivery. Calibration
was performed using a Capintec Model PR06-G cylindrical thimble ionization chamber,
traceable to the National Institute of Standards and Technology (NIST).

Radiation was

administered 2 hr before tumor cell implantation.

Tumor Cells and Tumor Induction
The Lewis lung carcinoma cell line, obtained from the American Type Culture Collection,
(ATCC; Rockville, MD) was maintained by subcutaneous (s.c.) in vivo passage. Tumors were
excised from maintenance mice, processed into a slurry, and injected s.c. into the right hind flank
at a volume of 0.1 ml/mouse. Mice, not implanted with tumor, were injected with PBS. Tumor
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dimensions were measured with vernier calipers and volumes were calculated: width x length x
height/2.

Hematological Analyses of Blood and Spleen
Whole blood was collected by cardiac puncture into syringes containing EDTA. Spleens were
processed into single-cell suspensions and erythrocytes were lysed in 2 ml of lysing buffer. The
remaining leukocytes were washed and suspended in 2 ml of RPMI 1640 medium (Irvine
Scientific, Santa Ana, CA) supplemented with 10% heat-inactivated fetal calf serum (PCS)
(Hyclone Laboratories, Logan, UT), 5 x 10'5 mM 2-mercaptoethanol (Gibco BRL, Grand Island,
NY), 50 I.U./ml penicillin, and 50 pg/ml streptomycin (Sigma Chemical Co., St. Louis, MO).
Leukocyte, erythrocyte, and thrombocyte parameters were evaluated using a Vet ABC
Hematology Analyzer (Heska Corporation, Waukesha, WI).

Spontaneous and Mitogen-Induced Blastogenesis
Aliquots of whole blood and spleen leukocytes were labeled for 3 hr with 3H-thymidine (3HTdR) and spontaneous blastogenesis was quantified using a beta scintillation counter as
previously described [16,21]. The proliferative response of spleen leukocytes cultured with T and
B cell mitogens (phytohemagglutinin, PHA; concanavalin A, ConA; lipopolysaccharide, LPS)
was evaluated after 2 days of coincubation by the 3H-TdR incorporation method [16,21]. All
mitogens were obtained from Sigma.

Analysis of Lymphocyte Populations and Cell Marker Expression
Blood and spleen lymphocytes were identified using the direct staining method and 4-color, 2tube mixtures of fluorescence-labelled monoclonal antibodies (mAb). Pharmingen designed mAb
specific for CD3+ T, CD3+/CD4+ T helper (Th), CD3+/CD8+T cytotoxic (Tc), B220+ B and
NK1.1+ NK cells in collaboration with Becton Dickinson (San Jose, CA). Immunophenotyping

131

of cells expressing CD25, CD71, TCRp, and NK1.1 (Pharmingen) was also carried out in order to
quantify cellular activation and NKT populations, respectively. All mAbs were conjugated with
fluorescein isothiocyanate (FITC), R-phycoerythrin (PE), allophycocyanin (APC), or peridinm
chlorophyll protein (PerCP).

At least 5,000 events were acquired before analysis with

CellQuest1M software version 3.1 (Becton Dickinson).
Lymphocyte populations are reported as the number of cells/ml of blood and the number of
cells/whole spleen after multiplying normalized percentages (obtained by FACS Calibur, TM
Becton Dickinson) by the total lymphocyte count per animal (obtained from the Vet ABC
Hematology Analyzer), the appropriate dilution factor, and the suspension volume (spleen only).

Cytokine Analysis
Commercially available kits were used to quantitate the levels of interleukin-2 (IL-2), IL-12,
IL-18, TGF-pi, and vascular endothelial growth factor (VEGF) in plasma, tumor and/or spleen
supernatants. Tumor supernatants were obtained from minced tissue centrifuged at 400 g for 10
min. Cytokine concentrations in supernatants were normalized to tumor weight. Spleen cell
supernatants were harvested after culture in unconditioned or PHA-containing media for 48 hr.
All enzyme-linked immunosorbent assay (ELISA) kits were purchased from R&D Systems,
Minneapolis, MN except for the IL-18 kit which was obtained from MBL Co., LTD, Naka-ku
Nagoya, Japan.

Immunohistochemistry and Laser Scanning Cytometer Analysis
At euthanasia, tumors from mice were excised and frozen in HistoPrep tissue-embedding
medium (Fisher Chemicals, Fair Lawn, New Jersey) at -70°C. After sectioning, tumors slices (5
pm) were fixed in -20°C 70% ethanol, rehydrated in PBS, then blocked with gelatin blocking
buffer. Macrophages, neutrophils, Tc cells, and NK cells were immunolabeled using primary
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antibodies against the following mouse leukocyte markers at the indicated dilutions: Mac-3 (1:20;
BD Pharmingen International), Ly6G/C (1:100 BD Pharmingen International), CD8b.2 (1:500
BD Pharmingen International), and Asialo GM1 (1:1000 Wako Chemicals USA, Inc., Richmond,
VA). Application of secondary antibody, propidium iodide (PI), and coverslips was performed as
previously described [22].
Slides were analyzed using a multiparameter laser scanning cytometer (LSC; CompuCyte
Corporation, Cambridge, MA) and Wincyte™ software (Compucyte Corp.) as previously
described [23]. To quantify cells of interest, gating parameters were set to contour red (PI) and
green (FITC or Alexa Fluor® 488, Molecular Probes, Eugene, OR) fluorescence intensity. Using
a phantom contour overlay, uniform counting was standardized for all tumor sections. The entire
tumor section was scanned and displayed in an x, y map. The average number of cells per tumor
section was 12,720+/-736. Display and threshold settings were adjusted after visual inspection
using a CCD camera and once protocols were determined, they were used for all samples within
an experimental set. Images were viewed with an Olympus BX-60-based microscope (Scientific
Instruments, Temecula, CA) then captured using an OLY-750 analog camera and Image Pro Plus
software (Media Cybernetics, Silver Springs, MD).

Statistical Analysis
Data were analyzed by one-way analysis of variance (ANOVA) using group as the
independent variable. Post-hoc Tukey’s HSD (honestly significant difference) multiple range test
was used to compare sets of two groups at each time point of assay. Differences were considered
significant only if the P value was < 0.05.
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Results
Slowed Tumor Progression Following TBI
To confirm whether TBI, administered at a moderate dose, can slow the progression of
lung carcinoma in a syngeneic model, mice were injected with Lewis lung carcinoma
(LLC) cells following a 3 Gy dose of y-rays. As shown in figure 1, tumor growth was
significantly protracted in mice receiving TBI two hours prior to implantation compared
with non-irradiated tumor-bearing controls (P<0.05). Tumor volumes in both groups
were not measurable on day 4.

Leukocyte Counts and Three-part Differential
Leukocyte populations were evaluated to measure the composition of immune cells in
the blood and spleen (table 1). Lymphocyte, monocyte, and granulocyte counts were
substantially reduced in both irradiated groups at both days 4 and 10, with the exception
of recovery of granulocyte numbers by the later time point. Additionally, while absolute
numbers of monocytes and granulocytes were decreased as a result of radiation, there was
a shift in relative percentages of these cells. On day 4, granulocyte percentages in both
radiation groups exceeded normal and tumor control levels in the blood (56.7+/-1.9 and
60.1+/-0.9 vs. 32.4+/-2.9 and 44.9+/-2.6 respectively) (P< 0.025).

Overall, tumor

presence alone contributed to increases in these leukocyte populations (table 1). The
analyzer also automatically provides red blood cell concentration, hemoglobin, and
hematocrit, all of which were reduced in both radiation groups when compared to normal
and tumor controls on days 4 and 10 (P < 0.02) (data not shown).
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Spontaneous and Mitogen-Induced Blastogenesis ofLeukocytes Following Irradiation
To determine the susceptibility of immune cells to the effects of ionizing radiation,
blood and splenic leukocytes were examined for basal DNA synthesis and response to
mitogen stimulation. Spontaneous blastogenesis of blood leukocytes was markedly
increased in both irradiated groups of mice at 4 days, following irradiation and
implantation (^<0.05) (table 2). At day 10, these groups also exhibited pronounced
uptake of 3H-TdR {P < 0.01). When compared together, the difference in cpm values
obtained for normal mice tested on days 4 and 10 (table 2) reflects the inherent variability
of the assay.

Similar increases in spontaneous blastogenesis were observed for

splenocytes. Tumor-bearing mice receiving radiation (test animals) exhibited the highest
levels of spontaneous, splenic blastogenesis compared to all other groups, although
statistically significant differences were seen only at day 4 (23,442 +/- 4,235 cpm for test
mice compared to 10,604+/- 1,308 and 9,203 +/- 574 for normal and tumor control mice,
respectively). In contrast, a dramatic reduction in proliferative response to both T (PHA
and ConA) and B (LPS) cell mitogens was observed for splenocytes from tumor-bearing
mice receiving radiation (table 2). Radiation exposure was correlated to this effect.

TBI-Induced Alterations in Cytokine Expression
The expression of selected cytokines was quantified to determine the nature of the
immune response as well as to elucidate NK cell involvement.

IL-2 levels were

depressed in both radiation groups compared to normal controls at days 4 and 10 as
measured in conditioned spleen supernatants (P<0.05) (table 3). In contrast, substantial
increases in the expression of IL-12 occurred in both stimulated and unstimulated spleen
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supernatants from irradiated groups, as shown in figure 2 (P<0.05). While neither IL-12
nor IL-18 concentrations were significantly different in tumor supernatants of control and
tumor-bearing mice receiving radiation, a slight trend toward upregulation of IL-18 in
irradiated animals was noted. Further, TGF-f31 expression was reduced in tumor-bearing
irradiated mice compared to all other groups (table 3).
To determine whether VEGF expression was modified following irradiation, we
measured VEGF concentrations by ELISA. VEGF levels were depressed in plasma from
test mice compared to normal control values (P < 0.05) (table 3).

In contrast, no

statistically significant differences were observed in supernatants derived from tumor
(2,844+7-518 pg/g in tumor control mice; 2,782+7-199 pg/g in test mice).

Distribution and Reconstitution ofLymphocyte Populations after Irradiation
In order to evaluate the distribution and reconstitution of leukocytes following TBI, we
used flow cytometry to analyze lymphocyte populations in the blood and spleen. At day
4, mice receiving radiation, regardless of tumor presence, had dramatically depleted
populations of CD3+ T, B220+ B, CD3+/CD4+ Th, and CD3+/CD8+ Tc cells in both
blood and spleen (.PcO.CG) (fig. 3). Lymphocyte populations in tumor controls, however,
were statistically similar to normal control mice at this first time point. By day 10, partial
repopulation of depleted subsets within irradiated groups had occurred. CD3+/CD4+ Th
cells from tumor-bearing mice receiving radiation had returned to normal control levels
by the 10 day time-point in the spleen and blood, but these values were still below the
elevated concentrations seen in tumor control mice.

In both the blood and spleen,

CD3+/CD8+ Tc cells remained statistically depressed in both radiation groups when
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compared with normal controls. On day 10, as on day 4, the B cell population in both
irradiated groups was below normal densities.

In contrast, tumor control mice had

heightened counts at both time points. NK cell numbers in spleens from test mice were
reduced compared to all other groups at the earlier measurement (fig. 3). By day 10,
however, this population had dramatically increased to greater than three times normal
and tumor control levels and was twice that of radiation control values.

NKT

(NKl.l/TCRp double positive) cell percentages were elevated in spleens of test mice
compared to all other groups on day 10 (P<0.02). However, no differences in relative
values of NKT cells were observed in the blood (data not shown).
To clarify the radiosensitivity of T cell subsets, we calculated CD4:CD8 (Th:Tc) ratios
from population data. In all instances and time-points measured, the CD4:CD8 ratio was
significantly enhanced in irradiated groups compared to normal and tumor controls (table
4). This shift can be attributed to radiation rather than tumor presence.
We also performed LSC analysis to quantify leukocyte infiltration within tumors of
irradiated and non-irradiated mice after immunostaining for Tc cells, macrophages,
neutrophils, and NK cells using primary antibodies directed against CD8b.2, Mac-3,
Ly6G/C, and Asialo GM1 respectively. No differences were observed in percent tumor
infiltration of any individual leukocyte population as related to the administration of
radiation (fig. 4). The most noticeable alteration was a trend toward a reduction in Tc
cell presence within tumors of irradiated mice (P<0.087).
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Alterations in Activation Marker Expression Following TBI
To evaluate the activation state of lymphocyte populations, we gauged the expression
of CD25 and CD71 by flow cytometry analysis. In blood and spleen, the proportion of
lymphocytes with CD25 and CD3/CD25 markers was selectively increased on day 4 in
mice receiving radiation, regardless of tumor presence (fig. 5) {P< 0.05). Conversely,
percentages of lymphocytes expressing CD71 and CD3/CD71 in these groups were
reduced in the blood, but not the spleen. Figure 5 also depicts the proportion of CD71 +
cells per group in representative blood samples, collected on day 4.
By day 10, expression of CD25 and CD3/CD25 was still elevated in the spleens of
radiation control mice compared to normal control and tumor control groups (fig. 5)
(PO.Ol). Significance was not seen in test mice. In the blood, CD25 cell percentages
were heightened in both test and radiation control mice although CD3/CD25 percentages
were similar between these groups. In tumor-bearing mice receiving radiation (test),
relative CD71 expression in the blood and spleen was not altered compared to other
groups; in contrast, CD3/CD71 percentages in the spleen were significantly greater than
in all other groups (P<0.02).
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Table 6.1. Blood leukocyte population counts at 4 and 10 days post-irradiation
expressed as 106 cells/ml

Normal

Tumor-bearing

control

control

control

+ Radiation

Radiation

Tumor-bearing

Day 4
WBCsa(xl06/ml)

4.98+/-0.61b

6.60+/-0.59

1.48+/-0.11 c,d

1.58+/-0.10c,<l

Lymphocytes

2.91+/-0.27

3.13+/-0.23

0.48+/-0.03 c,d

0.48+/-0.03c,d

Monocytes

0.26+/-0.04

0.34+/-0.02

0.04+/-0.02c’d

0.05+/-0.02c,d

Granulocytes

1.80+/-0.40d

3.14+/-0.40

0.96+/-0.08c,d

1.05+/-0.06c,d

WBCsa (x 106/ml)

4.66+/-0.341’

7.15+/-0.57

2.39+/-0.36c,d

3.24+/-0.41d

Lymphocytes

2.05+/-0.25

2.38+/-0.26

0.80+/-0.23 c,d

0.46+/-0.03c,d

Monocytes

0.25+/-0.03

0.31+/-0.04

0.14+/-0.02c'd

0.14+/-0.03c,d

Granulocytes

2.36+/-0.39d

4.46+/-0.46

1.45+/-0.15d

2.64+/-0.38d

Day 10

After collection by cardiac puncture, leukocyte counts within whole blood were measured
using a Vet ABC Hematology Analyzer. aWhite blood cells. bMean +/- SEM, n= 8
mice/group. CP < 0.05 vs. normal control. AP < 0.05 vs. tumor-bearing control.
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Table 6.2. Spontaneous blastogenesis in blood and mitogen stimulation indices for
spleen leukocytes at two time points subsequent to irradiation and tumor implantation

Normal
control

Tumor-bearing
control

Radiation

Tumor-bearing

control

+ Radiation

Day 4
Spont. blood3

4709+/-392c

4274+/-S53

12641+/-1093 d,e

13995+/-3121 d,e

SI PHAb

157.2+/-14.6

136.4+/-9.2

42.8+/-12.9d,e

35.8+/-10.1 d,e

SI ConAb

202.1+/-14.8

182.9+/-9.9

55.9+/-20.3 d,e

30.8+/-10.0<l’e

SI LPSb

221.4+/-27.9

177.0+/23.2

103.6+/-27.3d

Spont. blood3

2664+/-380c

3616+/-500

7663+/-1037d,e

7587+/-992d,e

SI PHAb

164.9+/-26.4

215.2+/-42.0

64.2+/-7.8e

35.0+/-6.7d,e

SI ConAb

213.8+/-36.3

277.4+/-58.7

167.5+/-25.7

84.6+/-16.5e

SI LPSb

277.7+7-85.3

219.1+/-50.7

156.1+/-25.7

64.2+/-17.3 d,e

Day 10

105.8+/-10.1

Following a three-hour incubation with 3[H] TdR, spontaneous blastogenesis of blood
leukocytes (Spont. Blood) was quantified by scintillation counter. To determine the
proliferative response of spleen leukocytes to various B and T cell mitogens, 3[H] TdR
incorporation was measured after two days of coincubation with specified mitogen.
Spontaneous blastogenesis of blood (cpm). bStimulation Indices for specified mitogen
where SI = (cpm with mitogen - cpm without mitogen)/cpm without mitogen. cMean +/SEM, n = 8 mice/group. dP < 0.05 vs. normal control. CP < 0.05 vs. tumor-bearing
control.
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Table 6.3. Cytokine expression within plasma, tumor, and/or spleen supernatants at 4
and 10 days post-irradiation.

Normal
control

Tumor-bearing
control

Radiation
control

Tumor-bearing
+ Radiation

Day 4
Spleen
IL-2a

46.6+/-1.6d

25.1+/-10.4

6.9+/-3.6e

4.0+/-2.3e

Day 10
Spleen
IL-2a

93.1+/-6.6d

26.1+/-7.5'

37.9+/-1.9e

19.2+/-9.0e

Tumor
IL-12b

317+/-19

IL-18b

8,936+/-783

Plasma
TGFpc
mVEGFc

322+/-2S
10,434+/-643

23.82+/-4.39

18.82+/-3.48

15.10+/-2.47

9.77+/-1.23e

20.6+/-4.7

14.8+/-2.5

10.9+/-4.0

4.2+/-2.6e

Commercially available ELISA kits were used to determine concentrations of cytokines
in plasma, tumor, and/or spleen supernatants. aSpleen supernatant sample stimulated with
PE1A (pg/ml). bTumor supernatant sample (pg/g). cPlasma sample (TGF-pl, mg/ml;
mVEGF, pg/ml). dMean +/- SEM, n = 8 mice/group. eP < 0.05 vs. normal control.
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Table 6.4. Ratio of CD4+:CD8+ (Th:Tc) lymphocytes within the blood and spleen of
irradiated tumor-bearing mice at two time points following irradiation and tumor
implantation3

Normal

Tumor-bearing

Radiation

Tumor-bearing

control

control

control

+ Radiation

Day 4

Spleen

1.60+/-0.07b

1.67+/-0.08

2.51+/-0.12 c,d

2.54+/-0.12c'd

Blood

1.56+/-0.08

1.56+/-0.05

2.77+/-0.06 c,d

2.78+/-0.13 c,d

Spleen

1.67+/-0.08b

1.74+/-0.10

2.66+/-0.11 c,d

2.44+/-0.19c’d

Blood

1.64+/-0.10

1.68+/-0.04

2.79+/-0.11 c,d

2.92+/-0.17c,d

Day 10

CD3+/CD4+ Th and CD3+/CD8+ Tc cell counts were determined by flow cytometry
analysis of blood and spleen using a 4-color, 2-tube mixture of fluorescence labeled mAb
to stain for lymphocyte populations. aRatios were calculated from cell population
densities. bMean +/- SEM, n = 8 mice/group. CP < 0.05 vs. normal control. dP < 0.05 vs.
tumor-bearing control.
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Fig. 6.3. Major lymphocyte populations in peripheral blood and spleen from test and
control mice at 4 and 10 days following irradiation. Blood and unlysed spleen samples
were stained using a 4-color, 2-tube mixture to distinguish among T, T helper, T
The first tube contained CD3*FITC, NK1.1*PE,
cytotoxic, B, and NK cells.
CD45*PERCP, and B220*APC; the second tube contained CD3*FITC, CD8*PE,
CD45*PERCP, and CD4*APC. Labeled cells were analyzed using a flow cytometer.
Each point represents the mean +/- SEM for 8 mice/group calculated from absolute
lymphocyte numbers. Statistical analysis compared groups within day of testing, a:
P<0.05 vs. normal control; b: P<0.05 vs. tumor control (non-irradiated), c: P<0.05 vs.
radiation control, d: R<0.05 vs. test mice (tumor-bearing mice receiving radiation). Panel
A: blood (total lymphocytes/ml), Panel B: spleen (total lymphocytes/whole spleen).
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Fig. 6.4. Tumor infiltration of CD8+ Tc cells in irradiated and non-irradiated mice at 10
days post-exposure. Propidium iodide (red) stains the nuclei of cells while Alexa Fluor®
488 conjugated anti-rat secondary antibodies identify anti-CD8 (CD8b.2) labeled cells.
Images, taken at 60x magnification, are representative samples from each group where a.
positive control spleen section, b: tumor section from non-irradiated (tumor control)
mouse, c: tumor section from irradiated (test) mouse. The experimental section, panel c
has a slightly reduced % of infiltrating CD8 cells, but the % is not significantly different
from the non-irradiated sample shown in panel b. The table shows average tumor
infiltration of Tc cells (CD8+), macrophages (Mac-3+), neutrophils (Ly6G/C+), and NK
cells (AsialoGMl+) within tumor control mice and test mice as quantified by LSC
analysis. Infiltration is shown as a percentage of the total cells scanned and each value
represents the mean +/- SEM for 7-8 mice/group on day 10.
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Fig. 6.5. CD71 expression in peripheral blood at 4 days following irradiation.
Identification of cells expressing CD71 and CDS was performed by flow cytometry using
mAbs designed by Pharmingen. Expression is shown as a percentage of gated
lymphocyte populations. Dot blots are representative samples from each group on Day 4
where A: normal control, B: tumor control, C: radiation control, D: test (tumor-bearing +
radiation). The table shows average expression of CD71 and CD25 within the blood and
spleen respectively, and each value represents the mean +/- SEM for 8 mice/group on
days 4 and 10 after irradiation and tumor cell implantation, a: P<0.05 vs. normal control;
b: P<0.05 vs. tumor control (non-irradiated), c: PO.05 vs. test mice (tumor-bearing mice
receiving radiation).
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Discussion
While the prevailing consensus is that radiation exposure increases the risk for
development of malignancy, there is increasing evidence that low to moderate doses of
radiation may alter immune cell composition and function so that immune responsiveness
is heightened, rather than diminished. Data supporting this latter possibility have been
partly derived from studies in which relatively low priming doses of radiation have
induced protection of lymphocytes, lymphoid tissues, and hematopoietic progenitors
against subsequent exposure to a high dose of radiation, i.e., a radioadaptive response. In
some of these reports, it has been noted that the onset of thymic lymphoma is
significantly delayed in mice pre-conditioned with low-dose radiation [24]. Low dose
exposure has also been used to delay or inhibit the growth of transplanted tumors in mice
[25].
The results of this study illustrate that an acute, moderate dose of TBI administered
prior to tumor challenge significantly slows the growth of Lewis lung carcinoma in
C57BL/6 mice. The two time points selected for analysis in the present study were based
on data generated from our previous investigations in which the effects of whole-body
irradiation on immune parameters were measured at multiple intervals, ranging from 0.5
to 29 days post-exposure [16,21,22,26]. A significant difference in tumor volume
between irradiated and non-irradiated groups could also be attained by day 10. Our
previous study evaluating the effects of pre-irradiation on Lewis lung tumor progression
demonstrated that this effect is observable within a dose range of 1.33 to 3 Gy of y-rays,
but not below 0.46 Gy [26]. Radiation-induced alterations of immune cell parameters
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suggested a correlation with the dynamics of tumor growth and prompted us to
investigate further.
While TBI dramatically reduced all lymphocyte populations, the dynamics of recovery
and activation may be critical factors in the significantly slowed rate of tumor
progression.

Reductions in lymphocyte populations paralleled differences in

radiosensitivity among cell subsets [16,21,27]. Two facets of this alteration appear to be
important.

First, an increase in the CD4:CD8 ratio in both the blood and spleen

corresponded with a decrease in tumor growth rate. This ratio has been highly correlated
with the growth of certain cancers, and data from some studies suggest a connection
between an increase in the CD4:CD8 ratio and tumor regression [28,29]. Results have
also shown that a reduced CD4:CD8 ratio is indicative of metastatic spread [30].
A second alteration that appears to be critical is the increase in NK cell population,
observed within the blood and spleen of test mice by day 10. NK cells have been shown
to possess potent tumoricidal activity and can be activated by a variety of cytokines.
Lysis of targets is mediated through the release of cytotoxic factors and perforins that
form channels in target cell membranes. NK cell activity is greatly enhanced by cytokines
such as IL-12 and IL-18 [31], both of which were increased in the irradiated mice.
Furthermore, cytokines such as IFN-y and TNF-a that are secreted by activated NK cells
can augment the antitumor effects of macrophages that may be in the near vicinity. NKT
cells, a subpopulation of T cells typically expressing both NK1.1 and an invariant T cell
receptor chain, have also been shown to play a role in antitumor defense including the
regulation of conventional T cells [32]. We found increased proportions of NKT cells in
irradiated test mice compared to all other groups at the final time point. The shift toward
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increased granulocyte percentages in test mice may also facilitate malignant cell control
by direct tumor cytolysis or indirectly through removal of cellular debris. While the
analysis of leukocyte infiltration within tumors did not demonstrate any numerical
differences between irradiated and non-irradiated groups, this is not necessarily
descriptive of cytolytic or phagocytic activity. Concurring with other reports of enhanced
NK activity following low-dose TBI, one of our previous studies showed heightened NK
cytotoxicity in mice receiving 3 Gy of irradiation [26].
Spontaneous blastogenesis of leukocytes, a sensitive indicator of overall DNA
synthesis, was enhanced by radiation in the presence of tumor. TGF-(31, on the other
hand, can suppress aspects of immune responsiveness in vivo, as characterized by the
inhibition of NK activity and differentiation of naive T cells [33,34]. On day 10, TGF-|31
concentrations were diminished in the plasma of tumor-bearing mice receiving radiation.
While mitogen responses were reduced in both irradiated groups, it has been noted that in
vitro unresponsiveness as measured by stimulation assays can reflect activation of killers
in vivo [35]. The reduction in lymphocyte numbers combined with a downregulation of
IL-2 suggests that Thl cells were compromised by radiation. Consequently, T cytotoxic
cells appear to contribute little to the antitumor response given that they require IL-2 for
activation and clonal expansion.
In consideration of neoangiogenesis promotion, VEGF was not increased at the tumor
site as a result of irradiation.

We also observed a notable decrease in VEGF

concentration within the plasma of tumor-bearing mice receiving TBI. Evidence has
suggested that increased plasma and serum concentrations of VEGF may be indicative of
presence and/or stage of various cancers [36,37]. The reasons for the lack of increased
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VEGF concentration in the plasma of tumor-bearing mice are unclear.

To our

knowledge, this is the first study in which the circulating level of the factor has been
measured in this tumor model and hence there are no previous reports to compare our
data with. Minimally, our findings support the premise that the observed decrease in
VEGF expression may have contributed to the tumor-inhibitory effect of radiation.
The altered expression of activation markers following irradiation points to changes in
lymphocyte proliferation and activation status. Since IL-2 receptor (CD25) upregulation
was simultaneous with a decrease in IL-2 expression on day 4, radiation-induced damage
appears to limit T cell activity at this time point. Overall percentages of CD25 and
CD3/CD25 positive cells had returned to normal levels by the day 10 time point, while
cells with CD3/CD71 expression were elevated in the spleen compared to all other
groups. Since CD71 expression is closely associated with cell proliferation, the increase
could signal a repopulation of T lymphocyte numbers [38].
Taken together, the data lend credence to the concept that the effect of radiation
on the immune system is more complex than simply decreasing leukocyte numbers. It is
feasible that the increased CD4:CD8 ratio, augmentation of NK cell density, high levels
of activating cytokines and low levels of suppressing cytokines, as well as the altered
activation status of lymphocytes all act in combination to significantly slow tumor
growth. The conclusion that enhanced anti-tumor immune activity may play a major role
in the efficacy of TBI is supported by results from pre-clinical studies [3,39]. It has been
demonstrated that low-dose TBI of patients with non-Hodgkin's lymphoma is
immunologically beneficial, significantly increasing the rate of complete remission in
some studies [40,41]. Moreover, nonmyeloablative conditioning represents a promising
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therapeutic tool against malignancies while reducing the risk of complications [42], In a
very recent report of adoptive cell transfer therapy, patients with metastatic melanoma
were given immunodepleting chemotherapy prior to receiving highly tumor-reactive T
cells [43].

Tumor response was remarkably positive compared to numerous clinical

studies conducted previously and were partly attributed to immune destruction by
cyclophosphamide.

This presents the intriguing possibility that exposure to a single

fraction of relatively low-dose radiation could result in a similar degree (and perhaps also
similar pattern) of depletion as a 7-day course of cyclophosphamide. In keeping with this,
additional studies are in progress within our laboratory to further investigate the
immunobiology of this antitumor effect.
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CHAPTER SEVEN
INTERVENING DISCUSSION TWO
Experimental findings of the first two manuscripts highlighted the role of NK
cells in tumor eradication and suggested a probable if not substantial involvement of NK
cells in the antitumor effect of TBI on Lewis Lung carcinoma progression. In taking into
account the cumulative data, the prominence of NK cells came to the forefront based on a
number of observations. First, the NK compartment was found to expand within the
spleen of test mice as much as 300% of normal control values at 10 days post-irradiation
and tumor cell implantation. Along with this, cytokines promoting the activation and
cytolytic capability of NK cells, including IL-12 and IL-18, were upregulated in spleen or
tumor supernatants of tumor-bearing mice receiving TBI. Additionally, NK cytotoxicity
was enhanced at the 4 day time point in mice receiving radiation, regardless of tumor
presence.

Based on these results, we were prompted to investigate the overall

contribution of NK cells to the observed decrease in tumor progression in order to clarify
their role more accurately. In order to do so, we attempted to eliminate the NK cell
population in vivo by the administration of monoclonal antibodies (MAb) that targeted
these cells. As a consequence, this chapter identifies and discusses the methodologies
employed to achieve NK cell depletion.
Cell culturing of PK136 cells (hybridoma cells secreting MAb, specific for
NK1.1) using serum-free medium, the purification of anti-NKl.l antibodies from PK136
supernatants, and the determination of IgG2a concentrations of stock filtrates are
described in the Materials and Methods chapter. Following the completion of these
procedures, a number of protocols within the scientific literature were evaluated and later
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tested for their ability to achieve substantive reduction in NK populations. Overall, the
literature reported a wide variety of time/dose schedules, MAb concentrations, and routes
of injection. Seaman and colleagues tested doses of 1 pg, 10 pg, and 100 pg of antiNK1.1 MAb given as a single i.v. injection to female C57BL/6 mice (Seaman et al.,
1987). They reported a partial depletion with the two lower concentrations, while a loss
of 90% of NK activity was observed at 48 hours after treatment with 100 pg of antiNK1.1 MAb.

This loss of NK activity was sustained up to six days post-injection,

followed by a 40% recovery after 2 weeks. In a second study comparing the efficacy of
three NK depleting antibodies, researchers injected a single 200 pg dose of anti-NKl.l
MAb intraperitoneally and showed significant depletion in NK specific killing 24 hours
later (Ehl et al, 1996). C57BL/6 mice were also used in this evaluation, although they
had been ordered from a different animal supplier than the previous study (Institut fur
Zuchthygiene, Tierspital Zurich, Switzerland).

A protocol, described by Wang and

fellow researchers, outlined a schedule where C57BL/6 mice were injected with 300 pg
anti-NKl.l MAb on days -2 and 0 (day 0 being the initiation of experimental treatment)
and every 5 days thereafter until sacrifice (Wang et al, 1998). Antibody doses in this
protocol were given i.p. and the antibody preparation was diluted in 0.5 ml of saline prior
to injection. A final protocol achieved depletion by administering 100-500 pg of antiNKl.l IgG antibody either i.p. or i.v. via tail vein injection (Carroll et al, 2001). The
female C57BL/6 mice used in this study had been ordered from one of two different
animal labs - Jackson Labs (Bar Harbor, ME) or Taconic (Germantown, NY).
To titrate the anti-NKl.l and evaluate the efficacy of the purified antibody for in
vivo depletion, we employed two different injection/dose schedules. In the first schedule,

164

we administered a total of 600 jag of anti-NKl.l MAb given in two i.p. injections at days
2 and 0 (day 0 being the final time point of Ab injection). Mice were subsequently
sacrificed at days 1, 3, and 5 after the second injection (Table 7.1). In the second
schedule, we administered 500 pg of anti-NKl.l MAb in a single i.p. injection. NK
population percentage and NK cytotoxicity against YAC-1 targets were then assayed at
days 1, 5, and 7 following injection (Table 7.1).

Flow cytometric analysis was

performed to determine the percentages of surviving NK cells (i.e., NK1.1+ cells). The
antibody concentrations were chosen based on previously published data.
The results summarized in Table 7.1 provided several conclusions regarding the
efficacy of the anti-NKl.l MAb. According to these findings, the doses employed were
incapable of achieving the 90% loss of NK function reported in the scientific literature.
Rather, the observed maximum loss of function was only 46% and was seen one day
following treatment with 600 pg of anti-NKl.l antibody (given as 300 pg x 2 injections).
Also, the NK population within the blood was more susceptible to the effects of depletion
when compared with the spleen.

Depletion was sustained in the blood with both

experimental protocols whereas the single injection schedule was more effective in
producing prolonged reduction in NK populations within the spleen. NK cytotoxicity was
more dramatically reduced with the double injection schedule at both days 1 and 5 when
compared to the single injection schedule.
Based on these conclusions, a third protocol was employed in an attempt to
achieve up to 90% NK cell depletion. This protocol involved two 500 pg i.p. injections
of anti-NKl.l MAb, separated by a 2-day interval. NK cytotoxicity and population
density were analyzed 1 and 5 days following the final injection. Table 7.2 shows that
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Table 7.1. Initial anti-NKl.l MAb titration using two different time-dose protocols

Assay

NK Population %
Blood3 Spleenb

40 :1

NK Cvtotoxicitvc
20 :1
10:1

5 :1

Day I"

s.gv1'

Control6
NK(300, 2) \

2.85

Control
NK(500,1)b

4.48
3.72

4.97
2.29

65.7

48.1

37.3

35.5

28.2

19.6

4.05

61.9
44.8

43.2
37.0

39.2
28.6

24.7

3.86

5.76
1.60

10.52
7.36

41.3

37.6

27.5

45.0

32.5

18.9

15.9
11.6

Control
NK(300,2)

7.17
1.45

8.26
7.10

49.8

32.9

28.3

20.0

19.9
16.8

12.8
12.3

Control
NK(500,1)

9.47
2.31

11.12

46.0
31.7

35.3

25.3

7.38

22.9

13.9

14.5
9.9

7.16
1.87

9.66
6.71

61.3
45.1

43.0

26.1
25.1

19.3
14.6

21.5
13.4

16.5

Day 3
Control
NK(300, 2)
Day 5

Day 7
Control
NK(500,1)

31.0

aNK Population % (Blood) - NK population percentage within the blood as measured by flow cytometry.
bNK Population % (Spleen) - NK population percentage within the spleen as measured by flow cytometry.
CNK cytotoxicity determined against YAC-1 targets at effector-to-target ratios of 40:1, 20:1, 10:1, and 5:1.
dTime of euthanasia and assay following last injection (Day 0) of anti-NKl.l MAb.
eControl - PBS or anti-rat IgG (Sigma).
fNK(300,2) - anti-NKl.l MAb administered in two i.p. injections of 300 pg each (600 pg total) at days -2
and 0.
8NK(300,2) - anti-NKl.l MAb administered in one i.p. injection of 500 pg administered at day 0.
hMean, n=l-2 mice/group
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Table 7.2. Third anti-NKl.l MAb titration protocol

Assay

NK Population %
Blood3
Spleenb

40:1

NK Cytotoxicityc
20:1

10:1

Day ld
Control6
NK(500, 2)f

10.8+/-0.4S
5.1+/-0.211

5.8+/-0.3
2.6+/-0.1h

50.7+/-3.0
34.8+/-4.5h

34.3+/-2.2
23.3+/-1.8h

25.0+/-1.3
17.2+/-0.7h

10.7+/-1.0
4.5+/-0.9h

5.1+/-0.3
1.9+/-0.1h

36.6+/-1.7
20.3+/-l.lh

24.4+/-1.5
14.3+/-0.6h

19.0+/-1.6
9.7+/-0.6h

Day 5
Control
NK(500, 2)

aNK Population % (Blood) - NK population percentage within the blood as measured by flow cytometry.
bNK Population % (Spleen) - NK population percentage within the spleen as measured by flow cytometry.
CNK cytotoxicity determined against YAC-1 targets at effector-to-target ratios of 40:1, 20:1, 10:1, and 5:1.
dTime of euthanasia and assay following last injection (Day 0) of anti-NKl.l MAb.
"Control - PBS.
fNK(500,2) - anti-NKl.l MAb administered in two i.p. injections of 500 pg each (1 mg total) at days -2
and 0.
8Mean +/- SEM, n=3-5 mice/group.
HP < 0.025 compared to PBS control.
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NK population density within the blood and spleen were reduced to approximately 50%
of normal values at both times of measurement. The maximum depletion observed was
63% in the spleen at five days post injection. When compared to the previous protocol
and dosing schedule (Table 7.1), the higher dose yielded a greater reduction in NK
percentages especially within the spleen.

However, NK cytotoxicity was not

dramatically different compared to the former studies, even though specific killing was
significantly diminished compared to control groups.
Having observed a greater reduction in blood and splenic NK levels as a result of
increasing the total dose of anti-NKl.l administered, we determined to alternate the route
of injection to enhance this effect. Also, several reports indicated that an i.v. route of
injection requires a lesser concentration of depletion antibody to achieve a similar result.
Consequently, we depleted mice by administering 400, 986, or 1,972 pg of anti-NKl.l
MAb in two split doses administered i.v. into the tail vein. Injections were given at days
2 and 0 while assays were performed either one or two days following the final
treatment.
From the analysis presented in Table 7.3, reduction in NK cytotoxicity and cell
population percentages increased with increasing i.v. doses of the MAb, i.e., a dose
response was evident.

However, the greater than 4-fold increase in anti-NKl.l

concentration did not confer an equivalent amount of depletion/complement-mediated
lysis (i.e. a >4-fold reduction in NK cells was not achieved). NK cytotoxicity data serve
to highlight this feature of titration, in that when 986 pg (0.986 mg) of anti-NKl.l MAb
was given, NK cytotoxicity was essentially equivalent to when the highest dose was
administered. For NK percentage data, higher doses of anti-NKl.l MAb were inversely
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Table 7.3. Fourth anti-NKl.l MAb titration protocol

Assay

NK Population %
Blood3
Spleenb

80:1

NK Cytotoxicityc
40:1

20:1

Dayld
Contror
NK(200, 2) i

9.4+/-0.6'
4.5+/-0.3j

4.0+/-0.2
2.4+/-0.5j

62.3+/-1.2
35.5+/-4.9)

44.0+/-2.3
24.2+/-2.3J

29.S+/-2.7
19.5+/-1.2j

8.5+/-0.3

5.8+/-0.7
2.6+/-0.3j
2.3+/-0.2j

62.9+/-2.5
27.5+/-2.6j
30.3+/-0.8j

54.5+/-2.1
26.8+/-0.5J
26.8+/-1.4J

42.5+/-1.5
21.4+/-1.5J
26.4+/-2.1J

Day 2
Control
NK(493, 2)8
NK(986, 2)h

4.0+/-0.5J

3.3+/-0.5j

aNK Population % (Blood) - NK population percentage within the blood as measured by flow cytometry.
bNK Population % (Spleen) - NK population percentage within the spleen as measured by flow cytometry.
CNK cytotoxicity determined against YAC-1 targets at effector-to-target ratios of 80:1, 40 :1, and 20:1.
dTime of euthanasia and assay following last injection (Day 0) of anti-NKl.l MAb.
eControl - PBS.
fNK(200,2) - anti-NKl.l MAb administered in two i.v. injections of 200 pg each (0.4 mg total) at days -2
and 0.
8NK(493,2) - anti-NKl.l MAb administered in two i.v. injections of 493 pg each (0.986 mg total) at days
-2 and 0.
hNK(986,2) - anti-NKl. 1 MAb administered in two i.v. injections of 986 pg each (1.972 mg total) at days
-2 and 0.
'Mean +/- SEM, n=3-5 mice/group.
JP < 0.04 compared to PBS control.
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proportional to NK density although the level of depletion did not directly correspond to
the concentration injected. Thus, it appears that with i.v. injection there is a plateau, or
saturation point, beyond which increasing doses of the antibody do not increase the level
of NK cell destruction.
Since neither the route of injection nor dose of antibody appeared to have a
significant influence on enhancing the depletion capability of the antibody, we altered the
timing schedule in order to determine its effect on achieving reduction in NK populations
in the blood and spleen. Under a separate protocol, we attempted to achieve depletion by
administering anti-NKl.l MAh at multiple time points while using both i.v. and i.p.
routes of injection in the same animals. Prior to this, the stock solution of anti-NKl.l
MAh was assayed using an anti-mouse IgG ELISA to confirm the concentration of
antibody. The results of the ELISA indicated that the concentration of IgG2a present
within the filtrate stock solution was higher than the concentration estimated by the
Coomassie protein assay (12.10 mg/ml compared to 9.86 mg/ml).

Given the specificity

of the assay, the condition of having grown the PK136 cells in serum-free medium, and
the wide range of MAh doses used, the difference in MAh concentration did not appear to
be the source of the problem.

Following this, test mice were injected with 0.75 or 1.5

mg of anti-NKl.l given in six increments. Mice were injected with either 0.125 or 0.25
mg doses in four i.p. injections on four consecutive days along with two i.v. injections
given on the same day as the second and fourth i.p. injections. Mice were sacrificed four
days following the final treatment, at which time NK population percentages were
measured by flow cytometry.
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Table 7.4 shows NK population percentage within the blood and spleen of mice
treated under this protocol. Based on these results, no additional depletion was achieved
by increasing dose, by altering the timing of injection, or by using two different routes of
administration in the same animal. No significant differences were observed in NK cell
populations within mice receiving the different regimens of anti-NK 1.1 MAb within the
blood and spleen. Rather, it appeared as though a plateau had again been reached in each
of the protocols that was still substantially above the approximately 90% NK1.1 subset
depletion reported in the literature.
In order to explain the inconsistency between the results obtained and the reports
found within the scientific literature, we explored two different possible explanations to
rectify the incongruity. One possibility was that, as a result of the antibody purification
process, the biological activity of the antibody may have been compromised due to the
low pH buffer that was used for column elution. To prevent this occurrence, the antiNK1.1 MAb was reisolated from PK136 supernatants using a sepharose A column that
permitted elution of bound antibody at pH 5 rather than 3. This represented a 100-fold
reduction in acidity.

Secondly, it was suspected that the anti-NKl.l used for flow

cytometric analysis might be identifying a different population of NK cells than the
antibody that had been isolated from PK136 supernatants. To rule out this possibility, the
NK population within the blood and spleen of a mouse was assayed by the direct
cytometric method using purchased anti-NKl.l labeled with FITC as well as indirectly
using the anti-NKl.l antibody, prepared and purified in our laboratory. A goat anti
mouse FITC secondary antibody was used in the indirect labeling procedure. The
populations identified by these two methods overlapped, thus eliminating the possibility
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Table 7.4. Fifth anti-NKl.l MAb titration protocol

Assay

Blood3

NK Population %
Spleenb

Day 4C
Control
NK(0.125, 6)e
NK(0.250, 6)f

8.68+/-0.21g
3.27+/-0.36h
3.20+/-0.46h

6.07+/-0.01
4.56+/-0.29h
4.87+/-0.33h

aNK Population % (Blood) - NK population percentage within the blood as measured by
flow cytometry.
bNK Population % (Spleen) - NK population percentage within the spleen as measured
by flow cytometry.
cTime of euthanasia and assay was four days following last injection (Day 0) of antiNKl.lMAb.
dControl - PBS.
eNK(0.125, 6) - anti-NKl.l MAb administered in 4 i.p. injections and 2 i.v. injections of
0.125 mg each (0.75 mg total) at days -3, -2, -1, and 0.
f

NK(0.250, 6) - anti-NKl.l MAb administered in 4 i.p. injections and 2 i.v. injections of
0.250 mg each (1.50 mg total) at days -3, -2, -1, and 0.

8Mean +/- SEM, n=2-3 mice/group.
hP <0.04 compared to PBS control.
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that the commercially-available antibody and the one prepared in our laboratory were
identifying two distinct and separate NK subsets (data not shown).
As a final measure, the newly purified anti-NKl.l MAb was tested in vivo for
efficacy using a variation of the protocols previously undertaken.

Mice were given a

total dose of 1.25 to 5 mg anti-NKl.l MAb in two i.p. injections at days -2 and 0. Table
7.5 illustrates NK population percentages within the blood and spleen one day after
administration of the final dose. Whereas up to 70% depletion occurred within the blood
of mice receiving the lowest dose of depletion antibody, the amount of depletion was not
proportional to dose when evaluating the other concentrations used. NK counts within
the spleen were not found to be statistically different.
After reassessing the data, we opted to use the original batch of anti-NKl.l MAb
and administer 0.75 mg i.p. doses at two time points immediately before and after
irradiation/tumor cell implantation and six days thereafter. According to this model, we
predicted a 60-70% reduction of NK cells to occur in the blood and at least a 35%
reduction in the spleen. Although this was by no means optimal, this alteration in the NK
density could potentially identify whether or not NK cells were contributing significantly
to the antitumor effect of TBI. In addition, we also decided to compare the anti-NKl.l
MAb with the anti-asialo GM1 polyclonal Ab (Wako Chemicals USA Inc., Richmond,
VA), a commercially available product that is less specific for NK cells than anti-NKl.l,
but is nonetheless commonly used for NK depletion.
In order to verify the efficacy of the anti-asialo GM1 Ab prior to experimentation,
we compared NK cell depletion using anti-asialo GM1 and anti-NKl.l within spleen and
blood compartments. The employed dose of anti-asialo GM1 was 30 pi per injection,
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Table 7.5. Sixth anti-NKl.l MAb titration protocol.

NK Population%
Assay

Bloocf

Spleenb

13.00+/-1.4911
3.94+/-0.71
4.98+/-0.57
3.28+/-0.00 i

8.42+/-0.78
5.31+/-0.43
5.73+/-0.43
8.13+/-0.00

Day lc
Control
NK(0.625, 2)e
NK(1.25, 2)f
NK(2.50, 2) g

aNK Population % (Blood) - NK population percentage within the blood as measured by
flow cytometry.
NK Population % (Spleen) - NK population percentage within the spleen as measured
by flow cytometry.
c Time of euthanasia and assay following last injection (Day 0) of anti-NKl.l MAb.
dControl - PBS.
eNK(0.625, 2) - anti-NKl.l MAb administered in 2 i.p. injections of 625 pg each (1.25
mg total) at days -2 and 0.
fNK(1.25, 2) - anti-NKl.l MAb administered in 2 i.p. injections of 1.25 mg each (2.50
mg total) at days -2 and 0.
gNK(2.50, 2) - anti-NKl.l MAb administered in 2 i.p. injections of 2.50 mg each (5.00
mg total) at days -2 and 0..
hMean +/- SEM, n=l-3 mice/group.
'P < 0.045 compared to PBS control.
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administered at two different time points, compared with an amount of 0.75 mg per
injection of anti-NKl.l. The dose of anti-asialo GM1 was chosen based on the
manufacturer’s recommendations as well as studies within the scientific literature, which
reported achieving depletion with an amount varying between 10-30 pi (Ehl et al, 1996;
Osaki et al., 1998; Vicari et al, 2000). Two days following the final injection, the antiasialo GM1 Ab had eliminated greater that 75% of NK1.1+ cells within the blood and
greater than 55% of NK cells within the spleen (Table 7.6). In contrast to previous data,
anti-NKl.l, at a total dose of 1.5 mg, effectively depleted greater than 90% of NK1.1 +
cells within both compartments. While this result came as a surprise, we did not assign it
much weight because only one mouse was tested with the anti-NKl. 1 Ab and because
previous analyses had shown much less depletion. As a consequence, we determined to
use both antibodies for NK cell depletion using rabbit serum as a control preparation
since anti-asialo GM1 is a rabbit polyclonal antibody. However, according to the
findings presented in the study that follows hereafter, a 0.75 mg dose/injection of antiNKl. 1 eliminated nearly 90% of NK cells within the blood and spleen. Several
explanations can account for this shift in results. First, the 0.75 mg dose/injection was
not employed in any other titration experiment and may have been an optimum amount.
This possibility, however, seems unlikely since we used amounts close to, as well as
above and below, the 0.75 mg dose. Second, flow cytometric analysis of NK1.1 staining
in the final titration and NK-depletion experiment was performed according to a slightly
different protocol by a different technician (Judy Holbeck, M.S). In this procedure,
samples that had been labeled with primary antibody were placed on ice during
incubation and storage prior to analysis. Previously, incubation and storage steps were
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Table 7.6. Titration protocol for anti-asialo GM1 and anti-NKl.l: precursor to NKdepletion study

Assay

Blood3

NK Population%
Spleenb

Day 2C
Control

8.14+/-0.268

4.91+/-0.16

AGMl(30,2)e

1.80+/-0.20h

2.10+/-0.43h

NK(0.75, 2) !

0.61h

0.35h

aNK Population % (Blood) - NK population percentage within the blood as measured by
flow cytometry.
bNK Population % (Spleen) - NK population percentage within the spleen as measured
by flow cytometry.
c Time of euthanasia and assay following last injection (Day 0) of anti-NKl.l MAb.
dControl - DPBS; n=3.
eAnti-asialo GM1 Ab administered in 2 i.p. injections of 30 pi each (60 pi total) at days
-1 and 0; n=2.
f

NK(0.75, 2) - anti-NKl.l MAb administered in 2 i.p. injections of 0.75 mg each (1.5 mg
total) at days -1 and 0; n=T.
gMean +/- SEM, n=l-3 mice/group.
hP < 0.045 compared to PBS control.
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performed at room temperature. It is possible that the lower temperature reduced or
prevented non-specific binding via the Fc portion of the antibody; whereas, incubation
and storage at room temperature may have artificially enhanced NK1.1+ populations by
permitting this type of non-specific antibody attachment.
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Abstract. Background: Total body irradiation (TBI), given in low to moderate doses as a
single modality, can enhance leukocyte populations and immune modifiers, resulting in
slowed tumor progression. The aim of this study was to evaluate natural killer (NK) cell
involvement in mediating the antitumor effect of TBI by depleting NK populations and
monitoring tumor progression and immune status following exposure. Materials and
Methods: C57BL/6 mice (n=54) were injected with anti-NKl.l, anti-asialo GM1, or
rabbit serum prior to irradiation/tumor implantation.

Selected animal groups were

irradiated with a 3 Gy dose of y-rays and Lewis Lung carcinoma (LLC) cells were
subcutaneously implanted 2 hr later.

Tumor volumes, leukocyte populations, and

cytokine levels in blood and spleen were measured up to 10 days post-irradiation/tumor
implantation. Results: Depletion of asialo GM1+ cells, but not NK1.1+ cells, led to
significant acceleration of tumor growth (P< 0.05). Challenge with exogenous antigens
(rabbit antibodies or serum) when accompanied by administration of TBI resulted in a)
radioresistance of splenic lymphocytes, b) increased granulocyte and monocyte numbers,
and c) enhanced production of IgG, IL-10, and IL-18 within plasma and tumor
supernatants.

Delivery of TBI to NK1.1+ depleted mice, did not show similar

enhancement of leukocytes and/or their modulators. Conclusion: These data indicate
that TBI, in conjunction with immune challenge, activates leukocyte parameters and
redirects the immune system toward a T helper 2 (Th2) cell response. Additionally, NK
cells are involved in mediating the antitumor effect of TBI, while challenge with
exogenous protein attenuates the slowing of malignant growth that accompanies delivery
of radiation. These findings also support the premise that radiation exposure can activate
NK and some T cytotoxic lymphocytes, thereby leading to tumor suppression.
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Introduction
Natural Killer (NK) cells are a class of granular lymphocytes that play a critical role in
the suppression of tumor growth and metastases as well as other host defenses (1-4). As
mediators of innate immunity and tumor cytotoxicity, NK cells are an important source of
immunoregulatory molecules including interferon-y (IFN-y) and tumor necrosis factor-a
(TNF-a); and accordingly, these cells can modulate adaptive immune responses through
the cytokine network (5,6). Unlike B and T cells which are major histocompatibility
complex (MHC) restricted, NK cells are sensitive to signaling via inhibitory and
activating receptors, which under stimulatory conditions enable them to lyse both
transformed and virus-infected cells (7). A diversity of cytokines, such as interleukin-2
(IL-2), IL-12, IL-15, and IL-18, nonspecifically activate NK cells to express Fc receptors
and/or killer-activating receptors. Interaction between target molecules and these
receptors may induce antibody dependent cellular cytotoxicity (ADCC), as well as the
release of perforin, expression of Fas ligand, and upregulation of other related apoptotic
molecules (8,9).
While high-dose total body irradiation (TBI) can suppress the immune system, reports
have suggested that certain immune parameters may be primed by low-dose regimens
(10-13). Immune enhancement following TBI may be attributed to the elimination of T
suppressor subsets in conjunction with the augmentation of alternate immune cell
populations and biological modifiers (14-16).

TBI has been shown to mediate both

slowed tumor progression and metastasis reduction, which are correlated with the
induction of NK and T cell proliferative responses within rodents (12,17,18). In clinical
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settings, TBI has been used to successfully manage advanced non-Hodgkins lymphoma
and chronic lymphocytic leukemia (19,20).
Studies, investigating the underlying mechanisms of immune enhancement and tumor
control, have postulated the role of NK and T cells and their interplay as being important
components in limiting the spread of cancer. IL-12, a potent activator of NK cells, has
been shown to effectively induce cytotoxic effector cells, which in turn can inhibit the
progression of a B cell lymphoma (21). Additionally, the depletion of NK cells can
abrogate the generation and persistence of antitumor responses directed by cytotoxic T
lymphocytes (Tc), which are necessary to slow subcutaneous tumor growth (21,22). It is
thought that communication to expand Tc populations and activity is linked to activated
monocytes. Reports have also demonstrated that the relative density of T and NK subsets
within the blood and spleen can increase in irradiated mice, although population changes
are dependent upon the dose of TBI delivered (16,17,23).

Further, immunodepleting

chemotherapy, using cyclophosphamide, appears to enhance the activity of adoptivelytransferred, tumor-reactive T cells by eliminating regulatory cells and/or altering
homeostatic mechanisms that restrict lymphocyte numbers (24). It is therefore possible
that a single fraction of relatively low-dose radiation could stimulate activated and/or
radioresistant antitumor responses in a manner similar to a course of cyclophosphamide
or other nonmyeloablative conditioning regimens.
Having previously reported that increases in NK population density, as well as NK
cytotoxicity, can be observed in mice receiving a moderate dose of TBI when compared
to non-irradiated tumor-bearing controls, the present study was undertaken to follow lung
carcinoma progression and immune status subsequent to administration of a moderate
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dose of TBI and an NK-depleting regimen. This interaction was evaluated when NK cells
were depleted prior to irradiation and tumor cell implantation. The primary aims were to
correlate NK cell function with the antitumor effect incurred by TBI and to monitor
variations in leukocyte populations, regulatory cytokines, and activation marker
expression as indicators of immune status and tumor control.
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Materials and Methods
Animals. Eight- to nine-week old C57BL/6 male mice (n=54), obtained from Charles River
Breeding Laboratories, Inc. (Hollister, CA), were housed under standard vivarium conditions and
acclimatized prior to treatment. At study initiation, each animal was assigned to one of eight
groups: 1) Rabbit serum; 2) PBS (control); 3) Rabbit serum + tumor; 4) Rabbit serum + TBI +
tumor; 5) Anti-NKl.l + tumor; 6) Anti-NKl.l + TBI + tumor; 7) Anti-asialo GM1 + tumor; and
8) Anti-asialo GM1 + TBI + tumor. The mice were weighed at least twice weekly and monitored
for signs of treatment-related toxicities prior to euthanasia by rapid C02 asphyxiation as
recommended by the American Veterinary Medical Panel on Euthanasia. The study was approved
by the Institutional Animal Care and Use Committee of Loma Linda University.

NK Cell Depletion. Selected mice were depleted of NK cell activity by administration of either
anti-NKl.l or anti-asialo GM1 Ab.

PK136 hybridoma cells (ATCC, Rockville, MD) were

adapted to EX-CELL 620 HSF serum-free medium (JRH Biosciences, Lenexa, KS), and antiNKl.l Ab was purified from hybridoma supernatants by affinity chromatography using a
Sepharose Protein G Fast Flow column (Amersham Pharmacia, Piscataway, NJ). The anti-asialo
GM1 antibody was purchased directly from Wako Chemicals USA, Inc. (Richmond, VA). The
optimal amount of anti-NKl.l Ab for in vivo depletion was determined in preliminary assays of
flow cytometry, whereas, anti-asialo GM1 concentrations were based on commonly employed
schedules and recommended titrations of the manufacturer. Animals were given i.p. injections of
either 750 jag of anti-NKl.l or 30 pi of anti-asialo GM1 diluted in 0.5 ml of sterile Dulbecco’s
PBS (DPBS) (Cellgro® by Mediatech, Inc., Herndon, VA), at days -1, 1, and 6 relative to
irradiation and tumor implantation. Rabbit serum (Sigma, St. Louis, MO), diluted 1:10, or sterile
DPBS served as controls.
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Total-Body Irradiation.

Two hours prior to tumor cell implantation, mice were individually

restrained in 1-mm thick, rectangular plastic boxes (3 x 3 x 8.5 cm) and up to seven animals were
simultaneously irradiated with a single dose of 3 Gy photons (1.03 Gy/min) from a 60Co source.
A retired AECL Eldorado therapy unit (Atomic Energy Canada, Ltd., Commercial Products
Division, Ottawa, Canada) was used to deliver whole body radiation to three test groups (rabbit
serum + TBI + tumor, anti-NKl.l + TBI + tumor, and anti-asialo GM1 + TBI + tumor), while
remaining groups were sham irradiated.

A Capintec Model PR06-G cylindrical thimble

ionization chamber, traceable to the National Institute of Standards and Technology (NIST), was
used to calibrate the dose delivered by the radiotherapy unit.

Tumor Cells and Tumor Implantation. The Lewis lung carcinoma cell line (ATCC) was cultured
in Dulbecco’s minimal essential medium (DMEM) (Sigma Chemical Co., St. Louis, MO)
supplemented with 10% bovine calf serum (BCS) (Hyclone Laboratories, Logan, UT), 50 I.U./ml
penicillin, 50 Pg/ml streptomycin (Sigma), and 2 mM L-glutamine (Cellgro®). After reaching
near confluence, cells were harvested and injected subcutaneously (s.c.) into mice for in vivo
passage. Tumors were excised from these maintenance mice, processed into a slurry, counted,
and injected s.c. into the right hind flank (~2 x 106 cells/mouse). Animals, not implanted with
tumor, were injected with DPBS. Tumor dimensions were measured with vernier calipers and
volumes were calculated: width x length x height/2.

Hematological Analyses of Blood and Spleen, Relative Spleen Weight, and Spleen supernatants.
Ten days following irradiation and tumor implantation, whole blood was collected by cardiac
puncture into K2EDTA-containing syringes. Relative spleen weights (RSW) were calculated as
follows: RSW = [spleen weight (g) x 104]

body weight (g). After weighing, spleens were

processed into single-cell suspensions for hematological and flow cytometric analyses. Samples
(12 M-l) of whole blood and unlysed spleen suspensions were evaluated using a Vet ABC
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Hematology Analyzer (Heska Corporation, Waukesha, WI) for leukocyte, erythrocyte, and
thrombocyte parameters. Aliquots of splenocytes were subsequently lysed in 2 ml of lysing
buffer, washed, and resuspended in RPMI 1640 medium (Irvine Scientific, Santa Ana, CA)
supplemented with 10% heat-inactivated fetal calf serum (PCS) (Hyclone), 5 x 10'5 mM 2mercaptoethanol (Gibco BRL, Grand Island, NY), and antibiotics. Spleen supernatants were
collected after 44 hr stimulation with T cell mitogen (phytohemagglutmin, PHA; Sigma).

Evaluation of Lymphocyte Populations and Cell Marker Expression. Lymphocytes in the blood
and spleen were phenotyped by direct immunofluorescence staining in 3-color, 1-tube mixtures of
fluorescence-labelled monoclonal antibodies (mAb). CD8+ T cytotoxic (Tc), NK1.1+ NK cells,
and CD7L activated cells were identified using monoclonal antibodies (mAbs) conjugated with
peridinin chlorophyll protein (PerCP), R-phycoerythrin (PE), and fluorescein isothiocyanate
(FITC), respectively (Pharmingen, San Diego, CA). Following incubation with mAbs and
subsequent lysis of red blood cells, samples were analyzed using a FACSCalibur™ four-channel
flow cytometer (Becton Dickinson, Inc., Rutherford, NJ). At least 10,000 events were acquired
before analysis with CellQuest™ software version 3.1 (Becton Dickinson).
Lymphocyte populations are described as either percentages or absolute values. Absolute
values were calculated by multiplying normalized percentages (obtained by FACSCalibur, TM
Becton Dickinson) by the total lymphocyte count per animal (obtained from the Vet ABC
Hematology Analyzer), the appropriate dilution factor (spleen only), and the suspension volume
(spleen only). Consequently, absolute values are reported as number of cells/ml of blood and
number of cells/whole spleen.

Cytokine and IgG Quantification.

Concentration of IL-10, IL-12, IL-18, EFN-Y, and

immunoglobulin G (IgG) in plasma, tumor and/or spleen supernatants were measured using
commercially available enzyme-linked immunosorbent assay (ELISA) kits (MBL Co., LTD,
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Naka-ku Nagoya, Japan for IL-18; ZeptoMetrix Corporation, Buffalo, New York for mouse IgG;
R&D Systems, Minneapolis, MN for all others). Tumor supernatants were collected as previously
described (17).

Statistical Analysis. Data were evaluated by one-way analysis of variance (ANOVA) using group
as the independent variable. Post-hoc Tukey’s HSD (honestly significant difference) multiple
range test was used to compare between groups for each parameter.

These analyses were

performed with SigmaStat™ software version 2.0 (SPSS Inc., Chicago, IL). Differences were
considered significant only if the P value was < 0.05.
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Results
Tumor progression following NK cell depletion and irradiation. To determine whether
depletion of NK cell populations can enhance the progression of lung carcinoma in a
syngeneic model, mice were injected with LLC cells following administration of antiNK1.1, anti-asialo GM1, rabbit serum and/or irradiation. As shown in Figure 1, tumor
growth was accelerated in mice that received anti-asialo GM1, but not anti-NKl.l, when
compared with rabbit serum control animals (P< 0.05), although significance was not
achieved at every time point. However, TBI did not slow tumor progression in either
control or NK-depleted groups.

Tumor volumes were not measurable until 7 days

following implantation.

Leukocyte Counts, RSW, and Hematological Assays.

Lymphocyte, monocyte, and

granulocyte counts were evaluated to measure the composition of leukocytes in the blood
and spleen compartments (Figure 2A and B).

Overall, lymphocyte and monocyte

populations within the peripheral blood were sensitive to the effects of irradiation and
tumor burden, such that tumor-bearing mice receiving radiation evidenced the lowest
counts. In contrast, granulocyte levels in all tumor-bearing groups were significantly
elevated above rabbit serum and PBS control values (P< 0.05).

Within the spleen,

leukocytes showed differing sensitivities and were relatively resistant to population shifts
incurred by irradiation or tumor presence (Figure 2B). Administration of anti-NKl.l in
combination with TBI resulted in a significant decline in lymphocyte counts, but a similar
nadir was not seen in other irradiated or tumor-bearing groups. A substantial increase in
monocyte and granulocyte numbers was observed for two sets of tumor-bearing mice
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receiving TBI, namely those injected with either rabbit serum or anti-asialo GM1. A rise
in spleen mass coincided with the increases in monocyte and granulocyte subsets for
these two groups, which showed the highest RSW values (69.4+/-5.1 and 74.7+/-9.6
respectively, compared with the range of 29.2+/-1.7 to 46.2+/-0.9 obtained for the other
groups) (P< 0.02). As a result, the rabbit serum + TBI + tumor and anti-asialo GM1 +
TBI + tumor groups recorded elevated total leukocyte counts above all other animal sets.
We also monitored red blood cell concentration, hemoglobin, and hematocrit, and found
that irradiation and tumor burden resulted in a reduction in these parameters, with the
exception of the anti-NKl.l + tumor group which did not evidence a significant decline
in these measurements (data not shown).

Flow cytometry analysis of specific lymphocyte populations.

To assess NK cell

depletion, distribution of lymphocytes, and activation status, we analyzed NK1.1+, CD8+,
and CD71 populations. Figure 3 illustrates that administration of anti-NKl.l resulted in
greater than 90% depletion of NK1.1+ cells within the blood and greater than 85%
depletion within the spleen compared to non-depleted controls. Injection of anti-asialo
GM1 reduced NK1.1+ cell density to a lesser extent, and the anti-asialo GM1 + TBI +
tumor group was not substantially diminished as was its non-irradiated counterpart.
Within the spleen, the rabbit serum + TBI + tumor group demonstrated the highest peak
in NK cell levels on day 10 following irradiation and tumor implantation.
Using CD71 expression as a measure of activation status, the rabbit serum + TBI +
tumor and anti-asialo GM1 + TBI + tumor groups had elevated splenic levels of activated
NK cells (NK1.1+/CD71+) compared to all other groups (Figure 3). Within the blood,
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there was a dramatic decrease in activated NK cells that could be correlated to delivery of
anti-NKl.l. Furthermore, NK1.1+/CD71+ total counts were elevated in the blood for
anti-asialo GM1 + TBI + tumor mice above all other animal groups.
Similar to the pattern observed in lymphocytes, CD8+ cell numbers within the blood
were sensitive to both irradiation and tumor presence. Within the spleen, only one set of
mice, anti-NKl.l + TBI + tumor, showed significant depression of T cytotoxic cell
density (data not shown).

Cytokine and IgG Concentrations within Plasma, Spleen, and Tumor Supernatants. As a
measure of immune status, concentrations of selected cytokines as well as IgG were
quantified. IgG levels within the plasma and tumor supernatants were significantly
elevated in the rabbit serum + TBI + tumor group as well as both sets of mice receiving
anti-asialo GM1 (Table 1). Plasma IL-10, a cytokine which can induce class switching
from IgM to IgG, was also raised as a result of radiation. Similarly, both the rabbit serum

+ TBI + tumor and anti-asialo GM1 + TBI + tumor groups showed pronounced
concentrations of IL-10 and IL-18 within tumor supernatants, although the remaining
irradiated group, anti-NKl.l + LLC + TBI, did not demonstrate a similar increase
(Tables 1 and 2). Few statistically significant differences were seen in spleen supernatant
levels of IgG or IL-10 (data not shown). As a general rule, irradiated mice showed
decreased levels of IFNy and IL-12 within spleen and tumor supernatants, respectively,
compared with other test mice. One exception, however, was the non-irradiated antiasialo GM + tumor group, which also evidenced decreased levels of IFNy (Table 2). In
both plasma and tumor supernatants, IFNy levels were elevated only in the anti-asialo
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GM1 + TBI + tumor group, although significance was not achieved in comparison to all
other groups (data not shown).

191

Table 8.1. IgG and IL-10 concentrations within the plasma and tumor supernatants

Group

Plasma
IgG
IL-10
(mg/ml)
(pg/ml)

Tumor Supernatant
IL-10
IgG
(mg/g)
(pg/g)

No Tumor
a. Rb serum

13.0+/-1.4*dEh 4.0+/-1.8df

b. PBS

1 L0+/-2.2dgh

2.7+/-2.7dt11

c. Rb serum

13.9+/-4.4d8h

11.7+/-2.8

2.26+/-0.26gl1

89.5+/-9.8h

d. Rb serum + TBI

38.6+/-5.1h

23.S+/-3.9

3.88+/-0.6111

139.9+/-22.0

e. aNKl.l

12.3+/-1.0<lsh 4.3+/-2.5df

1.68+/-0.408'1

60.1+/-15.3<l11

f. aNKl.l + TBI

11.8+/-1.7dg1'

21.7+/-4.4

1.73+/-0.178h

70.9+/-7.4dh

g. aAGMl

52.7+/-6.1h

5.7+/-2.9df

5.47+/-0.76

66.7+/-6.3dh

h. aAGMl + TBI

78.6+/-4.2

16.9+/-2.6

6.68+/-0.90

167.1+/-17.9

Tumor (LLC)

Commercially available ELISA kits were used to determine concentrations of cytokines
in plasma and tumor supernatants. *Mean +/- SEM, n = 6-7 mice/group. Rb serum: rabbit
serum; TBI: total-body irradiation; aNKl.l and aAGMa: antibody directed against
NK1.1 and asialo GM1 molecules, respectively. Superscripts denote P < 0.05 compared
to indicated group.

192

Table 8.2. IFNy, IL-12, and IL-18 levels within spleen and tumor supernatants

Snleen Supernatant
IFNy
Group

(pg/ml)

Tumor Supernatant
IL-12
IL-18
(ng/g)
(Pg/g)

No Tumor
a. Rb serum

1087+/-207*

b. PBS

773+/-161

Tumor (LLC)
c. Rb serum

710+/-133

280+/-19

7.8+/-0.6dh

d. Rb serum + TBI

59+/-17 abe

171+/-12ce

16.0+/-1.1

e. aNKl.l

851+/-278

321+/-13

9.7+/-1.3 dh

f. aNKl.l + TBI

169+/-82ae

212+/-266

7.4+/-0.4dh

g. aAGMl

142+/-40ae

247+/-S

7.0+/-0.4dh

h. aAGMl + TBI

42+/-15 abe

153+/-21ceg

15.6+/-1.2

Commercially available ELISA kits were used to determine concentrations of cytokines
in spleen and tumor supernatants. *Mean +/- SEM, n = 6-7 mice/group. Rb serum: rabbit
serum; TBI: total-body irradiation; aNKl.l and aAGMa: antibody directed against
NK1.1 and asialo GM1 molecules, respectively. Superscripts denote P < 0.05 compared
to indicated group.
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Figure 8.1. Tumor progression following administration of rabbit serum, depletion
antibody, and/or TBI. Mice were irradiated with a single fraction of 3 Gy y-rays from a
60Co source. Tumor implantation occurred 2 hr following irradiation. Each point
represents the mean tumor volume +/- SEM for 6-7 mice/group. Rb: rabbit serum; TBI:
total-body irradiation; aNKl.l and aAGMa: antibody directed against NK1.1 and asialo
GM1 molecules, respectively, a: P<0.05 vs. Rb serum; b: P<0.05 vs. Rb serum + TBI;
c: P<0.05 vs. aNKl.l; d: P<0.05 vs. aNKl.l + TBI.
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Figure 8.2. Leukocyte populations in peripheral blood and spleen at 10 days following
irradiation. Each point represents the mean +/- SEM for 6-7 mice/group. Rb: rabbit
serum; TBI: total-body irradiation; LLC: Lewis lung tumor; aNKl.l and aAGMa:
antibody directed against NK1.1 and asialo GM1 molecules, respectively, a: P<0.05 vs.
Rb serum and PBS; b: P<0.05 vs. all non-irradiated groups; c: P<0.05 vs. Rb serum; d:
P<0.05 vs. Rb serum, PBS and Rb serum + LLC. e: P<0.05 vs. all groups except PBS; f:
P<0.05 vs. all groups except aAGMl + LLC and aAGMl + TBI + LLC; g: P<0.05 vs. all
groups except Rb serum + TBI + LLC; h: P<0.05 vs. all groups except aAGMl + TBI +
LLC. Panel A: blood (No. of WBCs/ml), Panel B: spleen (No. of WBCs/whole spleen).
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Figure 8.3. NK1.1+ and NK1.1+/CD71+ double positive populations in peripheral blood
and spleen at 10 days following irradiation. Each point represents the mean +/- SEM for
6-7 mice/group. Rb: rabbit serum; TBE total-body irradiation; LLC: Lewis lung tumor;
aNKl.l and aAGMa: antibody directed against NK1.1 and asialo GM1 molecules,
respectively, a: P<0.05 vs. Rb serum; b: R<0.05 vs. all groups except aNKl.l groups
and aAGMl + LLC; c: P<0.05 vs. all groups except aNKl.l groups; d: R<0.05 vs. Rb
serum, Rb serum + TBI + LLC; e: P<0.05 vs. Rb serum + TBI + LLC; f: P<0.05 vs. Rb
serum + TBI + LLC and aAGMl + TBI + LLC; g: RO.OS vs. all groups.
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Discussion
While the prevailing belief is that radiation exposure increases the risk for malignancy
and suppresses immune responses, numerous studies have reported that low-to-moderate
dose TBI can modify immune cell composition and function, thereby facilitating
heightened activation. We have previously documented that an augmentation of NK cell
numbers, high levels of activating cytokines including IL-12 and IL-18 and low levels of
suppressing cytokines, as well as an increase in the CD4:CD8 T cell ratio appear to act in
combination to significantly slow tumor growth following delivery of a 3 Gy dose of TBI
(17). As important mediators of malignant processes, both NK and NKT cells can
participate in surveillance to protect against tumor initiation, growth, and metastasis in
both rodents and humans; and the TNF-related apoptosis-inducing ligand (TRAIL)
pathway has been linked to these antitumor responses (25,26).
In contrast to our previous findings, in this study, we did not observe an expected
decrease in tumor progression when a single, moderate dose of TBI was administered
prior to LLC implantation, based on tumor volume data for rabbit serum + tumor groups
either with or without TBI. In earlier studies, we showed that pre-irradiation of C57BL/6
mice within a dose range of 1.33 to 3 Gy, but not below 0.46 Gy, resulted in delayed lung
carcinoma growth compared to non-irradiated control animals (23). Upon review of the
present data, it appears that rabbit serum antigens, which were not introduced in previous
experiments, diverted response mechanisms toward humoral (Th2) and away from cellmediated (Thl) aspects.

This conclusion is supported by data quantifying cytokine

levels, lymphocyte radiosensitivity, and NK population changes.

First, increased

production of IgG and IL-10 within irradiated control animals is consistent with an
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induction of a Th2/B cell response; whereas decreased IFNy levels correlate with
downregulated Thl activity. Second, lymphocytes in the blood and spleen of irradiated
mice were relatively resistant to the deleterious effect of irradiation suggesting that these
cells were primed against rabbit antigens. It has been demonstrated that activated
lymphocytes, including activated B cells, are highly radioresistant (27-29); and thus,
multiple injections with exogenous rabbit protein, appear to have activated a relatively
large number of lymphocytes, thereby conferring radioresistance. Third, at 10 days post
irradiation, absolute NK cell numbers within spleens of rabbit serum + TBI + tumor mice
were 1.75-fold greater than values for non-irradiated animals.

This shift was less

pronounced than the expected increase (as much as 4-fold) that has been observed in our
previous experiments in which irradiated and non-irradiated groups, not injected with
rabbit serum, were compared (17).

Overall, these results indicate that the antitumor

effect of TBI was markedly attenuated by a recruitment of immune cells against rabbit
proteins, which preempted responsiveness against the tumor.
The present study does illustrate that administration of anti-asialo GM1
(polyclonal rabbit antibody) significantly accelerated tumor growth. Asialo GM1+ cells
consist of a population that includes both NK1.1+ and Tc lymphocyte populations and
depletion of these subsets can strongly suppress splenic cytotoxic activity (30-32).
Furthermore, as a xenogeneic antigen, injection of anti-asialo G1 on days -1,1, and 6
served to direct the immune system against a foreign species antibody (33).
Consequently, the significantly increased tumor growth in anti-asialo GM1 test groups
was likely observed for several reasons. One factor appears to be the induction of a Th2
response, as evidenced by increased levels of plasma IgG, tumor IgG, and plasma IT-10
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within the groups depleted with anti-asialo GM1. However, this does not account for
tumor volume differences between the rabbit serum + TBI + tumor group and anti-asialo
GM1 + TBI + tumor groups, since both were challenged with rabbit antigens. Among
these groups, depletion of NK and Tc responses using anti-asialo GM1 resulted in greater
tumor progression. Since asialo GM1 is expressed by some Tc cells, as well as NKs, the
dynamics of NK and Tc contribution to slowed tumor progression cannot be determined.
However, it is known that NK cells are less radiosensitive than Tc cells (17,34,35).
Minimally, the results have demonstrated that asialo GM1+ cells do mediate slowed
tumor progression.
Of additional significance is that radiation elicited an impressive and sustained
immune response when preceded by challenge with either rabbit serum or rabbit
antibody, as seen in data for both the rabbit serum + TBI + tumor and anti-asialo GM1 +
TBI + tumor groups. As mentioned, lymphocytes within these sets of mice showed
heightened radioresistance and a significant increase in monocyte and granulocyte
numbers was observed. Further, TBI prompted an augmentation of the NK1.1+ subset and
stimulated production of the NK-activating cytokine, IL-18.

Irradiated groups also

showed the highest levels of NK cell activation (NK1.1/CD71 double positivity) within
the spleen. However, given the magnitude of Th2 induction, repetitive challenge with
rabbit antigens, and decreases in IL-12 levels, the overall immune response, while
notable, appears to have been directed away from tumor clearance.
Although depletion of asialo GM1+ cells resulted in accelerated tumor progression, a
similar loss of tumor control was not observed following delivery of anti-NKl.l, a mouse
mAb. Given that no differences in tumor volumes were observed between groups
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receiving either rabbit serum or anti-NKl.l, the elimination of NK cells may have an
effect similar to rabbit serum challenge, i.e. both suppress or direct away from immune
responses that have potential to slow tumor growth. However, since increases in tumor
growth were observed in anti-asialo GM1-depleted mice, the elimination of NK cells
likely fostered tumor progression, but pre-exposure to rabbit serum antigens modified
antitumor mechanisms. Hence, groups receiving rabbit serum (rabbit serum +/- TBI +
tumor), subjected to challenge, did not mount the predicted response against LLC tumor
and thus no differences in growth were observed compared to NK1.1-depleted mice. This
possibility is supported by several observations. Absolute NK1.1+ cell counts in the
blood and spleens of mice were significantly reduced (>85%) compared to normal values,
demonstrating that depletion was successful. Also, groups receiving anti-NKl.l did not
show increased levels of IgG, tumor IL-10 or IL-18, indicating that the administration of
mouse antibody did not induce a Th2 response similar to that induced by rabbit antigens.
Consequently, priming with a potent non-tumor antigen had an effect similar to that of
NK1.1+ cell elimination.
In conclusion, the experiments described in this study reveal a number of important
findings related to NK cells and tumor control. First, as demonstrated by tumor volume
data, asialo GM1+ cells are capable of limiting tumor progression in the LLC model.
Also, since depletion of these lymphocytes resulted in accelerated tumor growth, NK
cells likely participated in tumor clearance since they are the major target of these
depleting antibodies. Second, repetitive immune challenge with rabbit serum or antibody
attenuated the antitumor effect of TBI by focusing the immune system toward Th2/B cell
responses. Third, TBI alone induced a heightened state of immune “activation” that
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occurs during removal of damaged cell debris and that may also be partly related to the
recovery and/or reconstitution of lymphocyte subsets.

Evidence for this includes

enhanced relative spleen weights, monocyte and granulocyte numbers, lymphocyte
radioresistance, and production of IgG, IL-10, and IL-18 in irradiated groups.
Furthermore, the study also suggests that administering TBI may be contraindicated in
subjects recently exposed to potent foreign agents. In such a situation, TBI may serve to
enhance responsiveness against the foreign agent, but not against the tumor. In addition,
this report substantiates the role of asialo GM1+ cells and NK1.1+ cells in tumor
surveillance in the LLC model, as well as their involvement in mediating the antitumor
effect of TBI.

Future studies are necessitated to delineate whether this effect is

applicable in other animal and cancer models.
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CHAPTER NINE
FINAL DISCUSSION
This study relates to two important areas of cancer research. First, low-dose totalbody irradiation (TBI) or total lymphoid irradiation has been successfully prescribed as a
therapeutic regimen for low-grade non-Hodgkin’s lymphoma, chronic lymphocytic
leukemia, and Hodgkin’s disease. Further, animal experiments have suggested that lowdose TBI may exert its influence by enhancing immune responsiveness via increasing the
proliferative response of reactive T cells, altering cytokine profiles, and changing the
expression of cytokine receptors (Safwat, 2000).

However, many questions remain

unanswered due to the complex immunobiology of TBI.

A better understanding of

mechanisms by which TBI can alter lymphoid cell activity is of importance in optimizing
and extending the use of this potentially therapeutic practice to additional cancer types.
Second, little is known about the relative cancer risk incurred by astronauts during space
missions. As the exploration of space proceeds, increasing numbers of personnel will be
exposed and longer stays are inevitable.

Thus, studies are needed that specifically

address whether exposure to moderate doses of ionizing radiation increases malignant
processes.
In an effort to better understand the effects of TBI in the LLC model, we initiated
the study described within this document. Having observed that a moderate dose of TBI
can alter tumor progression, we proposed that immune system upregulation, independent
of angiogenic factors, was correlated with mediating an antitumor effect. The present
research demonstrated that a range of doses from 1.33 Gy to 3.0 Gy, resulted in
significantly slowed tumor growth. We also showed that timing of irradiation relative to
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tumor implantation is an important factor with direct bearing on tumor outcome.
Preliminary assessments, showing increases in spontaneous blastogenesis within the
blood and spleen, as well as shifts in absolute numbers and relative percentages of
lymphocyte populations, indicated that immune upregulation had occurred. Further, data,
comparing TBI with out-of-field radiation and radiation localized to the tumor
implantation site, illustrated that the effect of TBI was systemic in nature and was not
exerting its primary influence by disturbing the tumor bed or corresponding vasculature.
More prominently, the body of results supports the conclusion that NK cells
appear to be the most important cell type to function in tumor surveillance and mediation
of the antitumor effect of TBI within the LLC model. Data, which substantiated NK cell
involvement, ranged from highly significant increases in NK cell numbers to enhanced
levels of cytokines that stimulate NK activity. NK cell density within the spleens of
irradiated tumor-bearing mice were elevated as much as 4-fold above populations
observed in non-irradiated tumor-bearing mice on day 10 following TBI, while less
dramatic population shifts were seen in the blood compartment. Relative percentages of
NK cells within these compartments were dramatically altered by TBI, with shifts from
4.6% to 33.7% occurring within the blood for non-irradiated and irradiated animals
respectively, and shifts from 1.6% to 15.6% observed within the spleen. Percentages of
NKT cells, a lymphocyte population expressing both NK1.1 and a single invariant T-cell
receptor, were increased within the blood supply of tumor-bearing mice receiving doses
between 1.33 to 2.66 Gy. Also, the appearance of radiation-inducible cytokines may
have facilitated cytotoxic mechanisms within both NK and NKT populations. Levels of
IL-12, within stimulated and unstimulated spleen supernatants, were high among
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irradiated groups at a ten day time point, whereas IL-2 levels sharply declined. IL-18
concentrations were also elevated in tumor supernatants of animals receiving TBI. These
findings were relevant to NK status when considering that IL-12 and IL-18 positively
influence NK proliferation and cytotoxicity. At 4 days-post irradiation, NK cytotoxicity
was enhanced among irradiated groups of mice; whereas at day 10, these increases had
subsided to levels observed in non-irradiated animals. More convincingly, depletion of
NK populations with anti-asialo GM1 resulted in accelerated tumor growth amongst
irradiated and non-irradiated groups; and depletion with anti-NKl.l resulted in the
attenuation of the antitumor effect of TBI. In the final study, immune mechanisms,
including production of IgG and IL-10, were boosted following administration TBI,
demonstrating that TBI can promote the development of a vigorous and sustained
immune response.
Dudley and colleagues have hypothesized that a nonmyeloablative conditioning
regimen, such as cyclophosphamide treatment, may eliminate regulatory cells or alter
homeostatic mechanisms that limit lymphocyte numbers and that this depletion can play a
role in enabling the in vivo proliferation of transferred tumor reactive T cells (Dudley et
al, 2002; Jameson, 2002). In keeping with this, we propose that radiation, acting as a
conditioning regimen, enables the proliferation of radioresistant cell types when certain
suppressor cell populations and their regulatory cytokines are globally depressed.
Radioresistance may be acquired by cellular activation prior to exposure or through the
inherent sensitivity of the cell type. Thus, radiation serves to promote the activity of NK
cells, which are by nature radioresistant, as a consequence of a diminished level of
negative or inhibitory control. According to the model devised from these collective
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results (Figure 9.1), both TBI and a nonmyeloablative conditioning regimen can act to
eliminate radiosensitive lymphocyte subsets while sparing radioresistant leukocytes.
When immune challenge (i.e. tumor implantation or foreign antigen invasion) follows
irradiation,

proliferation

of

radioresistant

or

activated

lymphocytes

results.

Consequently, the immune environment favors cellular reactions driven by radioresistant
cell types, pushing a response that is tailored to the primary challenge. This may induce a
shift in the cytokine profile, so that cytokines, which stimulate the proliferation and/or
cytotoxic capability of NK cells, are preferentially produced. Depending upon the
processing and presentation of foreign antigen, cytokines may also drive either a Thl or
Th2 response. Following upregulation of radioresistant responses, enhanced immunity
occurs, as radioresistant cells, stimulated by the altered environment, show greater
cytotoxicity and antigen clearance capability. However, the response occurs only within
a window of time since lymphocyte populations are rapidly reconstituted. B cells, for
example, can recover within 15 days after exposure. Consequently, as reconstitution
occurs, TBI-promoted reactivity and proliferation decline to quiescence and a resolution
in immune enhancement ensues.
This model also helps to explain the results observed in Chapter Eight, where
challenge with either rabbit serum or rabbit antibody attenuated the antitumor effect of
TBI.

According to our proposal, B cells, which would normally be susceptible to

radiation, were rendered radioresistant when activated by rabbit proteins. Subjected to
TBI, these activated cells, which would have traditionally been eliminated by a moderate
dose of irradiation, constituted a relatively large percentage of the surviving lymphocytes.
When repeated challenge occurred on days 1 and 6, the immune system was additionally
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Figure 9.1. Model explaining the immune enhancing effects of TBI and conditioning
regimens.
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primed against rabbit antigens, memory cell populations were expanded, and the immune
environment fostered a humoral/ B cell-driven response to clear the foreign antigens.
The intensity of the humoral response, initiated by injection of highly potent, xenogeneic
proteins, obscured or directed away from reactivity to syngeneic, albeit aberrant, tumor
cells. Tumor antigens are well known to be less stimulatory than xenogeneic proteins.
Our model also accounts for the role of suppressor cells in modulating antitumor
mechanisms. Like the regulatory cells mentioned by Dudley, if suppressor cells are
sensitive to conditioning (TBI), their numbers may be curbed by the initial radiation
insult (Enker and Jacobitz, 1980; Gelber et al, 1992; Hellstrom et al, 1978; Sabbadini,
1974).

According to our research, evidence to support alterations in suppressor cell

function included a reduction in CD8+ T cytotoxic number, an upward shift in the
CD4:CD8 ratio, depression of IL-2 levels within spleen supernatants, and a decline in
activated T cell numbers (CD3+/CD71+) within the blood and spleen following TBI
administration. A low CD4:CD8 ratio has been correlated with negative tumor outcome
(Sheu et al, 1999). Thus, elimination of the suppressor subset permits the proliferation
of tumor-reactive or activated immune cells.
Although beyond the scope of this study and the model itself, NK cell receptor
signaling may also be modified by TBI, favoring the expression of NK activating
receptors, such as Ly49D and NKR-P1C, and downregulating inhibitory receptors
including CD94/NKG2A. Radiation may also alter the expression of stimulatory and
inhibitory cytokines, indirectly resulting in enhanced NK activity. Macrophages and TH1
cells are known to secrete NK stimulatory cytokines and radiation may influence the
production and expression of these molecules.
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Overall, the data warrant the pursuit of supplementary studies to further delineate
the efficacy of TBI in enhancing immune mechanisms. A 3 Gy dose of TBI, employed in
the majority of protocols in this study, approaches exposure doses that may result in long
term toxicities including anemia and thrombocytopenia. Therefore, it would be necessary
to determine the lowest dose that gives comparable immune enhancement and antitumor
response while minimizing risk for side effects, prior to more widespread use. From our
studies this dose should fall within the range of 0.46 to 1.33 Gy. Lowering total doses
would allow for fractionation, which might serve to maintain or perhaps even boost
activated and/or radioresistant cells at each time point of delivery.

Expanding

experimentation to other animal and tumor models is also essential in order to elucidate
whether the antitumor effect of TBI is applicable to a broad diversity of mammalian
models, especially human cancers.
Independent of radiation exposure, alternative strategies could likewise focus on
manipulating the balance of immune populations and leukocyte signaling through the use
of conditioning regimens which can also reduce suppressor cell densities. In conjunction
with this, cytokines that enhance NK activity, proliferation, and cytoxicity (i.e. IFN-y, IL12, and IL-18) could be employed in combination to further enhance NK responsiveness.
Farag and colleagues have also proposed manipulating the balance of NK signaling in
favor of NK activating receptors (Farag et al, 2003). This could include such strategies
as using monoclonal antibodies and NK-stimulating cytokines to better direct NK cells to
their tumor targets by promoting ADCC. Blocking inhibitory interactions between NK
receptors and ligands on tumor cells may also be efficacious. Further, methods that
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modulate the expression of NK inhibitory and activating cell receptors as well as their
corresponding ligands on the surface of tumor cells is also indicated.
Since this research does have implications for astronauts on extended space
missions, valuable information could be gained by studying long-term effects of TBI
exposure. Studies have shown that splenic lymphocyte populations are more sensitive to
dose-rate effects than those within the blood compartment (Pecaut et al, 2001); and thus,
comparing high-dose rate and low-dose rate radiation in a model incorporating tumor or
viral challenge would also be useful. Finally, it would be useful to evaluate the longevity
of immune enhancement that accompanies TBI in order to estimate possible risk for
tumor challenge.
As a whole, the results of this research have supported the original hypothesis,
demonstrating that 1) changes in LLC growth can be correlated with radiation-induced
shifts in specific immune system parameters, 2) the effect of TBI is systemic and
independent of modulation to the tumor bed or vasculature changes, and 3) selective
immune upregulation of NK cell populations is primarily responsible for the reduction in
lung carcinoma progression that follows administration of TBI. The data also indicated
that the effect of TBI may be dependent upon the type of primary challenge, since
subsequent immunomodulation can promote factors within the immune system toward
responses that are not dedicated for tumor clearance or abrogation. Overall, this research
substantiates the role of NK cells in malignant surveillance and mediation of the
antitumor response induced by TBI. Consequently, further study is necessitated to more
aptly tailor NK cytotoxic mechanisms toward greater antitumor efficacy.
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APPENDIX ONE
Table 11.1. Blood parameters in irradiated tumor-bearing mice (not included in Chapter
Four).

Assay3

Normal
control

Control

Tumor-bearing_______________
0.46 Gv
1.33 Gv
2.66 Gv

RBCb

7.7+/-0.5J

7.8+/-0.2

8.1+/-0.2

7.8+/-0.3

8.2+/-0.1

HGBC

11.3+/-0.7

11.8+/-0.3

12.1+/-0.3

11.9+/-0.4

12.3+/-0.1

HCTd

35.1+/-2.2

36.0+/-0.7

37.7+/-0.9

36.6+/-1.3

38.2+/-0.4

MCVe

46.0+/-0.3

46.4+/-0.2

46.7+/-0.2

46.6+/-0.2

46.8+/-0.2

MCHf

14.8+/-0.1

15.2+/-0.1

15.0+/-0.1

15.1+/-0.1

15.0+/-0.1

MCHCg

32.3+/-0.2

32.8+/-0.2

32.1+/-0.21

32.4+/-0.2

32.1+/-0.1

RDWh

15.8+/-0.1

15.4+/-0.1

15.8+/-0.2

16.4+/-0.11

16.5+/-0.1 k,l,m

MPV ,

10.1+/-0.5

9.8+/-0.2

9.3+/-0.2

9.3+/-0.2

9.7+/-0.2

aPerformed 16 days after irradiation and tumor cell injection.
bRBC - red blood cell count (109/ml), CHGB - red blood cell count (g/dl), dHCT hematocrit (%), eMCV - mean corpuscular volume (pm3), fMCH - mean corpuscular
hemoglobin (pg), gMCHC - mean corpuscular hemoglobin concentration (g/dl), hRDW
red blood cell distribution width (%), 'MPV - mean platelet volume (pm3).
JMean +/- SEM, n = 8-12 mice/group
kP < 0.05 vs. normal control.
P < 0.05 vs. tumor control.
mP < 0.05 vs. tumor-bearing mice receiving 0.46 Gy TBI.
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APPENDIX TWO
Table 12.1. CD4+:CD8+ (Th:Tc) ratio and NKT+ percentage of lymphocytes in
irradiated tumor-bearing mice3 (not included in Chapter Four).
Normal
control
CD4+;CD8+
Spleen
1.62+/-0.05b
Blood

1.94+/-0.20d

NKT % txlO-Q
Spleen
7.52+/-0.62b
Blood

1.78+/-0.39

Control

____ Tumor-bearing
0.46 Gv
1.33 Gv

1.85+/-0.07 1.75+/-0.05 1.98+/-0.07c

2.66 Gv
2.UH-Q.QTAe

1.49+/-0.07 1.58+/-0.08 2.01+/-0.07<l-e 2.31+/-0.08d'e

5.81+/-U1 5.61+/-0.49 7.71+/-0.89
15.10+/-2.82c 6.28+/-1.30d 8.47+/-3.21

6.23+/-0.77
11.20+/-1.20c

Performed 16 days after irradiation and tumor cell injection (both done on day 0); ratios
are based on cell numbers.
bMean +/- SEM, n = 8-12 mice/group.
CP < 0.05 vs. normal control.
< 0.05 vs. tumor control.
eP < 0.05 vs. tumor + 0.46 Gy TBI.
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APPENDIX FOUR
Table 14.1. Blood parameters in TBI mice compared with controls on day 4 (not
included in Chapter Six).
Normal
control

Tumor-bearing
control

Radiation
control

Tumor-bearing
+ Radiation

RBCa

9.34+/-0.17

9.08+/-0.13

y^y+z-o.o^

7.50+/-0.1 lJ,k

HGBb

13.51+/-0.30

13.31+/-0.15

10.58+/-0.1 T,k

11.00+/-0.16J,k

HCTc

42.40+/-0.76

41.26+/-0.57

32.73+/-0.40j’k

33.88+/-0.53J,k

MCVd

45.50+/-0.19

45.50+/-0.19

45.00+/-0.19

45.25+/-0.25

MCHe

14.44+/-0.08

14.69+/-0.08

14.54+/-0.07

14.66+/-0.08

MCHCf

31.81+/-0.19

32.31+/-0.17

32.33+/-0.12

32.48+/-0.14J

RDWg

15.23+/-0.17

15.13+/-0.16

14.74+/-0.13

14.64+/-0.11J

MPVh

8.95+/-0.24

8.88+/-0.17

7.53+/-0.14J’k

7.49+/-0.1(y,k

aRBC - red blood cell count (109/ml), bHGB - red blood cell count (g/dl), cHCT hematocrit (%), dMCV - mean corpuscular volume (pm3), eMCH - mean corpuscular
hemoglobin (pg), fMCHC - mean corpuscular hemoglobin concentration (g/dl), 8RDW
red blood cell distribution width (%), hMPV - mean platelet volume (pm3).
Mean +/- SEM, n = 8-12 mice/group
]P < 0.05 vs. normal control.
kP < 0.05 vs. tumor-bearing control.
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APPENDIX FIVE
Table 15.1. Blood parameters in TBI mice compared with controls on day 10 (not
included in Chapter Six).
Normal
control

Tumor-bearing
control

Radiation
control

Tumor-bearing
+ Radiation

RBCa

8.94+/-0.14

8.98+/-0.15

8.00+/-0.18J’k

7.28+/-0.25j,k

HGBb

12.94+/-0.17

12.80+/-0.19

11.64+/-0.23J’k

10.73+/-0.37J,k

HCTC

41.20+/-0.49

40.81+/-0.53

37.05+/-0.76J,k

34.06+/-1.18J’k

MCVd

46.13+/-0.30

45.38+/-0.26

46.25+/-0.25

46.63+/-0.32k

MCHe

14.50+/-0.08

14.28+/-0.07

14.58+/-0.08

14.69+/-0.10k

MCHCf

31.40+/-0.15

31.38+/-0.10

31.44+/-0.12

31.44+/-0.16

RDW8

16.71+/-0.41k

15.39+/-0.08

16.66+/-0.31k

16.41+/-0.08

MPVh

8.98+/-0.16

9.18+/-0.15

11.18+/-0.41

9.65+/-0.18

i

aRBC - red blood cell count (109/ml), bElGB - red blood cell count (g/dl), cHCT hematocrit (%), dMCV - mean corpuscular volume (pm3), eMCH - mean corpuscular
hemoglobin (pg), fMCHC - mean corpuscular hemoglobin concentration (g/dl), 8RDW
red blood cell distribution width (%), bMPV - mean platelet volume (pm3).
Mean +/- SEM, n = 8-12 mice/group
]P < 0.05 vs. normal control.
kP < 0.05 vs. tumor-bearing control.
P < 0.05 vs. radiation control.
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APPENDIX SIX
Table 16.1. NKT Percentage of Lymphocytes on Day 10 following TBI (not included in
Chapter six).
Normal
control

Tumor-bearing
control

Radiation
control

Tumor-bearing
+ Radiation

NKT % (xlO'1)
Blood

3.46+/-0.55a

6.09+/-1.05

6.01+/-0.72

6.05+/-0.71

Spleen

7.64+/-0.79

8.30+/-1.71

14.23+/-2.02

24.14+/-7.79b,c

aMean +/- SEM, n = 8-12 mice/group
hP < 0.05 vs. normal control.
CP < 0.05 vs. tumor-bearing control.
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APPENDIX SEVEN
Table 17.1. Hematological parameters in NK-depleted and non-depleted mice (not
included in Chapter Eight).

Group

RBC

HGB

HCT

No Tumor
a. Rb serum

9.44+/-0.12

13.7+/-0.1

43.3+/-0.4

b. PBS

9.26+/-0.07

13.3+/-0.1

42.6+/-0.3

c. Rb serum

7.34+/-0.34 *ab

10.7+/-0.5ab

33.7+/-1.6ab

d. Rb serum + TBI

5.81+/-0.32abceg

8.9+/-0.5abeg

27.8+/-1.5abeg

e. aNKl.l

8.46+/-0.15

12.3+/-0.2

38.9+/-0.6

f. aNKl.l + TBI

6.37+/-0.44 abe

9.5+/-0.6 abe

29.7+/-2.0 abe

g. aAGMl

7.47+/-0.21ab

10.9+/-0.3ab

34.1+/-1.1 abe

h. aAGM + TBI

6.19+/-0.41abeg

9.3+/-0.6abe

29.3+/-1.9 abe

Tumor (LLC)

After collection by cardiac puncture, blood parameters were measured using a Vet ABC
Hematology Analyzer. RBC = Red blood cell count (1x109 cells/ml). HGB =
Hemoglobin (g/dl). HCT = Hematocrit (%).Rb serum: rabbit serum; TBI: total-body
irradiation; aNKl.l and aAGMa: antibody directed against NK1.1 and asialo GM1
molecules, respectively. Mean +/- SEM, n = 6-7 mice/group. Superscripts denote P <
0.05 compared to indicated group.
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APPENDIX EIGHT
Table 18.1. CD8+ and CD8+/CD71+ populations within the blood and spleen of NKdepleted and non-depleted mice (not included in Chapter Eight).
Blood
CD8+
CD8+/CD71 +

Group

no5/mn

nos/mn

Spleen
CD8+/CD71+
CD8+
(106/spleen) (106/spleen)

No Tumor
a. Rb serum

5.72+/-0.32*

0.93+/-0.06

7.52+/-0.47f

0.40+/-0.07 dfh

b. PBS

4.65+/-0.34

0.94+/-0.08

6.72+/-0.39

0.38+/-0.03 diii

c. Rb serum

4.30+/-0.27

1.03+/-0.08

7.71+/-0.12 f

0.57+/-0.07dh

d. Rb serum + TBI

2.01+/-0.42 abce 0.53+/-0.09h

7.95+/-0.57f

1.16+/-0.10

e. aNKl.l

3.95+/-0.233

8.27+/-0.50 f

0.41+/-0.02 dfh

f. aNKl.l + TBI

0.85+/-0.04abceg 0.34+/-0.01abcgh 4.33+/-0.45

0.84+/-0.06

g. aAGMl

3.20+/-0.273

0.97+/-0.07

8.21 +/-0.41f

0.53+/-0.03

h. aAGM + TBI

2.62+/-0.71ab

1.20+/-0.30

7.62+/-0.31 f

1.14+/-0.13

Tumor (LLC)

0.88+/-0.05

dtii

CD8+ and CD8+/CD71+ populations within the blood and spleen were determined by
flow cytometric analysis using 3-color, 1-tube mixtures of fluorescence labeled mAb. Rb
serum: rabbit serum; TBI: total-body irradiation; aNKl.l and aAGMa: antibody directed
against NK1.1 and asialo GM1 molecules, respectively. *Mean +/- SEM, n = 6-7
mice/group. Superscripts denote P < 0.05 compared to indicated group.
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Table 19.1. IgG, IL-10, IFN-y concentrations within plasma, spleen and/or tumor
supernatants of NK-depleted and non-depleted mice (not included in Chapter Eight).
Spleen supernatants
IgG
IL-10
Group

(pg/ml)

(pg/ml)

Plasma
IFN-y
(pg/ml)

Tumor sup
IFN-y
-(Pg/g)

No Tumor
a. Rb serum

6.22+/-0.35*h 7.83+/-2.5S

b. PBS

6.32+/-0.23

0.79+/-0.493

4.05+/-0.07

c. Rb serum

6.34+/-0.27

7.09+/-2.07

3.82+/-0.18h

20.4+/-1.8h

d. Rb serum + TBI

7.95+/-1.27

3.96+/-2.40

4.20+/-0.08

28.0+/-2.1

e. aNKl.l

6.09+/-0.50h

1.46+/-0.79

4.25+/-0.24

24.8+/-6.2

f. aNKl.l + TBI

7.38+/-0.44

1.08+/-1.08a

4.02+/-0.03

15.3+/-1.8h

g. aAGMl

7.27+/-0.67

0.29+/-0.17a

4.12+/-0.11

17.2+/-1.0h

h. aAGM + TBI

9.31+/-0.66

0.61+/-0.61a

4.90+/-0.18

36.3+/-4.2

4.74+/0.43

Tumor (LLC)

Commercially available ELISA kits were used to determine concentrations of cytokines
in plasma, spleen, and tumor supernatants. Rb serum: rabbit serum; TBI: total-body
irradiation; aNKl.l and aAGMa: antibody directed against NK1.1 and asialo GM1
molecules, respectively. *Mean +/- SEM, n = 6-7 mice/group. Superscripts denote P <
0.05 compared to indicated group.
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